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Mutations in mtDNA can have severe consequences for cellular energy production and result 
in a severe class of incurable mitochondrial diseases. There is presently a lack of tools for 
the efficient editing of mitochondrial genomes which hinders the study of mitochondrial 
biology and disease. Since their development in 2013, CRISPR genome editing tools have 
had huge popularity and impact on molecular genetics due to their efficiency of targeting, 
versatility and ease of modification. Most studies using CRISPR have targeted the nuclear 
genome. This thesis details the first steps in the development of a suite of tools, which we 
have termed MitoCRISPR, broadening the current scope of CRISPR systems by tailoring them 
for the manipulation of mitochondrial genomes. Although we did not complete development 
of a MitoCRISPR system in this thesis, the work detailed here sets out a framework for the 
project to move forward within. 
Central to the development of a MitoCRISPR system is the targeted delivery of functional 
CRISPR machinery, namely a protein endonuclease and guide RNA, to the mitochondria. To 
this end, this thesis describes the cloning a plasmid encoding mitochondrially targeted 
SpyCas9 and its expression in mammalian cells.  
A library of modified CRISPR gRNAs were designed to incorporate RNA mitochondrial 
targeting aptamers. This thesis details our findings that SpyCas9 gRNAs can be modified at 
several sites without impacting Cas9 complex formation and activity and investigates the 
import of gRNAs into whole cells and isolated mitochondria. Building on these findings, gRNA 
modifications which do impact Cas9 endonuclease activity and modified LbCas12a crRNAs 
are also studied. 
Given that the development of tools for genome editing has real ethical implications, this 
thesis also details the development and findings from an art-science public engagement 
exercise through which we sought to open up a dialogue with the Bristol-based public and 
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1.1 Mitochondria  
All living things need energy to survive. Across all complex organisms, the molecule 
adenosine triphosphate (ATP) is the major source of chemical energy, enabling all metabolic 
processes. Eukaryotic and multicellular organisms have developed several pathways for the 
generation of ATP, the most significant of which are dependent on mitochondrial proteins1. 
Central to sustaining life as we know it, mitochondria are also responsible for the generation 
of important metabolites and play a key role in a number of intracellular pathways including 
Ca2+ homeostasis2, autophagy3, apoptosis and cellular ageing4 (summarised in Figure 1-1A). 
Mitochondria are believed to have originated as an endosymbiotic protobacteria from the 
Rickettsiales family which was taken up into a primordial eukaryotic cell5. As such, they 
contain their own genome — mitochondrial DNA (mtDNA)6 — distinct from nuclear DNA 
(nDNA), Figure 1-1B. 
1.1.1 The structure of mitochondria 
Distinct from their familiar oval shape described by illustrations of textbooks, mitochondria 
form extensive dynamic networks throughout cells7. The constant cycle of fusion and fission 
of mitochondrial structures is of key importance for mitochondrial function, and cellular 
health as a conseneuence8,9. Mitochondria are surrounded by an inner mitochondrial 
membrane (IMM), which is folded into cristae, and an unfolded outer mitochondrial 
membrane (OMM), Figure 1-1A. Together, these membranes give the organelle its 
characteristic structure. The two mitochondrial membranes generate four distinct 
mitochondrial environments: the OMM; the intermembrane space (IMS); the IMM; and the 
matrix, the internal environment of the organelle. The compartmentalisation of these distinct 
environments is central to many of the biochemical processes carried out by mitochondria. 
For example, the IMM incorporates macromolecular protein complexes that drive cellular ATP 
production through biochemical coupling in the oxidative phosphorylation pathway 
(OXPHOS).  
The mitochondrial OMM is permeable to small molecules, whereas the inner membrane is 
not. This allows the establishment of a proton gradient and membrane potential which drive 
ATP production in OXPHOS. Small molecules which function within the matrix are transported 
across the IMM via channels and pores10. Although mitochondria contain their own genome, 
some 1,500 proteins (approximately 99% of mitochondrial proteins) are encoded by nDNA11. 
Since proteins are not able to pass freely across either the OMM or IMM, these proteins are 




Figure 1-1 Mitochondrial Structure and Function A Mitochondria are involved in a wide range of functions, ranging 
from cellular signalling and health through biosynthetic pathways and energy production, as summarised here. 
These functions are often a result of the unique mitochondrial structure: mitochondrial are surrounded by two 
membranes, the outer and inner mitochondrial membranes (OMM, IMM) which separates the organelle into 
distinctive environments, the matrix and inter-membrane space (IMS). B mtDNA encodes 37 genes on a double 
stranded, circular genome. 13 proteins, all part of the OXPHOS pathway are punctuated by 22 tRNAs (red) (made 
with reference to MITOMAP.org) C Oxidative Phosphorylation (OXPHOS) is performed by proteins in the electron 
transport chain (ETC) in the inner mitochondrial membrane (IMM), and most of these multi-subunit complexes is 
made up of proteins encoded by both the mitochondrial and nuclear genomes, as summarised in the table below. 
1.1.2 OXPHOS  
Given the importance of cellular energy production through OXPHOS, mitochondrial health is 
central to cellular homeostasis. ATP generation is the result of electron transport between 
five multi-subunit protein complexes, also called the electron transport chain (ETC), Figure 
1-1C. Electrons enter the ETC via NADH at complex I, and succinate at complex II, ultimately 
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being transported to the terminal electron acceptor, oxygen, at complex IV. Electron transport 
is coupled to proton pumping into the IMS, generating a proton gradient between the IMS 
and the matrix. The resulting proton motive force drives ATP synthesis at the F1F0-ATPase.  
1.1.3 mtDNA 
The mitochondrial genome is a high copy number closed circular molecule of double stranded 
DNA distinct from the nuclear genome. The size of the mtDNA molecule is highly variable 
between species - in humans, it takes the form of a 16,569 bp genome encoding 22 tRNAs, 
2 rRNAs and 13 proteins6, Figure 1-1B.  mtDNA is present in hundreds to thousands of copies 
per cell13 and packaged in nucleoids, IMM associated structures responsible for the 
regulation, maintenance and transcription of mtDNA. mtDNA is transcribed into a long 
polycistronic RNA by mitochondrial RNA polymerase from the light and heavy strand 
promoters (LSP, HSP) respectively14. Not containing introns, mtDNA also encodes a higher 
density of information than nDNA and genes in mtDNA are interspersed with tRNAs, so-called 
‘tRNA punctuation’. The transcribed polycistronic RNA is processed into mRNAs and 
functional RNAs before translation by the mitochondrial ribosome15.  
Mitochondria have high levels of reactive oxygen species (ROS), a by-product of OXPHOS, 
resulting in a much higher rate of mtDNA damage in comparison with nDNA. This high rate of 
sporadic mutation in mtDNA results in a state of “heteroplasmy” where not every copy of the 
mtDNA is identical. mtDNA repair mechanisms, though poorly understood, are recognised to 
be limited in comparison with nDNA repair. Mitochondria have an absence of efficient double 
strand break (DSB) repair, any evidence for homologous recombination (HR) being seen as 
controversial in the field16. Together, these result in a particularly high mutation rates for 
mtDNA. The high copy number nature of mtDNA means that damage to mtDNA often leads 
to clearance rather than repair17,18. Mitochondrial genetics impact the inheritance, genotype 
and presentation of mitochondrial diseases, and mtDNA and mitochondrial genetics will be 
detailed explicitly in the context of mitochondrial diseases in section 1.2.2.  
1.2 Mitochondrial disease  
Given the crucial role of mitochondria in OXPHOS function, it is not surprising that mutations 
in mitochondrial genes can have severe consequences for the maintenance of cellular energy 
levels. All 37 genes in mtDNA encode or aid biosynthesis of the proteins of the OXPHOS 
pathway which is complemented by nuclear encoded subunits19 and although just 1% of the 
mitochondrial proteins are encoded in mtDNA, four out of the five complexes in the OXPHOS 
pathway contain mtDNA-encoded subunits, Figure 1-1C. Consequently, mutations in both 
nuclear and mitochondrial genomes can result in a severe class of incurable mitochondrial 
5 
 
diseases. Mitochondrial diseases have a range of clinical manifestations, broadly the result 
of defective OXPHOS. 
1.2.1 A brief description of mitochondrial diseases 
Although mitochondria were not discovered until 189020, the first mitochondrial disease was 
described almost two decades earlier in 1871 by Theodor Leber, a German ophthalmologist. 
Leber documented a group of young men with sudden loss of central vision, naming the 
condition Leber’s hereditary optic neuropathy (LHON). It was not until 1972 that LHON was 
linked to a mitochondrial dysfunction21; LHON remains one of the most prevalent 
mitochondrial diseases worldwide today.  





The 1970s and 1980s saw the beginning of the study of mitochondrial medicine, aided by 
the sequencing of the mitochondrial genome in 19816. The first link between a mitochondrial 
disease and mtDNA mutations were shown by Wallace in 198822 and there are now over 200 
reported pathogenic mutations in mtDNA registered in the online archive Clinvar23. The most 
recent study from the North of England calculated that 1 in 4,300 adults in the studied area 
suffer from a mitochondrial disease caused by either a nuclear (2.9 in 100,000) or mtDNA 
(1 in 5,000) mutation24. 1 in 200 people are estimated to be carriers of mitochondrial 
disease-causing mutations. Table 1 summarises some of the most common mitochondrial 
disease-causing mutations, including their associated genotype and clinical presentation. 
There is an apparent disconnect between the prevalence and notoriety of mitochondrial 
diseases which might be explained by their varied clinical presentation25. Where some 
pathogenic mutations only impact one tissue or organ (e.g. LHON), others are progressive 
multi-systemic diseases resulting in muscle weakness (myopathy), impacting the brain 
(encephalopathy) and heart muscle (cardiomyopathy), and resulting in major disability and 
often premature death. Individuals with the same genotype will often present differently 
clinically, meaning this class of diseases perhaps do not appear to sit naturally together. 
Although the onset of some mitochondrial diseases is in adulthood, most mitochondrial 
diseases emerge clinically at younger than 18 months and the majority before 18 years of 
age, meaning these rare diseases are often also diseases of childhood. 
1.2.2 mtDNA and disease  
Inherited disease-causing mtDNA mutations have been shown to be either homoplasmic, 
where near to 100% of mtDNA copies carry the mutation, or heteroplasmic, where the 
mutation is carried by a subset of the total mtDNA. Additionally, mutations can affect single 
nucleotides as with the NARP and Leigh causing m.T8993C/G mutation, and large deletions, 
such as the 5 kb KSS, PEO and PS causing ‘common deletion’, Figure 1-2A. The percentage 
of total mtDNA copies that carry a certain mutation confers the functional penetration, the 
severity of phenotype experienced by mitochondrial disease sufferers, in a phenomenon 
known as the threshold effect, Figure 1-2B26,27. In general, mtDNA mutation load above ~70% 
is required to present a severe phenotype, though this threshold is disease specific. For the 
m.T8993TG mutation in the ATP Synthase gene ATP6, a mutation load of less than 70% is 
asymptomatic; 70 – 90% mutation results in neuropathy, ataxia and retinitis pigmentosum 
(commonly known as NARP syndrome); and more than 90% results in Leigh syndrome (see 
Table 1 for more examples). In general, homoplasmic mtDNA mutations have only mild 






Figure 1-2 mtDNA and disease A A map of mtDNA detailing the most common disease-causing mutations, 
mentioned in Table 1 and the diseases they cause B A heteroplasmic distribution of mtDNA can still contain some 
disease-causing mutation encoding copies (blue) and result in healthy mitochondrial activity, left. Mitochondrial 
diseases display a disease-specific thresholding effect whereby only mutations above a certain threshold impact 
mitochondrial function, right. C Genotypic drift, that is to say a change in the mtDNA mutation load, is evident 
through individuals lives and bodies due to random mtDNA segregation at mitosis. The new cell will replicate the 
sub-set of mtDNA copies it receives, sometimes resulting in a mutation load above a disease-causing threshold. 
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A certain amount of genotypic drift means that the thresholding effect is also clear within 
individuals throughout their body, or indeed during an individual’s lifespan28,29. During 
mitosis, mitochondria and mtDNA segregate randomly, resulting in an asymmetrical 
distribution of mutated mtDNA copies between daughter cells, Figure 1-2C. Some mtDNA 
mutations also show phenotypic tissue specificity. For example, mutations in tRNAIle cause 
deafness but have no apparent effects elsewhere30. 
mtDNA is maternally inherited. Paternal mtDNA is ubiquitin labelled and degraded in the early 
stages of embryogenesis. As such, only mothers with mutations in mtDNA can pass on 
mitochondrial diseases, whereas disease-causing mutations in nDNA can be inherited from 
either parent. The heteroplasmic mix of mtDNA in the oocyte results in stochastic inheritance 
where mtDNA is randomly distributed in the ova of mitochondrial disease sufferers, meaning 
that offspring inherit only a random sample of maternal mtDNA. In this phenomenon, known 
as the genetic bottleneck, this small sample of mtDNA is then rapidly replicated, and results 
in vast phenotypic differences between generations due to the variable load of mutated 
mtDNA and the phenotypic thresholding effect31,32.  
Although complex in isolation, these factors intersect to give discrepancies in the clinical and 
biochemical presentation of mitochondrial diseases. This makes their diagnosis, and 
therefore treatment, very challenging. 
1.2.3 The complexities of treating mitochondrial diseases 
The complex genetics of mitochondrial diseases are just one of the many factors contributing 
to the barriers to the development of effective treatments25. A lack of understanding and 
expertise by medical professionals, alongside no standardised regime for diagnosis can often 
leave sufferers undiagnosed33. This is compounded by the biochemical complexity of the 
diseases – often patients with the same mutations will respond differently to biochemical 
analyses34. Though developments in high-throughput -omics and bioinformatic technologies 
are presently aiding the more comprehensive characterisation of mitochondrial pathways, 
remaining gaps in our understanding of mitochondrial biology also impact medicine and the 
identification of targets for the development of disease treatments35.  
Randomised double-blind clinical trials form a core component of many drug development 
pipelines. However, as with many rare diseases, traditional trial design often isn’t appropriate 
for mitochondrial disease treatments. Recruiting for trials is complicated by the lack of large 
group numbers - it is often impossible to find multiple patients with same genetic defect, 
mtDNA load and functional penetration. Assessment of drug efficacy is also impacted by a 
lack of robust biomarkers, also impacting diagnosis and monitoring of disease progression 
(36 and personal communication, Mitochondrial medicine conference, 2018). 
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A number of stories relating to mitochondrial diseases have been covered in the mainstream 
media in recent years, mostly due to difficulties and controversies surrounding treatment 
options. A lot of media attention was given to one recent example in 2017 culminating in a 
High Court legal case between Great Ormond Street Hospital and the family of a 
mitochondrial disease sufferer37. Charlie Gard was an infant who had mtDNA depletion 
syndrome resulting from mutations in a gene (RRM2B) of which there had only been 15 
recorded previous cases. This story brings together several of the difficulties surrounding the 
treatment of mitochondrial diseases. Due to the rare nature of his condition, there have been 
no treatments developed for the mitochondrial disease which Charlie Gard suffered. The only 
potential option, an experimental treatment, was unfortunately offered too late at which point 
doctors refused treatment in the best interests of the infant. With serious and rare diseases 
such as these, there not only needs to be continued study of basic mitochondrial biology and 
development of treatments, but also communication and connection between individuals in 
the mitochondrial disease field. It is only with a consensus on the importance of idea and 
knowledge sharing between clinicians and researchers that we will enable better 
understanding of diseases and treatment regimens to positively impact the lives of 
mitochondrial disease sufferers. 
1.2.4 Available and emerging treatments for mitochondrial diseases 
At present, mitochondrial diseases are incurable. Treatment largely focusses on individually 
tailored symptom management through exercise and supplementing diet with vitamins, 
enzymes and antioxidants38,39. For example, the MELAS m.A3243G mutation results in a 
dysfunction in the glutamate pathway. Switching to a ketogenic (high fat, low carbohydrate) 
diet in patients can have a significant impact on motor function40. However, across 
mitochondrial diseases there is much contradiction in the literature and it is difficult to 
predict the success of dietary and exercise-based interventions41. 
Throughout the timeline of this project, clinical trials have been ongoing for several drugs to 
improve cellular energy function. NeuroVive Pharmaceuticals currently have an NAD+ 
modulator (KL1333) in phase 1 trialsi. The same company also has several drugs in pre-
clinical trials. Several important technological advances have also been made regarding 
mitochondrial disease related vision loss, such as with LHON. GenSight Biologics have 
successfully treated the eyes of LHON model mice with adenoviral vector injection, 
expressing a mitochondrial targeted wildtype ND4 to recover lost function. They are currently 
                                                     
i Clinicaltrials.gov identifier: NCT03056209 
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undergoing clinical trials in humans ii. In 2018 there was also a successful trial to treat 
damaged retina in humans with age-related macular degeneration with engineered stem 
cells42, a technology which could be adapted for LHON patients. However, it remains to be 
seen whether tools such as these could be applied to other areas of the body; these 
treatments both benefit from the unique accessibility of the eye, and its immune privileged 
status - the eye does not have the same system for inflammation as the rest of the body43.  
1.2.5 Pre-implant genetic diagnostics and mitochondrial replacement therapies  
Given the lack of successful treatments for mitochondrial diseases, pre-implant genetic 
diagnostics (PGD) are relied upon by mtDNA mutation carriers who wish to have a child. PGD 
minimises the risk of passing on pathogenic mtDNA mutations by screening in vitro fertilised 
oocytes. However, there are several shortcomings with this process, including a number of 
ethical concerns. Given the random segregation of mtDNA in mitosis, the mtDNA of the tested 
blastomere might not be representative of the embryo as a whole. Moreover, given the 
possibility for heteroplasmy shifts, it is complex to decide the mutation load cut-off for an 
acceptable embryo. The conundrum behind both of these factors can be summarised to 
questioning whether, when there is still a risk of serious harm to the future child, is it ethical 
to still offer assisted reproductive therapies to a mitochondrial disease carrier wishing to 
conceive44? These concerns highlight the importance of informed consent for mitochondrial 
disease sufferers and proper genetic counselling45. Besides these shortcomings, PGD is very 
useful for some. However, where a mtDNA mutation is homoplasmic, or where after several 
rounds tested embryos are all unacceptable for implantation, PGD is unsuitable. In these 
cases, some individuals opt for oocyte donation. Unfortunately, this can often require long 
wait times for suitable oocyte donors, and some do not see this as an acceptable alternative. 
In 2017, the UK Human Embryology and Fertility Agency (HEFA) approved mitochondrial 
replacement therapy (MRT) by nuclear transfer for mothers carrying mtDNA mutations, 
making the UK the first country to approve the technique46. This development was widely 
covered in the press at the time, referred to as “three parent families”. Ethical concerns from 
families, experts and the public included conversations on whether this would make it more 
acceptable to genetically engineer offspring based on non-medical grounds, raising the 
importance of involvement of the public in ethical debate surrounding genome engineering. 
Despite, or perhaps because of this debate, the technique seemed to be widely accepted by 
the public47,48. 
                                                     
ii Clinicaltrials.gov identifier: NCT03293524 
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There are several methods for MRT, with pronuclear transfer and maternal spindle transfer 
being the most popular. MRT was first developed in the 90s as an infertility treatment after 
IVF clinics found that using a mitochondrial donor improved success rates49. The technique 
was stopped following a US Food and Drug Administration (FDA) request for further 
investigations into the technique, which was never completed. Although mitochondrial 
replacement therapy is now UK HEFA approved, it will be important to monitor these 
individuals’ quality of life. In particular, there is an unknown impact on mitochondrial-nuclear 
crosstalk50 and research in mice has highlighted a potential for corrected mtDNA 
heteroplasmy to shift back to mutant genotype51. 
PGD and MRT offer some hope for carriers of mitochondrial diseases who wish to have 
unaffected children. However, it is important to remember that these fertility techniques are 
still not suitable for all: some individuals might decline on ethical grounds52,53, and they are 
no use for individuals already suffering from mitochondrial disease in somatic cells.  
1.3 Tools for the manipulation of mtDNA 
1.3.1 Motivation 
Tools for the manipulation of nuclear DNA (nDNA) have expanded our understanding of 
replication, transcription and gene expression in health and disease. Given the unique 
structure and organisation of mtDNA, and its role in mitochondrial disease (as summarised 
above), the development of mitochondrial equivalents of nuclear molecular genetics 
techniques remains an important, unmet challenge. Furthermore, expanding understanding 
of mitochondria and mtDNA could have therapeutic potential with a view to meet the 
challenges highlighted in the previous section. To this end, a growing body of work has 
successfully developed mtDNA targeting nucleases, including mitochondrial restriction 
endonucleases (MitoREs), Zinc Finger Nucleases (MitoZFNs) and TALENs. Additionally, 
several more controversial studies have also focussed on the mitochondrial targeting of 
oligonucleotides. However, development of tools for the interrogation of mitochondrial 
genomes is not trivial, and it is still not possible to easily manipulate mtDNA. 
The main barriers to developing mtDNA-targeted tools are a consequence of mitochondrial 
structure: tools must be correctly trafficked within the cell and cross the OMM and IMM into 
the dynamic mitochondria. This is particularly difficult for large complexes. Proteins can 
usually be quite easily directed to the mitochondria through the addition of a mitochondrial 
targeting peptide sequence (MTS), however equivalents for polynucleotides remain unclear. 
Regardless of these challenges, an efficient and versatile method for manipulation of 
mitochondrial genomes would have a significant impact on our understanding of 
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mitochondrial biology. Moreover, there is potential for these techniques to be used as 
therapies for mitochondrial diseases. One could imagine the potential for an alternative to 
the MRT IVT techniques, or a gene therapy which could be used in the somatic cells of an 
individual to ameliorate symptoms in a tissue-specific manner and not be passed on to future 
generations. 
1.3.2 Heteroplasmy purification 
Heteroplasmy purification provides the clearest illustration of the therapeutic potential for 
mtDNA targeting tools. Due to the phenotypic threshold effect, a small change in mutant 
mtDNA load can result in a great change in the clinical presentation of a mitochondrial 
disease. Indeed, much of the work in this field has focussed on developing tools which 
selectively degrade sub-populations of mtDNA on the basis of sequence towards 
heteroplasmy purification, Figure 1-3. A cell heteroplasmic for a mtDNA mutation has a 
balance of mutated and wild-type mtDNA molecules. When the number of mutated mtDNA 
molecules is above a certain mutation-specific threshold, mitochondrial function is 
compromised. mtDNA editing techniques selectively cleave mutated mtDNA copies, which 
are degraded by the mitochondria, rather than being repaired17,18. The remaining wild type 
mtDNA is replicated to re-establish mtDNA copy number. This results in a heteroplasmy shift 
towards a ‘healthier’ mitochondria. A complete removal of mutated mtDNA results in mtDNA 
homoplasmy. 
 
Figure 1-3 Heteroplasmy purification involves the selective degradation of mutated (here blue) copies of mtDNA 
based on their sequence. This can be achieved via anti-sense RNAs, mitochondrial-targeted restriction 
endonucleases (REs), TALENs, zinc finger nucleases (ZFNs) or, theoretically, the CRISPR machinery. Following 
degradation of mutant mtDNA copies, the remaining ‘healthy’ (here black) mtDNA population is replicated to 
restore mtDNA copy number, resulting in a ‘healthy’ mitochondrion. 
Heteroplasmy purification has been successfully utilised in cells grown in culture and a 
number of model organisms with endonucleases expressed and targeted to mutant mtDNA. 
These include MitoREs and programmable nucleases including ZFNs and TALENs, which will 




1.3.3 Mitochondrial protein import is critical for tool use 
Developing strategies for the specific targeting of endonucleases to the mitochondria 
requires an appreciation of natural mitochondrial protein import pathways. Nuclear encoded 
mitochondrial preproteins are translated in the cytosol, containing a mitochondrial targeting 
sequence (MTS) which directs protein import into the appropriate mitochondrial 
compartment: namely the OMM, IMM, IMS, or the matrix. Most matrix targeted proteins 
contain a cleavable n-terminal MTS, often in the form of an amphipathic α-helical leader 
peptide, approximately 15-50 amino acids in length54 and recognised by proteins throughout 
the TOM/TIM pathway55. Termed the ‘presequence import pathway’, matrix targeted protein 
import is considered the classical import pathway. Preproteins in the cytosol are imported 
across the OMM by a translocase of the outer mitochondrial membrane (TOM) complex which 
delivers proteins into the IMS. A translocase of the inner mitochondrial membrane (TIM) 
complex delivers them into the matrix where the MTS leader peptide is cleaved off by the 
mitochondrial processing peptidase (MPP)56. Additional pathways which target proteins to 
other compartments of the mitochondria rely on internal MTSs. As they are not directly 
relevant here, these pathways will not be covered in this thesis; see Wiedemann & Pfanner 
for a recent review57. 
 
Figure 1-4 The presequence import pathway directs proteins with an MTS from the cytosol into the mitochondrial 
matrix. The schematic above shows import of an unfolded protein across the OMM and IMM following recognition 
of an N-terminal peptide MTS sequence (light green) by components of the TOM complex (1). Following 
translocation through TOM and TIM (2), the N-terminal MTS is cleaved by the mitochondrial processing peptidase 
(MPP, dark green) in the mitochondrial matrix (3). 
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1.3.4 Targeted mitochondrial protein import 
Mitochondrial protein import pathways are sufficiently understood to be harnessed for 
directed import of non-native proteins58. To this end, a naturally occurring MTS leader peptide 
sequence is cloned upstream of the protein of interest so that the MTS is expressed in-frame 
with the N-terminus of the protein of interest. The MTS from cytochrome c oxidase subunit 
viii (COX8A) is one of the most widely used in commercially available mitochondria-targeting 
constructs and comprises a 29-residue helix. The 69-residue mitochondrial targeting 
sequence from Neurospora crassa ATPase subunit 9 has also been characterised59 and used 
to target proteins of  interest to mitochondria60. Some MTSs display unique features, such as 
controlled cellular localisation. The mammalian ATG4D contains a cryptic 42-residue MTS, 
downstream of a caspase cleavage site. Upon cleavage by caspase, such as during cell 
stress, the cryptic MTS is revealed, and ATG4D localisation shifts from cytosolic to 
mitochondrial61.  
The relative simplicity of MTS addition has meant that targeting proteins to mitochondria in 
this way has become widely used since it was first shown in 198862. In the first example of 
allotopic rescue of a disease model, the low ATPase activity of S.cereviciae carrying a 
mutation in the ATP8 gene was rescued by expressing a functioning subunit appended to an 
MTS. Allotopic rescue of mutated OXPHOS proteins has also been shown in human cells. 
Targeting a functional ATP6 gene to mitochondria NARP cybrids carrying the m.T8993C/G 
mutation) successfully compliments complex V and rescues ATP synthesis and cell growth63. 
It is this same method which is being used to rescue defective ND6 function in LHON patients, 
as mentioned in section 1.2.4. MitoREs and programmable nucleases including ZFNs and 
TALENs, have also been targeted to the mitochondria, a brief review of which will be given in 
sections 1.3.5 and 1.3.6. 
1.3.5 Mitochondrial type II restriction endonucleases 
Type II Restriction Endonucleases (REs) have been widely used in molecular genetics since 
the 1970s to generate targeted DSBs in DNA64. Originally found in bacteria, REs defend 
against invading pathogenic DNA by cleaving upon recognition of a restriction site, a DNA 
sequence usually 4-8 nts in length65. There have been many successful attempts at targeting 
type II REs to mitochondria for heteroplasmy purification. The first demonstrations of this in 
cultured cells were the transient expression of PtsI66 and SmaI67 in disease model cybrid cell 
lines, published in 2001 and 2002 respectively. Cybrids (cytoplasmic hybrids) are cell lines 
which model mitochondrial diseases by fusing the patient mitochondria with immortalised 
cell lines. In both cases, a shift in heteroplasmy was observed, and the wild-type mtDNA 
population expanded.  
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Mitochondria-specific delivery of REs in animal models was first shown in 2002; EcoRI was 
in vivo electroporated into hamster skeletal muscle, showing a decrease in cytochrome c 
oxidase activity and no measurable off target impact in nuclei67. Heteroplasmy purification 
was also shown with recombinant viral transfection of ApaLI in heteroplasmic NZB/BALB 
mice muscle and brain tissues68, later targeting liver and heart69. Germline specific 
heteroplasmy purification using MitoREs has even shown the ability to prevent transmission 
of mtDNA mutations to offspring in NZB/BALB mice70. 
Although delivery mechanism into cells and living organisms differed in the publications 
highlighted above, in each case mitochondrial targeting was achieved by cloning the RE 
protein coding sequence downstream from the COX8A MTS. Though MitoREs can efficiently 
target mtDNA and be used for heteroplasmy purification, naturally occurring target sites 
match few clinically occurring pathogenic mtDNA mutations, and even fewer without off-
target specificity. Indeed, of the over 200 known mtDNA mutations, only the NARP/Leigh 
causing m.T8993C/G has been shown to be targeted by naturally occurring REs70. 
1.3.6 Mitochondrially targeted engineered nucleases (ZFNs, TALENs) 
Although naturally occurring REs have a broad range of target sequences, their short 
sequence specificities often occur several times in a genome. Moreover, it is extremely 
difficult to re-engineer proteins, such as REs, with no clear structure-sequence 
determinants71. 
Engineered nucleases fuse a programmable DNA recognition domain to a nuclease domain, 
providing more sequence specificity and fewer off-target effects. As well as being widely 
influential in molecular genetics, engineered nucleases can be used to expand the available 
endonucleases matching pathogenic mtDNA mutations as they can be engineered to target 
almost any sequence. Programmable DNA recognition domains including zinc finger and TAL-
like effector domains have both been used to target mtDNA, as summarised below: 
 Mitochondrial Zinc Finger Nucleases 
Zinc finger nucleases (ZFNs) are chimeric proteins containing a modular zinc finger DNA 
recognition domain and an endonuclease domain. Zinc finger motifs are naturally occurring 
Cys2His2 DNA interacting domains found in many transcription factors. Each designed to 
target a 3nt codon, a string of ZFs can be cloned together to target a DNA sequence, often 
about 20 base pairs long. DSB formation is usually through the dimeric RE FokI, achieved by 




MitoZFs have been designed to target both large scale deletions and single nucleotide 
mutations in mtDNA74, in addition to being used to bring alternative functionalities to mtDNA 
such as sequence specific methylation through fusion of methyltransferases to MitoZFs75. 
Fusion of MitoZFs targeting adjacent sequences to the dimerising endonuclease FokI has 
shown heterodimeric MitoZFNs to be able to recognise 1nt change in a 12nt sequence76.  
In cybrid cells and animal models, MitoZFNs can be designed and used for heteroplasmy 
purification and a rescue of disease phenotype. MitoZFNs designed to target mT89993G and 
the mtDNA common deletion showed a shift from mutant to wild-type mtDNA, and a rescue 
of oxygen consumption rate and functioning respiratory complex subunits77. 
 Mitochondrial TAL-like effector nucleases 
TAL-like effector nucleases (TALENs) are engineered endonucleases which target specific 
sequences on DNA by utilising the 34 amino acid repeat-containing TALE domains from the 
agrobacterium Xanthomonas78. Each TALE domain recognises a single nucleotide, and 
sequences of interest are targeted by ‘building’ TALE proteins. As with ZFNs, TALENs are often 
heterodimeric, utilising the split FokI for endonuclease activity. MitoTALENs have been 
developed which localise to the mitochondria and induce DSBs in mtDNA in a sequence 
specific manner, as shown in patient derived cybrid cell lines containing the common 
deletion79 and the m.T8993C/G point mutation80. In each case, eliminating mutated mtDNA 
copies rescued the oxygen consumption rate of the patient derived cells, a result of 
heteroplasmic purification. As with MitoREs, MitoTALENs have also been used to prevent 
germline transmission by clearing mutated mtDNA in mouse oocytes70. 
1.4 The case for a MitoCRISPR system 
Although MitoZFNs and MitoTALENs offer a much wider range of sequence specificity than 
MitoREs, there are still several shortcomings which hinder their application. Firstly, although 
there have been several advances in the cloning ZFN and TALEN libraries in recent years, 
engineering and verifying engineered nucleases can still be time consuming. Secondly, ZFN 
and TALENs have some inherent limitations which impact the breadth of sequence which can 
be targeted: TALENs have a requirement for a thiamine at the start of a sequence, and ZF 
modules do not exist for every combination of 3 nucleotides. There are also several issues 
relating to the cellular delivery and mitochondrial targeting of engineered nucleases. It has 
been shown that large protein complexes are inherently challenging to import into the 
mitochondria81 and indeed the DNA coding sequence for TALEN is likely to exceed the AAV 
size limit of 5 kbp, making viral delivery to cells complex if not impossible80. Finally, ZFs are 
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trafficked to the nucleus due to internal nuclear targeting sequences. It is important that a 
mtDNA targeting tool avoid off-target activity on nDNA. As such, nuclear export sequences 
such as the murine minute virus NS2 sequence in addition to mitochondrial targeting 
sequences can be included but must be considered to add an extra layer of complexity. 
Although some good progress has been made with regards to mitochondrial targeted 
endonucleases, the tools available for the manipulation of mitochondrial genomes are still 
meagre in comparison to those available for nuclear DNA. This project aims to fill the gap in 
the currently available technologies for the study of mtDNA by working towards making the 
varied toolbox of CRISPR methods available for mitochondrial genetics. 
The following section firstly contextualises the fast-moving field of CRISPR research before 
giving a brief overview of the mechanism of some of the most commonly used CRISPR 
systems, highlighting several applications which might be made available for the 
manipulation of mtDNA. 
1.4.1 “A new era of biological understanding and control”82 
Following the first published reports showing their potential in 2013, CRISPR systems have 
quickly revolutionised molecular genetics by providing a quick and convenient method for 
efficiently targeting proteins to almost any short DNA sequence. CRISPR has proven an 
incredibly adaptable and versatile tool, hurrying in a so-called ‘new era of biological 
understanding and control’ which has quickly offered a whole new toolbox for manipulation 
of DNA82. 
With applications from basic science to the clinic, the impact of CRISPR has been such that 
some scientists have, somewhat esoterically, begun calling molecular genetic techniques 
pre-2013 as ‘BC’ (to mean ‘before CRISPR’). It would be foolish to suggest that now in the 
CRISPR era there is no place for ‘traditional’ techniques, but the advantages of CRISPR over 
other genome editing techniques – namely high accuracy, efficiency and flexibility – has led 
to a surge in its implementation, giving an unparalleled level of control over nucleic acids 
with implications in the understanding of: genome editing and regulation, modification of 
genomes, control of living systems and much more. CRISPR tools are fast becoming standard 
laboratory techniques and a huge amount of research funding and a corresponding surge in 
literature has been published on the topic. In 2007, 12 papers were published that tagged 
‘CRISPR’ in pubmed. This rose to 283 papers in 2013, and an astonishing 3012 in 2017. 
Although the term CRISPR is now synonymous with its applications in genome engineering, 
in their natural form, the clustered regularly interspaced short palindromic repeats (CRISPR) 
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system is a bacterial and archaeal acquired immune system that works by specifically 
cleaving pathogenic DNA such as that from invading viruses and plasmids.  
1.4.2 CRISPR as adaptive immunity  
First identified in 1987 by their characteristic short repetitive DNA sequences interspersed 
with random sequences at regular intervals83, the biological significance of CRISPR arrays 
was unknown until the mid-to-late 2000s. It was then that they were recognised to be part of 
an almost ubiquitous acquired immune response found in 40% of all bacterial species and 
90% of archaeal species in one iteration or another84. The random sequences in those first 
observations are now known to be ‘spacers’ – sequences acquired from invading pathogenic 
DNA. Transcription and processing of the CRISPR array generate CRISPR guide RNAs (gRNAs) 
which target effector nucleases to form a DNA/RNA hybrid (R-loop) at the target sequence, 
displacing the non-complimentary DNA strand and cleaving the two strands of DNA, Figure 
1-5. Protospacer adjacent motifs (PAMs) in invading DNA are recognised by the CRISPR 
nuclease and prevent the cleavage of self-DNA.  
 
Figure 1-5 CRISPR DSB formation CRISPR ribonucleoprotein (RNP) complex formation on a dsDNA target requires 
recognition of a short protospacer adjacent motif (PAM, orange) followed by target sequence (light green) 
unwinding and CRISPR gRNA binding to form an R-loop. In the type IIA Spy Cas9 system, two nuclease domains, 
HNH and Ruv C cleave (red arrows) the backbone of the target and non-target strand, respectively, forming a 
blunt DSB.  
The study of CRISPR biology has been extensive over the past few years, revealing a growing 
family of proteins. Due to their rapidly changing nature and fast evolution (through its 
function, the CRISPR array is always acquiring new DNA sequences), CRISPR-cas genomic 
loci show a great diversity in sequence which has been challenging to classify. Nevertheless, 
a classification of CRISPR systems has emerged into 2 classes, 6 types and up to 33 sub-
classes 85,86 mainly on a basis of the phylogeny of cas genes but also the crRNA composition. 
Although many CRISPR family proteins are being used for a wide range of applications in 
molecular biology, the type IIA and VA are most common, and the main features of both are 
summarised in the following sections. Interestingly, the effector proteins of both type IIA and 
VA show functional similarity, both being roughly similar in size and jaw-like conformation 
containing a RuvC nuclease domain. Intriguingly, this functional similarity comes without a 
corresponding match at a sequence or structural level 87,88. 
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1.4.3 Type IIA CRISPR systems  
There are several naturally occurring type II CRISPR systems, separated into 3 sub-classes. 
It is the type IIA subclass, in particular those from Streptococcus thermophilus (Sth) and 
Streptococcus pyogenes (Spy) which have been the most widely used for genome 
engineering. The type IIA nuclease is Cas9, comprising two nuclease domains, the RuvC-like 
and HNH domains, that generate blunt ended DNA double strand breaks, targeting the 
displaced and target strand respectively, Figure 1-5.  
In naturally occurring CRISPR systems, Cas9 is guided by two RNA elements; the CRISPR RNA 
(crRNA), which directs Cas9 sequence specificity, and the trans-activating CRISPR RNA 
(tracrRNA), which mediates RNA/Cas9 contacts. However, these RNA components can be 
replaced by a single integrated synthetic alternative, the guide RNA (gRNA), and these 
integrated gRNAs have been widely adopted when using CRISPR for molecular genetics. The 
gRNA targets a 19-22 nt sequence and SpyCas9 has a 5′-NGG-3′ PAM requirement 89,90. 
Mismatches throughout target sequence impact specificity, and are not tolerated in the 8-12 
nt PAM-proximal seed region, due to mechanism of duplex unwinding and RNA-DNA duplex 
formation 91,92. 
The crystal structure of SpyCas9 in complex with gRNA and target DNA has been solved93, 
showing much of the gRNA to have extensive contacts with the Cas9 internal surface. It can 
be presumed that these interactions between the gRNA and Cas9 are crucial for optimal 
complex formation, and as a result optimal complex formation on DNA and positioning of the 
endonuclease domains and activity. However, the crystal structure also reveals some regions 
of the gRNA which are positioned externally from the Cas9 protein, which might be amenable 
to modification.  
1.4.4 Type VA CRISPR systems 
Cas12a, also referred to as Cpf1, is a type VA CRISPR endonuclease which naturally produces 
staggered nicks on DNA. There are several naturally occurring Cas12a systems from different 
species, of which the Lachnospiraceae bacterium (Lb) Cas12a and Francisella novicida (Fn) 
Cas12a have been shown to be suitable for mammalian cell genome engineering94. 
Containing a single RuvC endonuclease domain, Cas12a cleaves the two DNA strands in turn, 
resulting in a DNA DSB with a 5′ 3 nt overhang. Cas12a has a much smaller RNA than the 
type IIA Spy cr:tracrRNA. The Cas12a crRNA is naturally one-component, comparable to the 
designed gRNA. Cas12a also utilises a hairpin to mediate interactions between the 
endonuclease domain containing protein and the RNA but lies in the opposite direction to 
the Cas9 gRNA with the hairpin at the 5′ end of the protospacer sequence, Figure 1-6 bottom. 
LbCas12a has a 5′-TTN PAM requirement. A number of studies have solved the structure of 
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Cas12a95–97  which can inform potential structural modifications to the ribonucleoprotein 
complex. Figure 1-6 gives a comparison of the major features of the type IIA and VA systems. 
 
Figure 1-6 Comparing type IIA and VA CRISPR systems Top: Table comparing major characteristcs of type IIA and 
VA CRISPR systems Bottom: Schematic comparing RNA structures between type IIA and VA CRISPR systems. The 
main differences between the sgRNAs concern the structural component which mediates interactions between 
the sgRNA and nuclease. The type II sgRNA has a much larger structural component than type V, which is found 
3′ of the spacer in contract to the type V sgRNA which is 5′ of the spacer. 
1.4.5 CRISPR tools 
Genome editing using restriction enzymes, ZFNs, and TALENs has largely focused on the 
introduction of one or more DSBs to be repaired by the cell’s own repair mechanisms. 
Similarly, efficient generation of sequence-specific DSBs was perhaps the biggest initial 
revelation of CRISPR, widely becoming a standardised technique for creating knockout and 
mutant cell lines and model organisms. To this end, there was an initial boom of studies 
before the end of 2013, demonstrating CRISPR in: bacteria98; mammalian and patient-
derived cells 99–101; zebrafish102, mice103,104 and other model organisms. Several significant 
CRISPR studies also achieved increased on-target and reduced off-target DSB formation: for 
example, staggered nicks on DNA double the recognition domain and increase sequence 
specificity105.  
Without a template, DNA DSBs result in indels and mutations from non-homologous end 
joining (NHEJ) mediated repair. Much of the nuclear-targeted CRISPR toolbox has focussed 
on preferentially directing repair from a template via the homologous recombination (HR) 
pathway106. However, it is important for MitoCRISPR that we remember the distinct context 
of mtDNA. As highlighted in section 1.1.3, DNA repair mechanisms are not well understood 
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in mitochondria, and likely to be only a subset of those available for nuclear DNA 
maintenance.  
 
Figure 1-7 CRISPR toolbox includes: Nikases, where either one of the two endonuclease domains (RuvC, HNH) 
has been inactivated to form a single stranded break on DNA. These can be used separately or to introduce 
staggered nicks and broaden the specificity region; dCas9 where both RuvC and HNH endonuclease domains 
have been inactivated. These can be used to target functionalities to a DNA locus of interest including 
transcriptional control and fluorescent proteins; Regulation of CRISPR RNP formation, or RNP interaction with 
effectors, is also achieved through light and chemically induced complex formation. 
Although there may be potential for supplying a minimal HR cassette to the mitochondria, 
the potential for HR-repair is complicated by the absence of techniques to supply the DNA 
template. The applications of CRISPR systems have quickly expanded much beyond that of 
targeted DSB formation including break-less editing107, transcriptional regulation108, cellular 
imaging109,110, genome wide association studies (GWAS)111, building genetic circuits112, and 
much more.  
The HNH and RuvC nuclease domains can each be catalytically inactivated by point 
mutations. All three of the mutants — the double nuclease-null (dCas9) and the two nuclease-
null (D10A targeting RuvC and H840A, HNH) – localise to DNA with high sequence specificity. 
Furthermore, CRISPR complex formation has been tightly and spatial-temporally controlled 
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through split Cas9s, brought together by inteins113,114 or light and chemically inducible 
complex formation115–117.  
The enormous versatility of CRISPR systems has largely been thanks to the introduction of 
functional protein domains as fusion proteins. Several publications over the past few years 
have also proven that accessorising the gRNA structure to be a powerful tool, bringing in 
additional functionalities such as fluorescence and protein-interactions. This can be achieved 
for example through introducing protein interaction RNA sequences into the gRNA, such as 
bacteriophage MS2 hairpins which tightly bind MCP domains (MS2 bacteriophage coat 
protein domains), or S1m, an RNA structure which mimics biotin118,119. A unique function of 
the CRISPR system beyond protein-only DNA-targeting systems is the ability to bring together 
all three of the naturally encoded polymers (protein, RNA and DNA) into one ribonucleoprotein 
(RNP) complex. Based upon this, and the incredible versatility of the RNP, CRISPR has 
provided a fantastic platform on which to build an extensive toolbox for the interrogation of 
not just nDNA, but many other cellular processes.  
Although tools for the efficient and accurate generation of DSBs in mtDNA are useful, such 
as in heteroplasmy purification, and deepening understanding of mtDNA repair mechanisms, 
the expanded CRISPR toolbox offers even more novel functionalities for the understanding 
of mtDNA. dCas9 provides a protein chassis through which other effector proteins might be 
brought into proximity with a locus of interest; an excellent resource for understanding 
mtDNA-protein interactions. Tethering transcriptional enhancers and repressors to dCas9 for 
CRISPRa (activation) CRISPRi (inhibition) has been used for the understanding of gene 
function and might be interesting in a mtDNA context. Additionally, control and 
rearrangement of chromatin have also been studied using these tools. Although mtDNA 
packaging is distinct from the processes involved in nDNA packaging, a similar tool could be 
used to understand the structure of the mitochondrial nucleoid. Not all mutagenesis of DNA 
requires the formation of DSB. Tethering an adenosine deaminase to dCas9 results in an AT 
pair adjacent to a targeted site being mutated to a GC pair107. Given the limited complement 
of DNA repair proteins in the mitochondria, delivery of base editing machinery might be a 
possibility for targeted mtDNA mutagenesis. Finally, dCas9-GFP fusions have allowed the 
imaging of DNA loci110, and might be attractive as a tool for imaging specific mtDNA copies, 
potentially broadening understanding of the inheritance of mutated mtDNA (e.g. mtDNA 




1.5 Steps necessary to develop a MitoCRISPR system 
The overall ambition of the MitoCRISPR project is to design and evaluate a set of CRISPR 
tools to enable the manipulation of mitochondrial genomes. The development of this system 
will require the realisation of the following milestones, as summarised in Figure 1-8.  
1. Mitochondrial targeting of a CRISPR protein 
2. Mitochondrial targeting of a CRISPR guide RNA 
3. Proof of ribonucleoprotein complex assembly within mitochondria, and on mtDNA 
4. Proof of ribonucleoprotein complex activity on mtDNA in situ.  
 
Figure 1-8 MitoCRISPR project summary The four main steps required for the development of a MitoCRISPR 
system include 1 the targeted delivery of a CRISPR nuclease to the mitochondria by fusion to a peptide 
mitochondrial targeting sequence (MTS), 2 the targeted delivery of a CRISPR guide RNA (gRNA) to the 
mitochondria through fusion to a mitochondrial targeting structure (here, RNA), 3 the formation of a functional 
CRISPR ribonucleoprotein complex (RNP) inside the mitochondrial matrix on mtDNA, and 4 functional activity of 
the CRISPR RNP (this could be through cleavage activity, or another accessorised functionality). 
1.5.1 Mitochondrial targeting of CRISPR proteins 
The first aim of the MitoCRISPR project is the mitochondrial targeting of a CRISPR 
endonuclease protein. It is important that this is achieved without compromising 
mitochondrial viability, such as by causing fragmentation, or disturbances to mitophagy and 
OXPHOS. When this project was started, the most studied CRISPR endonuclease, particularly 
in the development of novel molecular genetics tools, was the SpyCas9. On the basis of 
extensive work targeting other proteins to the mitochondria through the addition of an MTS, 
initial work focussed on the modification of this protein for mitochondrial import, as detailed 
in Chapter 3. 
There are several ways in which a CRISPR protein might be delivered into the cell for 
subsequent trafficking to and import into the mitochondria, which can be broadly envisaged 
through the central dogma as being at the level of DNA, mRNA, or protein. Accordingly: DNA 
can be either stably expressed by incorporation into the genome, or transiently transfected 
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and expressed from a plasmid; the mRNA encoding the protein might be transiently 
transfected into the cell; the protein itself can be transiently transfected into the cell as a 
ribonucleoprotein (RNP) particle. Furthermore, reagents appropriate to each of these levels 
can be delivered into cells via a plethora of different methods, including (though not limited 
to) a range of commercially available lipid-based transfection techniques, electroporation, 
viral delivery mechanisms. 
1.5.2 Mitochondrial targeting of CRISPR RNAs 
The development of a CRISPR system for use on mitochondrial DNA requires the 
mitochondrial targeting of the gRNA. There are several ways through which this might be 
achieved, either harnessing natural mitochondrial RNA import machineries (reviewed below), 
or through non-natural means. The ability to modify the gRNA extensively has been shown, 
but little work had been done on the impact of modifications on complex formation and 
cleavage activity, which we aimed to interrogate through ensemble and single molecule 
biochemical techniques in Chapters 4 and 5.  
 Overview: ‘natural’ mitochondrial RNA import 
Section 1.3.4 described how the mitochondrial protein import pathway is sufficiently well 
understood to allow targeting of proteins of interest. In contrast, pathways for mitochondrial 
RNA import are poorly understood. Whilst multiple research groups have claimed to achieve 
mitochondrial targeting of RNAs120–123, there is not the same consensus of understanding as 
with protein import, and the existence of a dedicated pathway for mitochondrial import of 
RNAs is controversial 124,125.  
Whilst mitochondria contain a fully functional machinery for gene expression there is an 
incompatibility between mitochondrial and nuclear mRNA codon usage126. It is unlikely 
therefore that any imported mRNA would be translated inside the mitochondria. However, a 
number of functional non-coding RNAs (ncRNAs) are believed to be imported into the 
mitochondria, including tRNAs, the 5S RNA, MRP RNA, RNaseP RNA and mitochondrial micro 
RNAs (mitomiRs). Although whole transcriptome analyses of mitochondria and mitoplasts 
have confirmed the presence of these RNAs127,128, the mechanisms of import and impacts of 
these ncRNAs are still poorly understood124,129,130. 
1.5.2.1.1 Yeast tRNALys (tRK1) 
tRNA import illustrates the variability of naturally occurring RNA import between species. 
Mammalian mtDNA encodes all 22 mitochondrial tRNAs6; Yeast (S.cerevisiae) have one 
nuclear encoded tRNA, the tRNALys (tRK1)131; trypanosomes encode all their tRNAs on 
nDNA132. The nuclear encoded tRK1 is distributed unequally between the cytosol (97-98%) 
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and mitochondria (2-3%) in yeast133. Although the exact mechanism of tRK1 import into 
mitochondria is unknown, candidate protein import factors have been implicated. Enolase 
(ENO2P) binds tRK1, in doing so changing its stem loop structure, and delivers it to the 
OMM134. At the OMM, tRK1 binds pre-LysRS (the pre-curser of the mitochondrial lysyl-tRNA) 
which aids transport of tRK1 into the mitochondria135. The TIM/TOM complex is believed to 
be involved as an intact protein import machinery is required for tRK1 import136.  
 
Figure 1-9 Natural RNA import mechanisms Trypanosomes import all their tRNAs through TOM/TIM, whereas 
S.cerevisiae import just one, tRNALys. tRNALys import involves the protein factors enolase (ENO2P) and the pre-
curser of the mitochondrial lysyl-tRNA (pre-LysRS), and a functional protein import machinery.  Mammalian import 
of 5S ribosomal RNA (rRNA), mitochondrial RNase P RNA (MRP) and RNase P RNA (RP) occur through unknown 
mechanisms, though some proteins have been implicated. These include Rhodanese (Rhod) in the case of the 
5S ribosomal RNA (rRNA), and a potential role for PNPase in 5S, MRP and RP RNA import. 
1.5.2.1.2 5S RNA 
Although containing the sequences for two rRNAs, the 16S and 12S subunits of the 
mitoribosome, mtDNA does not contain the coding sequence for a 5S rRNA. The 
mitoribosome is poorly conserved between species137, and there is conflicting evidence over 
whether the a 5S rRNA is required for mammalian mitoribosome function. Some groups have 
suggested that the nuclear encoded 5S rRNA is imported into mitochondria, reporting 
interactions between 5S and the mitoribosome large subunit (LSU) and impacts on 
translation efficiency138–140. Contrastingly, cryo-EM structures have been solved of the 
mitoribosome without 5S rRNA141. In these structures, the LSU instead has mt-tRNAsPhe/Val 
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occupying the 5S location. The 5S rRNA contains key structural motifs (helix I, helix IV loop 
D) which are believed to direct its localisation to the mitochondria through interactions with 
the mitochondrial protein rhodanese, Figure 1-9138. Down regulation of rhodanese decreases 
mitochondrial localisation of 5S RNA and impacts translation by the mitoribosome139. 
Additionally, import of 5S rRNA into isolated mammalian mitochondria requires ATP and 
membrane potential142. 
1.5.2.1.3 RNaseP RNA 
Mammalian mtDNA is transcribed as a polycistronic RNA, with genes punctuated by tRNAs. 
tRNAs are processed by mitochondrial RNase P (MRP) which cleaves the 5′ tRNA leader 
sequence143. The nuclear equivalent of RNase P functions as an RNP with several protein 
subunits and an RNA subunit, the H1 RNA144. As with the mitoribosome 5S component, there 
are conflicting studies as to whether mitochondrial RNaseP requires an RNA component145 
or whether it is exclusively proteinaceous146. Despite this disagreement, there is compelling 
evidence that a stem loop structure from nRNaseP can direct import into the mitochondria 
regardless of whether it is required for mitochondrial RNaseP function147.  
1.5.2.1.4 RNase MRP RNA 
RNase MRP is mitochondrial RNA processing endoribonuclease, comprised of an RNA 
component, and several protein subunits, some shared with mitochondrial RNase P. RNase 
MRP has several nuclear functions including 5.8S rRNA processing and a role in yeast cell 
division. It was thought that primer processing by RNase MRP was necessary for initiation of 
mtDNA transcription148,149. However, further research has shown that other methods of 
mitochondrial transcription initiation are probably more likely, such as through G-quadruplex 
based priming150. Nevertheless, there is evidence of the RNase MRP 267nt lncRNA in the 
mitochondrial matrix. Although it remains unclear how the MRP RNA passes across the OMM 
and IMM, it contains a stem-loop structure which is recognised by PNPase151. PNPase is a 
homotrimeric 5′-3′ exoribonuclease, part of the mitochondrial RNA degradosome in the 
matrix. PNPase is also found in IMS and proposed to aid mitochondrial import of the 5S RNA, 
H1/MRP RNA/micro RNAs151,152 though the mechanism of this is unknown and more work is 
needed to confirm whether this is a genuine second role.  
 Synthetic methods for targeted mitochondrial RNA import  
Despite the conflicting evidence on the existence and mechanisms of mammalian RNA 
import, several studies have aimed to minimise the sequences of the reported nuclear 
encoded mitochondrial RNAs reviewed above with the aim of determining the minimal 
structural or functional motif(s) which direct their import122, Figure 1-10. It is worth noting 
that although all the RNAs mentioned in the previous section have publications to this end, 
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the work is rarely validated by independent study from other research groups, if at all. A brief 
summary is given below:  
1.5.2.2.1 Yeast tRNALys and F1D1 
The yeast tRNALys (tRK1) has been shown to be imported into isolated mammalian 
mitochondria153 and whole cells via binding of the pre-curser of the mammalian lysyl-tRNA 
synthetase, preKARS2154. tRK1 derived structures, screened for their ability to direct RNA 
import, have been shown to target RNAs to the mitochondria much more efficiently than the 
natural tRK1 structure122,123,142. Interestingly, many of these RNAs lose their ability to adopt 
a classical tRNA structure as they require the unfolding and re-folding of the tRK1 hairpins. 
The F1D1 RNA, Figure 1-10, derived from tRK1, is the structure found to have the highest 
import efficiency. Delivery of RNAs to mitochondria of a KSS cybrid cell line with F1D1 RNA 
has shown potential therapeutic potential; RNAs complimentary to mutated mtDNA 
specifically impacts mtDNA replication, resulting in a heteroplasmy purification effect155. A 
related control sequence, the AD RNA, does not have the same effect.   
 
Figure 1-10 Minimised RNA import motifs have been identified for tRK1, 5S rRNA, MRP RNA and RP RNA, the 
sequences of which are given here. Each of these motifs has been shown to be capable of directing RNA 
sequences of interest into the mitochondria.  
1.5.2.2.2 5S RNA 
As with tRK1, understanding the potential natural import of 5S RNA has aided the use of 5S 
RNA structures to recombinantly target RNAs to the mitochondria142. The 5S helix IV loop D 
and helix I, Figure 1-10, are required for import, and other structural components can be 
deleted without negatively impacting import138, instead being replaced by an RNA sequence 
of interest. As with tRK1 structures, 5S RNA structures have been shown to target desired 
RNA sequences to KSS cybrid cells and decrease heteroplasmy155. It is these structures 




1.5.2.2.3 RP and MRP hairpins 
Truncating RNase RP and MRP RNAs has allowed identification of similar approximately 20 
nt RNA hairpins in both RP and MRP RNA which direct mitochondrial import, Figure 1-10. 
Attaching these hairpins into non-imported RNAs can also target RNAs for import, as shown 
with GAPDH152. Wang et al showed that the presence of PNPase aids MRP/RP-directed 
delivery of RNAs into yeast and mammalian mitochondrial matrix where they can ameliorate 
a disease phenotype. Delivering RP-tRNAAAALys and RP-tRNAUURLeu to MERRF and MELAS cell 
lines respectively partially rescues their respective translation defects157.  
1.5.3 RNP complex assembly and action on mtDNA 
Once both CRISPR nucleases and RNAs have been selectively targeted to the mitochondria, 
it will be necessary to prove their colocalisation and ability to fold into a functional complex. 
Immunofluorescence could form the basis for this, though sensitive reporters, such as FRET 
mutants which demonstrate gRNA/CRISPR endonuclease complex formation, would be a 
valuable addition. The proof-of-principle experiment for MitoCRISPR will be to produce a 
heteroplasmy purification in a mitochondrial disease cybrid cell model - as has been achieved 
with MitoTALENs and MitoZFNs. 
1.6 Published attempts to develop a MitoCRISPR system 
When the MitoCRISPR project was started at the beginning of this PhD in 2014, there were 
no published attempts at developing a MitoCRISPR system, though the potential impact of 
such a system had been alluded to in a number of publications80,158,159. As our work and 
ideas have developed in Bristol, so they have for research groups elsewhere, and there have 
been several reviews and research papers demonstrating opinions and work towards the 
same objective in the intervening years. 
The first published attempt at developing a CRISPR machinery for mtDNA was in 2014. In 
“Efficient Mitochondrial Genome Editing by CRISPR/Cas9”, Jo et al detail their work towards 
editing mtDNA with a standard nuclear targeted CRISPR/Cas9 system160. In contrast with our 
expectations that delivery of Cas9 to the mitochondria would require an MTS, the paper 
showed nuclear-targeted Cas9 functioning in the mitochondria. The gRNAs also did not 
appear to require modification for mitochondrial activity. As yet, there have not been any 
published applications of the tool as developed by Jo et al, and our own attempt to reproduce 
this data was not successful, as summarised in Appendix A3-III. 
The second published attempt at a mitochondrial CRISPR system was published in a Russian 
language journal, гены & клетки (Genes & Cells). The paper does not have an English 
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translation beyond the abstract and consequently does not appear in PubMed. In Импорт 
нуклеазы Cas9 в митохондри (Import of Cas9 nuclease in mitochondria), Orishchenko et al 
targeted FLAG-Cas9 to the mitochondria of viral-producing cells (Phoenix cell line) by 
appending a COX8A MTS. The paper shows a confocal image of a cell where anti-FLAG 
colocalises with very fragmented mitochondria as stained with MitoTracker. The paper did 
not describe any experiments to address mitochondrial gRNA localisation. As with the Jo et 
al paper, there have not yet been any subsequent papers published which repeat this work. 
A third publication of interest was published in 2017, a review which outlines the potential 
difficulties which would need to be overcome to develop a MitoCRISPR system, with the 
daunting title that “Mitochondrial Genome Engineering: The Revolution May Not Be CRISPR-
ized”125. This article highlights the complexity of the task at hand, focussing on challenges of 
efficient gRNA import. The article provides a thorough review of work to date targeting RNAs 
to the mitochondria, particularly bringing to light controversies surrounding natural RNA 
import mechanisms and suggesting the need for potentially more sophisticated and inventive 
methods for achieving this. 
A fourth paper, “Can Mitochondrial DNA be CRISPRzed: Pro and contra” has been published 
during the writing of this thesis in 2018156. The research comes from the Entelis lab who 
have previously published a large body of work on RNA mitochondrial import. Consequently, 
this was the first publication which attempts to add mitochondrial-targeting structures to the 
gRNA structure. In the paper, Loutre et al achieve a decrease in mtDNA copy number with a 
mitochondrial targeted CRISPR system comprised of a COX8A-Cas9 and gRNAs modified to 
contain the targeting sequences from 5S RNAs (section 1.5.2.2.2). Two gRNAs were required 
to produce a reduction of mtDNA copy number; a single target gRNAs had no significant 
influence on mtDNA content. The work was carried out in a heteroplasmic cell line, but the 





On commencing the MitoCRISPR project, the objectives of this PhD project encompassed all 
the milestones detailed in section 1.5 towards the overall aim of developing a MitoCRISPR 
system. However, it soon became apparent that that body of work required of this project 
was far too ambitious for one student in four years, and the scope of the PhD was 
readdressed. Although the work done in the earlier years of the project also included 
mitochondrial targeting of the Cas9 protein as the project progressed, the focus has very 
much become the design and modification of gRNAs for MitoCRISPR. Subsequently, two 
postdoctoral researchers, Zuriñe Anton and Holly Ford, have joined the project. The modified 
objectives of this PhD are as follows: 
1. Modifying Cas9 for MitoCRISPR – Chapter 3 
2. Modifying Cas9 gRNAs for MitoCRISPR – Chapters 4 and 5  
3. Assessing gRNA mitochondrial import – Chapter 6 
Given that there are clear and real ethical issues regarding gene editing, with the MRT 
legislation already paving the way for mtDNA manipulation in patients, there is a need to 
engage the public in an ethical discussion surrounding the development and application of 
these tools. The additional Chapter 7 details a public engagement project undertaken to start 




 Materials and Methods  
32 
 
2.1 Chemicals, Reagents and Solutions 
2.1.1 Table of Chemicals and Reagents  
Table 2 Chemicals and Reagents 
Reagent Supplier 
50 bp DNA ladder ThermoFisher Scientific 
Acetic acid (glacial) Fisher 
Acetone Fisher 
Acrylamide Bis-Acrylamide 30% stock solution  Severn Biotech 
Acrylamide Bis-Acrylamide 40% stock solution  Severn Biotech 
Ammonium persulphate (APS) BDH VWR 
ATP Sigma 
Agarose (molecular biology grade) Helena Bioscience 
β-mercaptoethanol (98%) Sigma 
Boric acid Fisher 
Bovine Serum Albumen (BSA) Sigma 
Bromophenol blue Sigma 
Caesium chloride Fisher 
cOmplete ULTRA protease inhibitor tablets, EDTA-free Roche 
DEPC treated H2O Invitrogen 
Digitonin  Santa Cruz Biotechnology 




Ethidium bromide Sigma 
Ficoll 400 Sigma 
Formamide, deionised BDH VWR 
Gene Ruler 1 kb DNA Ladder ThermoFisher Scientific 
D - (+) - Glucose Sigma 
Glycerol Fisher 
Glycogen New England Biolabs 
HEPES Apollo Scientific 
Hydrochloric acid (HCl) Fisher 
Hionic-Fluor Scintillation Cocktail Perkin Elmer 
Imidazole Fisher 
InstantBlue™ Protein Stain Expedeon 






Table 3 Enzymes 
Enzyme Supplier Catalogue No 
Antarctic Phosphatase New England Biolabs M0289 
RQ1 RNase-free DNase I Promega M6101 
HiScribe™ T7 High Yield RNA polymerase New England Biolabs E2040 
Phusion High-Fidelity DNA Polymerase Thermo Scientific F530L 
Proteinase K (PK) New England Biolabs P8107 
   
Table 2 Chemicals and Reagents ctd.   
Reagent Supplier 
IPTG Fisher 
LB and LBA capsules MP Biomedicals 
Magnesium chloride hexahydrate  Alfa Aesar 
MOPS Sigma 
NADH PauReac AppliChem 
NTPs New England Biolabs 
Polyethylenimine (PEI) Sigma 
Phosphate Buffered Saline (PBS)  Sigma 
PMSF Sigma 
Polyvinylpyrolidone (PVP) Sigma 
Potassium Chloride (KCl) Chem Cruz 
Propan-2-ol Fisher 
Sodium Dodecyl Sulphate (SDS) Fisher 
Sodium Acetate Sigma 
Sodium Perchlorate Fisher 
Sodium Chloride (NaCl) Fisher 
Sodium Hydroxide (NaOH) Fisher 
Sucrose BDH VWR 
SYBR-Gold Invitrogen 
TEMED BioRad 
Tris base (Trizma) Sigma 
Triton-X100 Sigma 
TriZOL Invitrogen 
0.05 % Trypsin-EDTA (1X) Gibco 
Tween-20 Sigma 
Urea Fisher 




Table 3 Enzymes ctd.   
Enzyme Supplier Catalogue No 
Restriction Endonucleases (various) New England Biolabs various 
RNase A Thermo Scientific EN0531 
SUPERase In™ RNase Inhibitor (20 U/μl) Invitrogen AM2694 
T4 DNA ligase New England Biolabs M0202 
T4 polynucleotide kinase (PNK) New England Biolabs M0201 
 
2.1.3 Buffers 
Table 4 Buffers 
Name Composition 
10 % (w/v) APS 10% (w/v) APS in ddH2O, filter sterilise and store aliquots at  
–20 °C 
0.2 M ATP 0.2 M ATP in ddH2O, prepare fresh 
Blocking Solution (Western) 5% (w/v) milk powder in PBS, store at 4°C 
0.1 M CaCl2 0.1 M CaCl2 in ddH2O, autoclaved 
20% Casamino acids Prepared by media kitchen 
CsCl saturated TE 
isopropanol 
An excess of CsCl in equal volumes TE (50 mM Tris pH 8.0: 50 
mM EDTA pH8.0 in ddH2O) and Isopropanol 
100 X Denhardt’s Solution 2% (w/v) BSA, 2% (w/v) Ficoll 400, 2%  (w/v) polyvinylpyrolidone 
in ddH2O and filter sterilise. Aliquot and store at -20 °C. 
Digitonin solution Prepare to 1 mg/ml in ddH2O, preheat to 90 °C for 1 minute 
1 M DTT 1 M DTT in 0.01 M sodium acetate pH 5.2, prepare fresh or 
store aliquots at – 20 °C 
DTT buffer 100 mM Tris-SO4 pH 9.4, 10 mM DTT in ddH2O 
0.5 M EDTA pH 8.0 0.5 M in ddH2O, pH with NaOH and autoclave  
Gel Filtration buffer 20 mM Tris pH 7.5, 200 mM KCl, 1 mM TCEP, 10% glycerol  
Gel Fixing Solution   10% (v/v) MetOH, 10% (v/v) Acetic Acid in ddH2O 
20 mg/ml Glycogen Prepare to 20 mg/ml in DEPC H2O and filter sterilise 
HisElution 50 mM Tris pH 9.0, 500 mM NaCl, 1 mM β-mercaptoethanol, 
500 mM imidazole pH 8.0 in ddH2O 
HisWash 1 50 mM Tris pH 9.0, 500 mM NaCl, 1 mM β-mercaptoethanol, 
30 mM imidazole pH 8.0 in ddH2O 
HisWash 2 50 mM Tris pH 9.0, 200 mM NaCl, 1 mM β-mercaptoethanol in 
ddH2O 
Homogenisation buffer 0.6 M sorbitol, 10 mM Tris-HCl pH 7.4, 0.5% BSA, 1 mM PMSF 





Table 4 Buffers ctd.  
Name Composition 
Hybridisation solution  Prehybridisation solution containing 2 ng/ml 5′ -32P -labelled 
oligonucleotide probe 
1 M Imidazole pH 8.0 1 M Imidazole in ddH2O – adjust to pH 8.0 with NaOH and 
autoclave 
1 M IPTG 1 M IPTG in ddH2O – filter sterilise and store aliquots at – 20 °C 
3 M KCl 3 M KCl in ddH2O – autoclave 
0.2 M NADH 0.2 M NADH in ddH2O – prepare fresh 
5 M NaCl 5 M NaCl in ddH2O – autoclave  
Mitochondrial Isolation Buffer  
(mammalian) 
0.44 M Sorbitol, 40 mM EDTA, 10 mM HEPES-NaOH pH6.7,   
0 %, 0.01 % or 0.1 % (w/v) SDS 
Mowiol 2.4 g mowiol, 6g glycerol, 12mL 0.2M Tris, pH 8.5, 
supplemented with 25mg/mL DABCO 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 in 
ddH2O 
Prehybridisation solution 6 X SSC, 0.1 % (w/v) SDS, 10 X Denhardt’s solution in ddH2O 
RIPA buffer 150 mM NaCl, 10 mM Tris, pH 7.2, 0.1 % SDS, 1.0 % Triton X-
100, 1 % Deoxycholate, 5 mM EDTA in ddH2O 
5 X RNA aptamer buffer 0.15 M KCl, 40 mM HEPES (pH 7.5), 0.1 mM MgCl2 
10 X RB (Reaction buffer) 100 mM Tris pH 7.5, 1 M NaCl, 100 mM MgCl2, 1 mM DTT, 0.05 
mg/ml BSA in ddH2O, filter sterilised, aliquoted and stored at -
80 °C 
2 X RNA loading dye 95 % deionised formamide, 0.025 % (w/v) bromophenol blue, 
0.025 % (w/v) xylene cyanol, 5 mM EDTA pH 8.0, 0.025 % (w/v) 
SDS in ddH2O 
RNA resuspension buffer 10mM Tris pH7.5, 100mM NaCl, 1mM EDTA 
10 X SB (Sample buffer) 100 mM Tris pH 7.5, 1 M NaCl, 10 mM EDTA, 1 mM DTT, 0.05 
mg/ml BSA in ddH2O, filter sterilised, aliquoted and stored at -
80 °C 
2 X SDS-PAGE loading dye 100 mM Tris-Cl pH 6.8, 4 % (w/v) SDS, 0.2 % (w/v) bromophenol 
blue, 20 % (w/v) glycerol – filter sterilise and store at room 
temperature. Add 200 mM β-mercaptoethanol immediately 
before use 
Seahorse Assay Buffer 70 mM sucrose, 220 mM mannitol, 10mM KH2PO4, 5mM MgCl2, 
2mM HEPES, 1mM EGTA and 0.2% (w/v) BSA, pH 7.2 in ddH2O 
SM buffer 250 mM sucrose, 10 mM MOPS-KOH pH 7.2, store at -20°C 
Solution I 25% (w/v) sucrose, 50 mM Tris pH 8.0  





Table 4 Buffers ctd.  
Name Composition 
Solution III 200 mM EDTA pH8.0  
Solution IV 2% (w/v) Triton X100, 50 mM Tris pH 8.0, 50 mM EDTA pH8.0 
Sonication buffer 50 mM Tris pH 8.0, 500 mM NaCl, 1 mM  β-mercaptoethanol, 5 
mM MgCl2, 0.5 mM EDTA, cOmplete ULTRA protease inhibitor. 
1 M Sorbitol 1 M Sorbitol in in ddH2O – filter sterilise or autoclave  
20 X SSC 3 M NaCl, 0.3 M Sodium citrate, 1 mM EDTA in ddH2O 
DNA loading buffer (3 X STE) 0.05 M Tris-HCl ph 8.0, 0.05 M EDTA, 20 % (w/v) sucrose  
DNA loading buffer (3 X STEB) 0.05 M Tris-HCl ph 8.0, 0.05 M EDTA, 20 % (w/v) sucrose, 
0.0125 % (w/v) bromophenol blue, 0.0125 % (w/v) xylene 
cyanol 
1M Sucrose 1 M Sucrose in ddH2O – autoclave before use 
1/1,000 SYBR Gold staining 
solution 
1 μl SYBR Gold in 1 ml 1 X TBE  
50 X TAE 2 M Tris-acetate, 50 mM EDTA 
242 g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA 
pH 8.0 
1 X TBE/0.5 X TBE Dilute 5 X TBE 1/5 or 1/10 respectively in ddH2O 
5 X TBE 450 mM Tris-borate, 10 mM EDTA 
54 g Tris base, 27.5 g boric acid, 20 ml 0.5 M EDTA pH8.0 in 
ddH2O 
TE (50:50) 50 mM Tris pH 8.0: 50 mM EDTA pH8.0 in ddH2O 
TE CsCl 1.085 g/ml 108.5 g CsCl dissolved in 100 ml TE (50:50) - 1 ml weighs ~ 
1.63 g  
TE CsCl 1 g/ml 100 g CsCl dissolved in 100 ml TE (50:50) – 1 ml weighs ~ 1.58 
g 
1 M Tris pH 7.5 1 M Tris in ddH2O – adjust to pH 7.5 with HCl and autoclave  
1 M Tris pH 8.0 1 M Tris in ddH2O – adjust to pH 8.0 with HCl and autoclave 
1 M MgCl2 1 M MgCl2 in ddH2O – autoclave before use 
1 M MgSO4 1 M MgSO4 in ddH2O – autoclave before use 
VOA mix (death cocktail) 1 mM valinomycin, 10 mM oligomycin, 8 mM antimycin A 
Yeast RNA import buffer 50 mM sucrose, 80 mM KCl, 5 mM MgCl2, 10 mM 
KH2PO4/K2HPO4 pH 7.2, 10 mM MOPS, in ddH2O 
Yeast RNA import mix 100 μl yeast RNA import buffer with 2 mM ATP, 2 mM NADH. 




2.2 General microbiology techniques 
2.2.1 Escherichia coli (E.coli) strains 
Table 5 E coli strains 
Cell line Supplier Genotype Use 
One Shot™ TOP10 
Chemically 
competent E.coli 
Invitrogen F- mcrA Δ( mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 Δ lacX74 recA1 araD139 




HB101 Promega F–, thi-1, hsdS20 (rB–, mB–), supE44, 
recA13, ara-14, leuB6, proA2, lacY1, 
galK2, rpsL20 (strr), xyl-5, mtl-1 
3H CsCl 
Maxipreps 





2.2.2 Yeast strains  
Table 6 Yeast strains 
Cell line Source Genotype Use 
YPH499 Collinson lab 
(University of 
Bristol) 
MATa ura3-52 lys2-801_amber ade2-101_ochre 





All media was prepared with ddH2O and autoclaved at 121 °C for 15 minutes at 15 psi. 
Table 7 Media 
Media Composition Use 
20% Casamino acids Prepared by media kitchen CsCl plasmid preparation 
Luria-Bertani (LB) Capsules dissolved in ddH2O Liquid E.coli culture 
LB-Agar (LBA) Capsules dissolved in ddH2O E.coli culture on plates 
5 X M9 Salts 33.9 g/L Na2HPO4, 15 g/L KH2PO4, 5 g/L 
NH4Cl, 2.5 g/L NaCl 
CsCl plasmid preparation  
SOC 0.5 % (w/v) yeast extract, 2% (w/v) 
tryptone, 10 mM NaCl,  
2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM Glucose 
Heat-shock 
transformation recovery  
YPG 1% (w/v) yeast extract, 2% (w/v) peptone, 
3% (w/v)  glycerol in ddH2O, adjusted to pH 






Table 8 Antibiotics 
Antibiotic Stock concentration Used at Concentration Supplier 
Ampicillin 100 mg/ml in ddH2O 100 µg/ml Sigma 
Kanamycin 50 mg/ml in ddH2O 50 µg/ml Sigma 
Chloramphenicol 34 mg/ml in 100% EtOH 0.2 mg/ml Sigma 
 
2.2.5 Transformation techniques 
Transformation of commercial competent E.coli cell lines was performed by heat shock 
according to the protocols supplied by the manufacturer. Transformed cells were grown for 




2.3 General DNA techniques 
2.3.1 Plasmid DNA handling and purification  
Plasmid DNA purification was performed with either GeneJET plasmid Miniprep Kit (Thermo 
Scientific) or Plasmid Mini-, Midi- or Maxiprep kits (Qiagen), according to the manufacturer’s 
instructions. Plasmids were either eluted in ddH2O or the supplied TE buffer and stored at -
20 °C. DNA concentrations were calculated using a DeNovix DS-11 spectrophotometer to 
measure absorbance at 260 nm. The A260/280nm ratio was used as an indication of purity. DNA 
sequencing was performed by DNA Sequencing & Services (MRC I PPU, School of Life 
Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-
Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. 
 Plasmids 
Table 9 Plasmids 
Chapter 3: Mito-Cas9 and associated plasmids 
Name Use Source 
pD1301-AD Cloning Cas9 and gRNA plasmids, below DNA2.0 
pD1301i Expression of NLS-Cas9 and gRNA cassette  this thesis 
pD1301iABC Expression of MTS-Cas9 this thesis 
pD1301iE Expression of NLS-Cas9-GFP and gRNA cassette this thesis 
pD1301iABCE Expression of MTS-Cas9-GFP this thesis 
pDsRed-Mito Expression of MTS-RFP Lane lab 
pEGFP-N1 Expression of EGFP Clontech 
pMTS-EGFP Expression of MTS-EGFP this thesis 
pEX-A2-MTS and Spinach COX8A MTS sequence Eurofins 
Sequence in A2 
phCas9D10A Expression of NLS-Cas9D10A and gRNA cassette  Addgene #41816118 
phCas9WT Expression of NLS-Cas9 and gRNA cassette  Addgene #41815118 
Chapter 4: Modified gRNAs 
Name Use Source 
pD1301i-SP1 Unmodified gRNA template generation this thesis 
pEX-A2-g#GM SP1gRNA 5′ 
Baby Spinach 
5′ Baby Spinach (fluorescent RNA structure) 
gRNA template generation 
Eurofins 
Sequence in A2 
pEX-A2-g#GM SP1gRNA 3′ 
Baby Spinach 
3′ Baby Spinach (fluorescent RNA structure) 
gRNA template generation 
Eurofins 
Sequence in A2 
pEX-A2-g#GM SP1gRNA 5′ 
RP 
5′ RP-gRNA template generation Eurofins 
Sequence in A2 
pEX-A2-g#GM SP1gRNA 3′ 
RP 
3′ RP-gRNA template generation Eurofins 
Sequence in A2 
pEX-A2-g#GM SP1gRNA 
US RP 
RP US gRNA template generation Eurofins 
Sequence in A2 
pEX-A2-g#GM SP1gRNA H 
RP_1 
RP H1 gRNA template generation Eurofins 
Sequence in A2 
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Table 9 Plasmids ctd   
Chapter 4: Modified gRNAs ctd  
Name Use Source 
pEX-A2-g#GM SP1gRNA H 
RP_2 
RP H2 gRNA template generation Eurofins 
Sequence in A2 
pEX 5′ RP U  5′ RP-U gRNA template generation this thesis 
pEX 5′ RP 2U 5′ RP-2U gRNA template generation this thesis 
pEX 5′ RP 4U 5′ RP-4U gRNA template generation this thesis 
pEX 5′ RP 8U 5′ RP-8U gRNA template generation this thesis 
pEX-A2-BoBS & tRNA(K) BoBs and tRK1 templates for HiFi Eurofins 
Sequence in A2 
pEX US tRK1 US tRK1 gRNA template generation this thesis 
pEX US BS US Baby Spinach gRNA template generation this thesis 
pEX US BoBS US BoBS gRNA template generation this thesis 
pSUMOCas9hinge Expression of Cas9hinge Szczelkun lab 
pSUMOdCas9HNH Expression of dCas9HNH Szczelkun lab 
pSP1 Plasmid cleavage assays substrate plasmid Siksnys lab92 
pUC19 Negative control, plasmid cleavage assays  
 
2.3.2 DNA electrophoresis  
 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed in a horizontal transfer system (Flowgen 
Biosciences). Agarose gels were prepared by dissolving 1 – 3% (w/v) Agarose in 1X TAE and 
heating in a microwave oven. Once cooled, the gel mix was supplemented with Ethidium 
bromide to 0.05 % (w/v) and set in gel trays with an appropriate comb. Once set, gels were 
placed in a tank containing 1X TAE with Ethidium bromide to 0.05 % (w/v). DNA samples 
were prepared by adding 1/3 volume 3X STEB, heated to 80 °C for 10 minutes and loaded 
onto the gel and run at 25 – 120 V until DNA bands were appropriately separated. Gels were 
imaged using the GelDoc™ XR+ system (BioRad). 
2.3.2.1.1 DNA isolation from Agarose gels 
DNA fragments separated by agarose gel electrophoresis were extracted from gel slices with 
the QIAEX-II Gel Extraction Kit (Qiagen), following the manufacturer’s instructions.   
 TBE-PAGE  
TBE-PAGE was performed in the Mini-PROTEAN 3 vertical transfer system (BioRad). TBE gel 
mix (1X TBE, 8/10 % (v/v) acrylamide (from 40% Acrylamide/Bis-acrylamide (19:1)) was 
prepared and passed through a 0.45 μm nitrocellulose filter prior to the addition of 0.05% 
(w/v) APS and 0.05% (v/v) TEMED. Gels were set at room temperature in the Mini-PROTEAN 
3 apparatus, as per the manufacturer’s instructions. Once set, gels were placed in a tank 
containing 1X TBE. DNA samples were prepared by adding 1/3 volume 3X STEB, loaded into 
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the gel and run at 180 V until DNA bands were appropriately separated. Gels were soaked in 
a 1X TBE solution containing 0.05 % (v/v) Ethidium bromide for 15 minutes and imaged using 
the GelDoc™ XR+ system (BioRad). 
2.3.2.2.1 DNA isolation from TBE-PAGE gels 
DNA was isolated from TBE-PAGE gel by electroelution. Once separated by TBE-PAGE, gels 
were soaked in a 1X TBE solution containing 0.05 % (v/v) Ethidium bromide for 15 minutes 
and viewed on the DarkReader transilluminator (Clare Chemical Research). The band of 
interest was cut out of the gel and sealed into a length of pre-soaked snakeskin dialysis 
tubing containing 250 µl 0.1 X TBE. The tubing was placed into a gel tank in 0.1 X TBE and 
run at 30mA for 30 minutes.  
2.3.3 Molecular Biology and Cloning 
All restriction enzymes (New England Biolabs) were used according to the manufacturer’s 
instructions. DNA ligation with T4 DNA Ligase (Roche) was performed according to the 
manufacturer’s instructions at 16 °C for 16 hours.  
 Polymerase Chain Reaction (PCR) 
PCR was performed with Phusion high-fidelity DNA polymerase according to the 
manufacturer’s instructions. Amplified DNA was purified with QIAquick PCR purification kit 
(Qiagen). 
2.3.4 Oligonucleotides and Synthetic genes 
All oligonucleotides and synthetic genes were purchased from MWG Eurofins. 
Oligonucleotides for cloning and sequencing pD1301 (Chapter 3 - MTS-Cas9 expression) 
Table 10 Oligonucleotides 1 
Primer/Oligo Sequence (5′-3′) Application  
oli#GM_SeqF1 AGTACAAAATACGTGACGTAGAAAG (25) Sequencing primer 
oli#GM_SeqF2 ATAGGGACTTTCCATTGACG (20) Sequencing primer 
oli#GM_SeqF3 AGAGACCACACCCAAGCTGG (20) Sequencing primer 
oli#GM_SeqF4 ACCTGAACCCCGACAACAGCG (21) Sequencing primer 
oli#GM_SeqF5 AGCCAGGAAGAGTTCTACAAG (21) Sequencing primer 
oli#GM_SeqF6 ACCAACCGGAAAGTGACCGT (20) Sequencing primer 
oli#GM_SeqF7 AGTGATGGGCCGGCACAAGC (20) Sequencing primer 
oli#GM_SeqF8 ACTCCCGGATGAACACTAAG (20) Sequencing primer 
oli#GM_SeqF9 AGTACGGCGGCTTCGACAGC (20) Sequencing primer 
oli#GM_SeqF10 ACGCCACCCTGATCCACCAG (20) Sequencing primer 
oli#GM_SeqF11 AGGACGGGCATATTCTTCGGAAG (23) Sequencing primer 
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Table 10 ctd.   
Primer/Oligo Sequence (5′-3′) Application  
oli#GMpD1303_Af 
P-GGCACATCTGAGGGCAGGGGAAG (23) 3′ NLS removal 
primer F 
oli#GMpD1303_Ar 
P-GTCGCCTCCCAGCTGAGACAGG (22) 3′ NLS removal 
primer R 
oli#GMpD1303Ar2 
P-GTCGCCTCCCAGCTGAGACAGGT (23) 3′ NLS removal R + 
3′ T 
oli#GMpD1301iT CCGTGAAGAGCGCTCTTCA (19) 2x SapI sites F 
oli#GMpD1301iB AACTGAAGAGCGCTCTTCA (19) 2x SapI sites R 
oli#GMpD1301iTs 
CCGTGAAGAGCAGAGTGGCTCTTCA (25) SapI sites + 6bp 
stuffer  
oli#GMpD1301iBs 





5′ NLS removal and 






5′ NLS removal and 





Primer C F truncated 
oli#GMpD1301CRt CATGGTGGCGGCCAGCTTG (19) Primer C R truncated  
oli#GM NestRev 3  
CGCCGGGCCGAGCCTGTCAAGCCCCGCAGCAGC
AG (35) 
Nested PCR MTS 
insertion 
oli#GM NestFow 3  
GCTCCCAGTGCCGCGCGCCAAGATCCATTCGTT
G (34) 
Nested PCR MTS 
insertion 
oli#GM NestRev 1  
TCAGGACGGACATGGTGGCGGCCAGCTTG 
(29) 
Nested PCR MTS 
insertion 
oli#GM NestRev 2  
GCAGCAGCAGCGGCGTCAGGACGGACATG 
(29) 
Nested PCR MTS 
insertion 
oli#GM NestFow 1  
TCCACCGGTCGACAAGAAGTACAGCATCG 
(29) 
Nested PCR MTS 
insertion 
oli#GM NestFow 2  
TCCATTCGTTGGGGGATCCACCGGTCGAC 
(29) 
Nested PCR MTS 
insertion 
 
Oligonucleotides for generating gRNA library: 5′ insertions with inverse PCR (Chapter 4) 
Table 11 Oligonucleotides 2 
Primer/Oligo Sequence (5′-3′) Application  
oli#GM PS1 fow  CGCTAAAGAGGAAGAGGACAG (21) Forward primer 
oli#GM 5′ RP U rev  ACTCCCTGAAGCTCAGGG (18) U insertion 
oli#GM 5′ RP 2U rev  AACTCCCTGAAGCTCAGGG (19) 2U insertion 
oli#GM 5′ RP 4U rev  AAAACTCCCTGAAGCTCAGGG (21) 4U insertion 
oli#GM 5′ RP 8U rev  AAAAAAAACTCCCTGAAGCTCAGGG (25) 8U insertion 
oli#GM MRP fow  CCCGCTGAGCCCGCGCTAAAGAGGAAGAGG (30) MRP insertion 
Forward 





Oligonucleotides for generating gRNA library: Upper Stem insertions with HiFi (Chapter 4) 
Table 12 Oligonucleotides 3 
Primer/Oligo Sequence (5′-3′) Application  
oli#GM USBS iFP1  TTTAGAGCTAGGTGAAGGACGGGTCCAGTAG 
(31) 
US BS insertion 
oli#GM USBS iRP1  TAACTTGCTAGGAGCTCACACTCTACTCAAC 
(31) 
US BS insertion 
oli#GM USBS vFP2  TGTGAGCTCCTAGCAAGTTAAAATAAGGC (29) US BS insertion 
oli#GM USBS vFP2  GTCCTTCACCTAGCTCTAAAACTGTCCTCT (30) US BS insertion 
oli#GM BoBS FP1  TTTAGAGCTAAAGGACGGGTCCGGACGCAA (30) US BoBS insertion 
oli#GM BoBS RP1  TAACTTGCTACTCACACTCTACTCAACGGA (30) US BoBS insertion 
oli#GM BoBS FP2  AGAGTGTGAGTAGCAAGTTAAAATAAGGCT (30) US BoBS insertion 
oli#GM BoBS RP2  ACCCGTCCTTTAGCTCTAAAACTGTCCTCT (30) US BoBS insertion 
oli#GM tRK1 FP1  TTTAGAGCTAgaGCCTTGTTGGCGCAATCG (30) US tRK1 insertion 
oli#GM tRK1 RP1  TAACTTGCTAGAGCCCTGTAGGGGGCTCGAA 
(31) 
US tRK1 insertion 
oli#GM tRK1 FP2  TACAGGGCTCTAGCAAGTTAAAATAAGGC (29) US tRK1 insertion 
oli#GM tRK1 RP2  AACAAGGCtcTAGCTCTAAAACTGTCCTCT (30) US tRK1 insertion 
 
Oligonucleotides for generating gRNA IVT template by PCR (Chapter 4 and 6) 
Table 13 Oligonucleotides 4 
Primer/Oligo Sequence (5′-3′) Application  




oli#GM SP1 T7 (GG) GACACTAATACGACTCACTATAGGCGC 
TAAAGAGGAAGAGG (41) 
T7 introduction, 5′ GG 
oli#GM SP1 T7 (GGG) GACACTAATACGACTCACTATAGGGCG 
CTAAAGAGGAAGAGG (42) 
T7 introduction, 5′ GGG 
oli#GM SP1 T7rev AAAAGCACCGACTCGGTGCC (20) Reverse primer, 
unmodified 3′ 
oli#GM  RP T7 (G) gacacTAATACGACTCACTATAGTCTCCC
TGAGCTTCAGG (40) 
T7 introduction, RP 5′  
oli#GM 5′ BS T7 (G) gacacTAATACGACTCACT 
ATAGGGTGAAGGACGGG TCCAG (41) 
T7 introduction, BS 5′ 
oli#GM 3′ RP T7 R AAAACTCCCTGAAGCTCAGG (20) Reverse primer, RP 3′ 
oli#GM 3′ BS T7 R AAAAGGAGCTCACACTCTAC (20) Reverse primer, BS 3′ 
oli#GM5′ MRPT7fow gacacTAATACGACTCACTATAGAGAAGC
GTATCCCGCTGAGC (43) 
T7 introduction, MRP 5′ 
Oli#GM5′ FDT7fow gacacTAATACGACTCACTATAGGCGCAA
TCGGTAGCGCTTCG (43) 







Oligonucleotides for generating Baby Spinach (fluorescent RNA) IVT template by PCR 
(Chapter 4) 
Table 14 Oligonucleotides 5 





oli#GM Spin2 Rev GATGTAACTAGTTACGGAGCTCACACTC (28) 
 
Oligonucleotides for generating gRNA template by annealing (Chapter 5) 
Table 15 Oligonucleotides 6 
Primer/Oligo Sequence (5′-3′) Application  
oli#GM LbCas12a crRNA T7 
top 
GAAATTAATACGACTCACTATAGGG (25) LbCas12a 
crRNA IVT 
template 














crRNA 5′ U IVT 
template 






crRNA 3′ U IVT 
template 







crRNA 5′ RP IVT 
template 
 
Oligonucleotides for AD and FD RNA IVT template PCR (Chapter 6)  
Table 16 Oligonucleotides 7 
Primer/Oligo Sequence (5′-3′) 
oli#GM T7 AD T  TAATACGACTCACTATAGGGCCTTGTTGGCGCAATCGGTAGCGCAAATACA
GGGCTCCA (59) 
oli#GM AD T7 B  TGGAGCCCTGTATTTGCGCTACCGATTGCGCCAACAAGGCCCTATAGTGAG
TCGTATTA (59) 
oli#GM T7 F1D1 T  TAATACGACTCACTATAGGGCGCAATCGGTAGCGCTTCGAGCCCCCTACAG
GGCTCCA (58) 
oli#GM T7 F1D1 B  TGGAGCCCTGTAGGGGGCTCGAAGCGCTACCGATTGCGCCCTATAGTGAGT
CGTATTA (58) 
oli#GM T7 FD fow  GACACTAATACGACTCACTATAGG (24) 





Oligonucleotides for Northern Blotting probes (Chapter 6)  
Table 17 Oligonucleotides 8 
Primer/Oligo Sequence (5′-3′) 
cyto tRNALysUUU hybridisation probe ACTTGAACCCTGGACC (16) 
Mito tRNALeu hybridisation probe GAACCTCTGACTCTAAAG (18) 
mito tRNAThr hybridisation probe TCTCCGGTTTACAAGAC (17) 
tRK1 hybridisation probe TGGAGCCCTGTAGGGG (16) 
gRNA hybridisation probe GCACCGACTCGGTGCCACTT (20) 
 
Oligonucleotides for dCas9HNH FRET assay (Chapter 4)   
Table 18 oligonucleotides 9 





55 bp dsDNA 






55 bp dsDNA 
template for FRET 
assay 
 Oligonucleotide annealing 
Desired oligonucleotides were mixed in equimolar ratios in 150 mM NaCl and heated to 90 °C 




2.4 General RNA techniques 
2.4.1 RNA handling  
RNA is readily degraded by environmental RNases, such as those found on the skin. The 
following precautions were taken when working with RNA containing samples: Gloves were 
regularly changed; all tubes and tips were certified RNase-free (Ambion, Gilson); the bench 
and pipettes were regularly cleaned with RNaseZap™ (Invitrogen); DEPC-treated water 
(Invitrogen) was used in reaction buffers and experimental set-up.  
2.4.2 in vitro transcription (IVT) 
Except in the case of G/GG/GGG gRNAs (Chapter 5) IVT was performed with HiScribe™ T7 
High Yield RNA synthesis kit (New England BioLabs) as per the manufacturer’s instructions. 
gRNAs were purified by either phenol chloroform extraction or with RNA Clean and 
Concentrator™ Columns (Zymo Research) and eluted in DEPC treated H2O. gRNA 
concentration was calculated by taking A260 with a DeNovix DS-11 spectrophotometer. gRNA 
size and integrity was monitored by separation with urea-polyacrylamide gel electrophoresis 
(urea-PAGE) with 10% (w/v) acrylamide. 
EnGen IVT (NEB)  IVT by EnGen kit (gRNAs with 5′ guanines) was performed as per the 
manufacturer’s instructions. gRNAs were purified as above. 
 gRNA template design 
Templates for gRNA library IVT double stranded DNA templates amplified by PCR from the 
relevant plasmid (see Table 9). These incorporations were made to plasmid DNA templates 
through a number of standard cloning methods and synthesised by in vitro transcription to 
give the modified gRNA library, Appendix A4. Primers were designed for gRNA IVT that 
amplified the gRNA spacer and structural component from pD1301 and introduced the T7 
promoter upstream of the gRNA sequence, Table 13.  
 in vitro transcription of 33P-UTP labelled RNA  
In vitro transcription was performed using the T7 HiScribe High Yield RNA synthesis kit. The 
reaction was prepared to a final volume of 20 µl, containing a final concentration of 1X 
reaction buffer, 1 mM ATP, GTP and CTP. UTP was added to a final concentration of 4 µM 
with 0.25 µM α33P UTP, 0.5 MBq/reaction (Hartman Analytic, SRF 210). To this, 0.25 µg 
template DNA and 1 µl T7 RNA pol mix was added. The assembly was incubated at 37°C for 
10 minutes, treated with DNase and purified with MicroBioSpin (BioRad) columns.  
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2.4.3 Purification and analysis of RNA 
RNAs were purified with RNA Clean and Concentrator–5 columns (Zymo Research), eluted in 
DEPC-treated ddH2O and stored at -80 °C. RNA concentrations were calculated using a 
DeNovix DS-11 spectrophotometer to measure absorbance at 260 nm. The A260/280nm ratio 
was used as an indication of purity. 
2.4.4 Denaturing urea-PAGE 
RNA was separated on a denaturing urea-PAGE gel containing 10% (w/v) acrylamide, 1X TBE 
and 50% (w/v) urea. Gel mix was prepared, filter sterilised with a 0.2 μm nitrocellulose 
membrane and stored at 4 °C for up to 2 weeks. Gels were set using the BioRad Mini-
PROTEAN 3 system and pre-run in 1 X TBE at 200 V for 45 minutes prior to loading samples. 
RNA samples were heated to 90 °C with 1X RNA Loading Dye for 10 minutes and migrated 
in 1 X TBE at 200 V. Gels were stained with 1 ml 1/1,000 SYBR Gold Nucleic Acid Gel Stain 




2.5 General Protein techniques 
2.5.1 Polyacrylamide gel electrophoresis (PAGE) 
SDS-PAGE for Western blotting SDS polyacrylamide gels were made and run using the 
MiniPROTEAN 3 system (BioRad). Resolving gels for protein separation were prepared from 
30% (w/v) Acrylamide/Bis-acrylamide (37:1) stock at a percentage tailored to the size of 
protein of interest (30-95 kDa, 8%; 20–80 kDa, 10%; 10-60 kDa, 12%). Stacking gel was 
consistently 4% (w/v) acrylamide. Samples were boiled at 98 °C for 5 minutes with 3X 
sample buffer prior to loading. Gels were run at 100 V until all samples had migrated through 
the stacking gel, and then at 180 V through resolving gel. 
SDS-PAGE for protein purification For protein purification, Mini-PROTEAN TGX™ Precast gels 
were used for protein separation. Proteins were stained with InstantBlue™ Protein stain 
(Expedeon) and imaged with the GelDoc™ XR+ system (BioRad).  
2.5.2 Western blotting 
Proteins separated by SDS-PAGE were transferred to nitrocellulose membrane using the 
Trans-Blot® Turbo™ Blotting System (Bio Rad) as per the manufacturer’s instructions. 
Following transfer, the nitrocellulose membrane was stained with ponceau for 5 minutes to 
reveal protein distribution.  
Nitrocellulose membrane was incubated in blocking solution for 1 hour prior to incubation 
with primary antibody, prepared to the required concentration in blocking solution. Primary 
antibody incubation was for 45 minutes at room temperature or overnight at 4°C. 
Membranes were washed three times in 1X TBS-T (Tris Buffered Saline with 0.1% (v/v) Triton 
X100) prior to incubation with secondary antibody prepared to the correct dilution in blocking 
solution for 45 minutes at room temperature. Membranes were washed a further three times 
with TBS-T. Membranes were incubated for 3 minutes with freshly prepared EZ-ECL Enhanced 
Chemiluminescence detection substrate (Biological Industries). For detection of 
chemiluminescence, membranes were exposed to Hyperfilm (GE Healthcare) in a dark room 





2.6 General Mammalian Cell Culture Techniques 
2.6.1 Cell lines 
Table 19 Mammalian Cell Lines 
Cell line Description Source  
RPE-1 hTERT-immortalised Human Retinal 
Pigment Epithelial cells 
Lane lab 
HeLa Human cervix epithelioid carcinoma Lane lab 
94αT4 MELAS Cybrids Cytoplasmic hybrid cells carrying 
m.A3243G mtDNA mutation 
Dr José Sanchez-Alcázar, Seville161 
wild type ACH Cybrids Cytoplasmic hybrid cells not carrying 
m.A3243G mtDNA mutation 
Dr José Sanchez-Alcázar, Seville 
 
Unless otherwise stated, cultured in Standard Cell Culture Media in 10cm culture dishes at 
37°C and 5% CO2. 
2.6.2 Media 
Table 20 Media 
Media Components Use 
Standard Cell Culture 
Media 
Dulbecco’s Modified Eagle’s 
Medium – high glucose (DMEM, 
Sigma) with 10% (v/v) FBS 
Culturing HeLa and RPE-1 
cells 
Cybrid media DMEM 
4.5 g/L glucose,  
10% (v/v) FBS 
100 μg/ml sodium pyruvate 
50 μg/ml uridine 
Culturing MELAS and WT 
cybrid cell lines 
Reduced Serum medium OptiMEM (Gibco) Transfecting HeLa and RPE-1 
Freezing media 50% Standard Cell Culture Medium 
40% (v/v) FBS 
10% (v/v) DMSO 
Freezing cell stocks 
 
2.6.3 Transient transfection 
 Lipofectamine 2000 
Transient transfection was performed with Lipofectamine®2000 (Invitrogen) as per 
manufacturer’s instructions: Cells were grown to 70-80% confluency before transfection. 
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 Polyethylenimine (PEI) 
PEI working solution of 1 mg/ml PEI in ddH2O was prepared by dissolving PEI overnight at 
room temperature, adjusting to pH 7.5 and sterilising through 0.2 μm nitrocellulose filter. For 
a 6-well dish, 20 pmoles RNA was added to 100 μl OptiMEM. 12 μl PEI working solution was 
added, tube pulse vortexed (15 x 1 second bursts) and incubated at room temperature for 
10 minutes. 0.6 ml full media was added to PEI-RNA mix, mixed thoroughly and added to 70-
80% confluent cells and returned to 37 °C incubator. After 2-3 hours, 1ml media was added 
to each well.  
2.6.4 Immunofluorescence  
Cells were grown on glass coverslips (13mm, thickness 1, VWR) and fixed and permeabilised 
with either Methanol or Formaldehyde fixation followed by permeabilization with Triton.  
Methanol fixation: Coverslips were washed three times with PBS, then incubated in -20 °C 
methanol for 4 minutes before a further three washes with PBS.  
Formaldehyde Fixation: Coverslips were washed three times with PBS and incubated in 3.7% 
formaldehyde in PBS for 10 minutes. Coverslips were washed three times in PBS and 
permeabilised by incubation with 0.1% (v/v) Triton X100 in PBS for 5 minutes. Following three 
further PBS washes (once with a drop of 1 M glycine to block non-specific binding of 
antibodies to unreacted aldehyde groups), coverslips were incubated with primary antibody 
diluted in PBS for 30 minutes (see Table 21 for a complete list of primary antibodies). 
Coverslips were then washed three times in PBS before incubation with secondary antibody 
diluted in PBS for 30 minutes followed by a further three washes with PBS. Nuclei were 
stained with DAPI (4′, 6-diamino-2-phenylindole) by incubation in 0.1 µg.ml-1 for 5 minutes. 
Coverslips were then washed with PBS and ddH2O prior to mounting on slides with Mowiol.  
2.6.5 Fluorescence Imaging 
Widefield microscopy was performed using an Olympus IX-71 inverted microscope. 
2.6.6 Antibodies 
The primary antibodies used are detailed in the table below: 
Table 21 Antibodies 
Antibody Supplier Cat. No. Type Dilution 
Anti-Cas9 Abcam Ab204448 Rabbit polyclonal WB: 1:5000 
IF: 1:1000 
Anti-GFP Covance MMS-118R Mouse monoclonal WB 1:2000 
Anti-Hsp60 Sigma H4149 Mouse monoclonal WB: 1:3000 
IF: 1:1000 
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Table 21 ctd.     
Antibody Supplier Cat. No. Type Dilution 
Anti-Lamin B1 Santa Cruz SC-216 Goat polyclonal WB: 1:2500 
Anti-LC3B Sigma L8918 Rabbit Polyclonal IF: 1:400 
Anti-Tubulin 
B-512 
Sigma T5168 Mouse monoclonal WB: 1:2500 
HRP-conjugated secondary antibodies (Jackson Immunoresearch Laboratories) used for 
western blotting were diluted to 1:20,000 in blocking solution. Alexa Fluor™ 594 conjugated 
secondary antibodies (Molecular Probes, Life Technologies) used for immunofluorescence 
were diluted to 1:100 in PBS.  
2.6.7 Cell lysis and protein quantification for Western blotting  
Cell culture medium was aspirated, and cells were washed twice with ice-cold PBS. Cells were 
incubated in Lysis Buffer (RIPA buffer + 1% (v/v) NP40, 1 mM PMSF and 1 µM protease 
inhibitors) - 150µl for a 12-well dish and 300µl for a 6-well dish. Cells were scraped from the 
culture dish and transferred to a 1.5ml Eppendorf and incubated on ice for 15 minutes with 
occasional disruption. Cells were spun at 20,000 x g for 5 minutes, 4°C and lysates stored 
at -20°C until required. Protein concentration was quantified using the Pierce™ BCA Protein 




2.7 Techniques to study SpyCas9 domain motions162,163 
2.7.1 Purification of Cas9hinge and dCas9HNH 
Unless stated otherwise, all columns were run on an AKTA Prime Plus Liquid Chromatography 
System (GE Healthcare) at 4 °C. 
 Bacterial growth of Cas9hinge and dCas9HNH 
BL21 Rosetta 2 (DE3) cells were transformed with pSUMOCas9hinge and pSUMOdCas9HNH and 
grown overnight on LBA with appropriate antibiotic. 500 ml LB was inoculated with a single 
colony and cells were grown at 37 °C in a 2.5 L flask at 250 rpm for 16 hours. Once grown, 
bacteria were pelleted by centrifugation for 20 mins at 4,000 x g, 4 °C, and supernatant 
discarded. Pellets could be frozen in liquid nitrogen and stored at -20 °C at this point.  
 Cas9hinge and dCas9HNH purification  
Sonication buffer, HisWash 1, HisElution and HisWash 2 buffers were prepared in advance, 
filtered through a 0.2 μm nitrocellulose filter and chilled to 4 °C. β-mercaptoethanol and 
protease inhibitors were omitted and added immediately before use. The bacterial pellet was 
resuspended in 25 ml sonication buffer and lysed by sonication 2 x 2 minutes (10 seconds 
on/off) at 75% of maximum with a standard sonication tip. Total lysate was cleared by 
ultracentrifugation for 40 minutes at 37,000 x g, 4 °C and supernatant was dialysed at 4 °C 
against 1L HisWash1 in Snakeskin™ 10,000 MWCO Dialysis tubing (Thermo Scientific). 
Sample was filtered through a 0.45 μm nitrocellulose filter and loaded onto a 5 ml HisWash1-
equilibrated HisTrap HP column (GE Healthcare. 2 ml fractions were collected through a 
linear gradient over 100ml up to 100% HisElution. Both Cas9hinge and dCas9HNH were eluted 
in the range of 120 - 170 mM imidazole (roughly 20 – 30 % HisElution). Pooled fractions 
were dialysed at 4 °C against HisWash2 and total protein concentration estimated using a 
DeNovix DS-11 spectrophotometer to measure absorbance at 260 nm. The His tag-SUMO 
was cleaved overnight with SUMO protease (2 μl SUMO protease was added per mg Cas9 
protein) in Snakeskin dialysis tubing, dialysed against 2L HisWash2 at 4 °C. The next morning, 
an appropriate amount of NaCl and imidazole were added to give a final concentration of 30 
mM imidazole, and the cleaved sample was loaded onto a HisWash2 equilibrated 5 ml 
HisTrap HP column (GE Healthcare). Cas9 containing flow-through was collected as 2 ml 
fractions, and bound tag and SUMO protease eluted with HisElution. Cas9 containing 
fractions were concentrated and buffer exchanged into GelFiltration buffer with Amicon Ultra-
15 50 kDa cut-off centrifugal filter units (Millipore). Protein was frozen with liquid nitrogen 
and stored at -80°C. See Appendix A4 for column traces and summary gels. 
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 Labelling Cas9hinge and dCas9HNH with Cy3 and Cy3/5 
Cas9hinge and dCas9HNH were either single labelled with Cy3 only or double labelled with Cy3 
and Cy5 maleimide monoreactive dyes (Amersham, GE Healthcare). 10 μM Cas9 was 
labelled with 25 μl dye in GelFiltration buffer in a dark tube following the manufacturer’s 
instructions. Proteins were incubated for 2 hours at room temperature, and overnight at 4 
°C. Labelling reaction was quenched with 10 mM DTT and free dye was separated by size 
exclusion chromatography on a HiLoad Superdex 200 16/60 column (GE Healthcare). 
Collected 2ml fractions were pooled and concentrated with Amicon Ultra-15 50 kDa cut-off 
centrifugal filter units (Millipore), frozen with liquid nitrogen and stored at -80°C. See 
Appendix A4 for column traces and summary gels. To assess labelling efficiency, proteins 
were diluted and scanned in a quartz cuvette (Sigma C2043) with a Cary 60 UV-Vis 
spectrophotometer (Agilent). Extinction coefficients for Cas9, Cy3 and Cy5, the absorbance 
at 280 nm (protein), 552 nm (Cy3) and 650 nm (Cy5) were used to calculate the protein 





















2.7.2 FRET measurements 
100 nM RNA was assembled with 50 nM Cas9hinge labelled with Cy3 or Cy3/Cy5 in FRET 
buffer on ice. Following a 10 min incubation at room temperature, tubes were spun (5 
minutes, benchtop microfuge). Measurements were collected with a FluoroLog 
Spectrophotometer (Horiba) at room temperature in a 130 μl Quartz cuvette (Hellma); 5 mm 
slit widths, 1s integration time. For each RNA, the sample was excited at 530 nm and 630 
nm and spectra collected from 550 – 800 nm and 650 – 800 nm respectively. RatioA, 




2.8 Techniques to study CRISPR endonuclease activity 
2.8.1 CsCl maxi prep and 3H labelling  
HB101 cells were transformed with pSP1 or pUC19 and selected on LBA plates with 
ampicillin. One colony was grown overnight in LB with ampicillin. 4 ml overnight culture was 
inoculated into 500 ml M9 minimal medium with 2 mM MgSO4, 0.2 % (w/v) glucose, 0.005 
% (w/v) CaCl2, 0.2 % (w/v) casamino acids, 2 µg/ml thiamine, 100 µg/ml ampicillin and 
incubated at 37°C until A260 = 0.8. chloramphenicol was added (final concentration 0.2 
mg/ml) to inhibit further protein synthesis, and cells were labelled by addition of 18.5 MBq 
tritiated thymine 3H before incubation overnight at 37°C. Cells were chilled and pelleted at 
2,000 x g for 25 mins at 4°C. Pellets were resuspended in 6.25ml solution I and lysed by 
addition of 1ml solution II and incubated at room temperature for 30 minutes. 3ml ice cold 
solution III was added, and samples incubated on ice for 5 minutes prior to addition of 
solution IV and incubation on ice for 30 minutes with occasional mixing. Samples were 
pelleted by ultra-centrifugation at 140,000 x g for 37 minutes at 4°C. The DNA-containing 
supernatant was purified by phenol chloroform extraction and isopropanol precipitation. DNA 
was resuspended in TE and then separated by caesium chloride gradient at 31,0000 x g for 
5 hours. 
2.8.2 gRNA/Cas9 Cleavage Assays    
 CRISPR (gRNA/Cas9, crRNA/Cas12a) complex assembly 
Unless stated otherwise, 50 nM Streptococcus pyogenes Cas9 or 250 nM Lachnospiraceae 
bacterium Cas12a protein was mixed with 50 nM gRNA or 250 nM crRNA in SB and incubated 
at 37 °C for 1 hour. This assembled CRISPR complex can be stored for up to 24 hours at 
4°C.  
 CRISPR (gRNA/Cas9, crRNA/Cas12a) complex plasmid cleavage assays 
For each cleavage reaction, 3 mM plasmid substrate (pSP1 or pUC19) was assembled in RB 
buffer at 37 ᵒC and preheated for 5 minutes. The reaction was started by addition of 10/50 
nM assembled Cas9/Cas12a CRISPR complex which was incubated for the time period 
specified. The reaction was quenched by adding 80 ᵒC 3X STEB and incubating at 80 ᵒC for 
5 minutes. Samples were separated by agarose gel electrophoresis on a 1.5 % (w/v) agarose 




2.8.3 Liquid Scintillation Counting 
Agarose gel bands containing supercoiled, linear and open circle DNA were excised from the 
agarose gel and placed into scintillation vials, including blank gel segments at corresponding 
heights for calibration. 0.5 ml sodium perchlorate was added to each gel slice, and tubes 
were incubated at 67ᵒC for 2 hours to melt the agarose. The vials were cooled to room 
temperature and 10 ml Hionic-Fluor Scintillation Cocktail (Perkin Elmer) was added to each 
vial and shaken thoroughly. Each vial was counted in a Tri-Carb Trio 3100TR Liquid 
Scintillation Counter for 10 minutes.  
Scintillant optimisation: the above protocol was developed when Perkin Elmer Emulsifying 
Scintillator plus scintillation cocktail, as previously used by this lab, was discontinued. The 
previous protocol called for 5ml H2O to be added with the scintillation cocktail, however this 
yielded a biphasic mixture with a range of tested reagents (Ultra Gold XR; Ultra Gold LLT; 
InstaGel Plus; Hionic-Fluor). Following decreasing the volume of H2O, the scintillation 
cocktails were checked for a linear increase in counts with increasing DNA and the Hionic-
Fluor Scintillation Cocktail was found to perform the best. 
2.8.4 Berkeley Madonna 
The Berkeley Madonna 8.0.2 (R. Macey, G. Oster, T. Zahley) software package was used for 
curve-fitting cleavage assays using the following model: 
STARTTIME = 0 
STOPTIME = 300 
DT = 0.02 
d/dt (CCC) = -ka*CCC - kini*CCC 
d/dt (ucCCC) = kini*CCC 
d/dt (OC) = ka*CCC - kb*OC - kini2*OC 
d/dt (ucOC) = kini2*OC 
d/dt (LIN) = kbOC 
Tot CCC = CCC + ucCCC    uncut OC/CCC allows for reaction 
Tot OC = OC + ucOC    not going to completion. 
Init CCC = 95     these values changed to actual 
init LIN = 1     percentage amounts DNA/time for 
init OC = 5     each run 
init ucCCC = 0 
init ucOC = 0 
ka = 0.10      these values allowed to be fit 
kb = 0.10      by software 
kini = 0.02 
kini2 = 0.02 
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2.9 Techniques to study R-loop formation 
2.9.1 Magnetic Tweezers 
Experiments undertaken and analysed by Mark Szczelkun using pSP1 following the protocols 
in Szczelkun et al92. 
2.10 Techniques to study RNA in isolated mitochondria 
2.10.1 Isolation of mammalian mitochondria 
RPE-1 cells were seeded to be 90% confluent on the day of the mitochondrial isolation. Media 
was aspirated, cells washed two times with PBS and cells removed from the culture dish by 
addition of 2 ml trypsin. Once dissociated, cells were transferred into a 14 ml falcon tube and 
centrifuged at 600 x g at 4 °C for 10 min. The cell pellet was resuspended in 1.5 ml ice-cold 
Mitochondrial isolation Buffer. Cells were homogenized using the Cell “cracker” Homogeniser 
(HMG Precision Engineering) with a 10 μm spacing ball bearing. Optimal cell cracking results 
in completely disrupted plasma membranes but intact nuclei, which was monitored by 
observing the integrity of a few μl of cells on a light microscope following successive passages 
through the homogeniser. RPE-1 cells required passing through the homogeniser 14 times 
on average. The homogenate was centrifuged at 600 x g for 10 minutes at 4 °C to pellet 
nuclei. Mitochondria containing supernatant was collected into a new tube and centrifuged 
at 7,000 x g for 10 min at 4 °C to pellet mitochondria. Supernatant was discarded, and pellet 
was washed with isolation buffer. Mitochondrial protein was assessed with the Pierce assay 
as stated above. Three dishes of RPE-1 cells at 90% confluency produced approximately 60 
µg mitochondrial protein.   
2.10.2 Isolation of yeast mitochondria 
Yeast (YPH499) was grown in 400ml YPG with Pen/Strep at 24°C, 150 rpm for ~ 48-72 
hours. When OD600 = 7.5, cells were subcultured into 2 X 1 L YPG pH 5.2 supplemented with 
Pen/Strep to OD600 = 0.5, then grown overnight at 19°C, 120 rpm. When OD600 = 1.2-1.8, 
cells were pelleted (4,000 x g, 10 min, RT), supernatant discarded and pellets re-suspended 
in dH20. Cells were pelleted again (1670 x g, 5 min, RT) and supernatant discarded. Pelleted 
cells were resuspended in DTT buffer (100 mM Tris-SO4 pH 9.4, 10 mM DTT; 2 ml/g pellet) 
and suspension incubated (100 rpm, 15 min, 30°C) before centrifugation (1670 x g, 5 min, 
RT). Supernatant was discarded, and pellet washed with 150 ml zymolyase buffer (1.2 M 
sorbitol, 10 mM KPi pH7.4) and pelleted again (1670 x g, 5 min, RT). Pellet was resuspended 
in zymolyase buffer (6.5 ml/g pellet) and zymolyase added (4.5 mg/g pellet). Suspension was 
incubated (100 rpm, 30 min, 30°C), and cells pelleted by centrifugation (1670 x g, 5 min, 
RT). Pellet was washed with 150 ml zymolyase buffer as before. Cell pellet was resuspended 
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in homogenisation buffer (6.5 ml/1 g; 0.6 M sorbitol, 10 mM Tris-HCl pH 7.4, 0.5% (w/v) BSA, 
1mM PMSF, added just prior to use) and homogenised with a glass potter (1,000 rpm, 15 
strokes). Homogenate was pelleted by centrifugation (1480xg, 5 min, 4°C). Supernatant was 
transferred to a fresh tube, and remaining pellet re-suspended in homogenisation buffer, 
homogenised and centrifuged as before. Supernatants were centrifuged (17,370 x g, 15 min, 
4°C) and supernatants discarded. Pellets were combined and re-suspended in 1 ml ice cold 
SM buffer Resuspended mitochondria were washed with 15 ml SM and centrifuged (1480 x 
g, 5 min, 4°C), supernatant was transferred to a new tube and mitochondria pelleted (17,370 
x g, 15 min, 4°C). Pellet was re-suspended in ice cold SM and diluted to 10 mg/ml following 
quantification by BSA assay. 1 mg aliquots were snap frozen and stored at -80°C. 
2.10.3 Assessing mitochondrial respiration 
Oroboros Oxygraph O2 electrode (Oroboros Instruments) 
Isolated mitochondria were resuspended in a minimal volume respiration buffer (75 mM 
sucrose, 50 mM KCl, 5 mM KH2PO4, 3mM MgCl2, 0.5mM EDTA, 30 mM Tris) and loaded into 
the oxygen electrode chamber containing respiration buffer. Respiration chain substrates, 
such as 2 mM Glutamate, 5mM Malate, 1.5mM ADP, and inhibitors such as 10 µM 
cytochrome c, 10 µM rotenone, 10 µM Antimycin A and FCCP were added directly to the 
chamber using Hamilton syringes.  
XFe96 Extracellular Flux Analyser (Seahorse Bioscientific) 
Mitochondria were diluted in cold Seahorse Assay Buffer to 15 µg protein in 25 μL buffer and 
pipetted into a chilled 96 well cell culture microplate, suitable for the machine. The 
microplate was transferred to a centrifuge equipped with a swinging bucket microplate 
adaptor (Jouan C3i), and spun at 2,000 x g for 20 minutes at 4°C. After centrifugation, 155 
μL 1X Assay Buffer (37°) was added to each well. The mitochondria were viewed under a 
microscope to ensure consistent adherence to the well and the plate was then transferred to 
the XFe96 Analyser. 
Import of protein into isolated yeast mitochondria 
Experiment performed by Dr Holly Ford. Isolated yeast mitochondria were thawed on ice and 
diluted in ice cold Yeast Import Buffer with 2 mM ATP and 2 mM NADH added just before 
use. 100 μg mitochondria were diluted into 100 μl import buffer per condition. The 
mitochondrial suspension was preheated to 25°C in a thermo-mixer with gentle shaking and 
import started by addition of cytochrome b2 Δ43-65 Δ159-591-mouse DHFR-myc-his-cys 
protein, gentle vortex and incubation at 25°C. Import was stopped after 5 minutes with 1 µl 
VOA mix. “- import” condition was treated with VOA mix before addition of protein. Each 
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condition was split int two tubes and treated with proteinase K to digest unimported protein, 
washed twice with 250 μl Yeast Import Buffer and run on a SDS-PAGE gel. 
2.10.4 Import of radiolabelled RNA into isolated yeast mitochondria  
Isolated yeast mitochondria were thawed on ice and diluted in ice cold Yeast Import Buffer 
with 2 mM ATP and 2 mM NADH added just before use. 100 μg mitochondria were diluted 
into 100 μl import buffer per condition. The mitochondrial suspension was preheated to 
25°C in a thermo-mixer with gentle shaking and import started by addition of 33P-labelled 
RNA, gentle vortex and incubation at 25°C. Import was stopped after 5 minutes with 1 µl 
VOA mix. The sample was split into two Eppendorf tubes (50 µl each) and one tube incubated 
with 5 µg RNase A for 15 min at 25°C. RNase was stopped with 1.5 μl RNase inhibitor and 
incubated for 10 min at 25 °C, then washed twice with 250 μl Yeast Import Buffer with 1 μl 
RNase inhibitor (centrifugation at 17,000 x g, 10 mins). Washed pellets were then either run 
on a denaturing urea-PAGE gel directly, or RNA extracted with TRIzol reagent.  
For TRIzol extraction of RNA: each pellet was resuspended in 250 μl TRIzol reagent and tubes 
were incubated at RT for 5 mins, 50 μl chloroform was added and tubes incubated for a 
further 5 mins at RT. Tubes were spun for 15 minutes at 12,000 x g, 4 °C. The upper aqueous 
phase was transferred to a new tube with 125 μl isopropanol with 0.05 μg/μl glycogen and 
incubated for 10 minutes at RT. Precipitated RNA was pelleted by centrifugation at 12,000 x 
g for 10 mins, 4°C. Pelleted RNA was washed twice with 250 μl 75% (v/v) EtOH (spins at 
7,500 x g, 5mins, 4°C), air dried and resuspended in 10 μl 2X formamide RNA loading buffer. 
For direct separation by denaturing-PAGE electrophoresis: Pellets were resuspended in 5 μl 
Yeast Import buffer and 5 μl 2X formamide RNA loading buffer.  
Gel running and processing (for both): RNA in formamide RNA loading buffer was heated to 
100°C for 10 mins before separation by denaturing urea-PAGE (see section 2.4.4). Once run, 
gel was fixed in Gel Fixing Solution for 1 hour, then 30 minutes Gel Fixing Solution with 5% 
(v/v) glycerol. The gel was dried with a pre-programmed schedule (up to 80°C, over 2h) on a 
BioRad model 583 gel dryer, and then exposed on a phosphorimager screen (Fujifilm). 




2.11 Techniques to study RNA from whole cells 
2.11.1 Northern blotting 
 Cellular fractionation and isolation of RNA for Northern blotting 
HeLa cells were seeded to be 90% confluent on the day of the fractionation. Media was 
aspirated, and cells were washed two times with PBS. Cells were detached with trypsin and 
transferred into a 14 ml falcon tube and centrifuged at 600 x g at 4 °C for 10 min. The cell 
pellet was resuspended in 1 ml ice-cold isolation buffer (0.44 M sorbitol, 40 mM EDTA, 10 
mM HEPES-NaOH (pH 6.7), 0.1 % (w/v) SDS). Cells were homogenized using the Cell 
“cracker” Homogeniser (HMG Precision Engineering) with an 8 μm spacing ball bearing, 
according to the manufacturer’s instructions. Perfect cell cracking results in completely 
disrupted plasma membranes but intact nuclei, which was achieved with HeLa cells by 
passing ten times. 100 μl of the whole cell extract was kept for later RNA extraction. The 
remaining homogenate was centrifuged at 1,500 x g for 5 minutes at 4°C to pellet nuclei. 
Mitochondria containing supernatant was collected and centrifuged at 15,000 x g for 20 min 
at 4°C to pellet mitochondria. The supernatant, cytosolic fraction was kept on ice and the 
pellet was washed with isolation buffer and resuspended in 300 μl isolation buffer prior to 
disruption of the outer mitochondrial membrane with 60 ng/μl digitonin for 7 minutes at 
room temperature. Digitonin was diluted by a wash with 700 μl isolation buffer, and after a 
final wash the mitochondrial pellet, nuclear pellet, cytoplasmic fraction and whole cell sample 
were resuspended in 500 μl TRIzol and stored at -80 °C prior to RNA extraction as per the 
manufacturer’s instructions.  
 Northern blotting  
Urea-PAGE gels containing separated RNAs were electro-transferred to Hybond XL nylon 
membrane (GE Healthcare) at 12 V over 12 hours in 0.5X TBE for Northern hybridisation 123. 
RNAs were fixed onto nylon membrane by UV irradiation at 1,500 x 100 μJ/cm2. Membranes 
were prehybridised in 6 X SSC, 0.1 % (w/v) SDS, 10X Denhardtʹs solution for 1h at 65 °C. 20 
X SSC – 3 M NaCl, 0.3 M sodium citrate, 1mM EDTA; 100X Denhardtʹs - 2 % (w/v) BSA, 2 % 
(w/v) Ficoll 400, 2 % (w/v) polyvinylpyrolidone. Hybridisation of 8 x 7cm membranes in 50ml 
falcons used 2.9 ml prehybridisation solution. Membranes were then hybridised in one 
volume prehybridisation solution containing one volume ([probe]f: 2ng/ml) 5ʹ- 32P-labelled 
oligonucleotide probe by incubation overnight at Tm - 5°C. Probes, Table 17, of known 
cytoplasmic and mitochondrial RNAs were used as positive controls for cellular 
compartments, and designed hybridisation probes against gRNAs and mitochondrial 
targeted RNA aptamers determined transfected RNA cellular localisation. Following 
60 
 
hybridisation, membranes were washed 3 times for 10 mins in 2X SSC and 0.1% (w/v) SDS 
at room temperature and exposed on a phosphorimager screen which was imaged with a 
Typhoon-Trio scanner (GE Healthcare). 
Labelling hybridisation probes: dephosphorylated DNA oligonucleotides were labelled with 
bacteriophage T4 polynucleotide kinase by incubation for 1 hour at 37°C with a 5-times molar 
excess of 10 mCi/ml γ-32P ATP (Hartman Analytic, SRP 301) as per the manufacturers’ 
instructions. The reaction was terminated by addition of EDTA (final concentration 20 mM), 
and probes were purified from unincorporated nucleotide with BioRad Micro Bio Spin P-6 
columns. 
HeLa transfection for AD/FD time course (Figure 6-3) In a 6-well dish, 70-80% confluent 
HeLa cells were transfected with 20 pmoles RNA using Lipofectamine. Cells were harvested 
at the indicated timepoint, whole-cell RNA extracted, separated by urea-PAGE and Northern 
Blotted with tRK1 as above. 
HeLa transfection for northern blotting AD/FD: A 10 cm dish of 70-80% confluent HeLa cells 
were transfected with 80 pmoles AD and FD RNA using Lipofectamine. Cells were harvested, 
fractionated and northern blotted as above.  
HeLa transfection for northern blotting gRNA±RP/FD: A 10 cm dish of 70-80% confluent 
HeLa cells transfected with 300 pmoles gRNA, gRNA 5' RP and gRNA 5' FD using 
Lipofectamine. Cells were harvested and fractionated and northern blotted as above. 
2.11.2 Cellular distribution of fluorophore-labelled RNAs 
In a 6-well dish, RPE-1 cells were grown on glass coverslips. When 70-80% confluent, cells 
were transfected with 20 pmoles Alexa™ 488-labelled RNA by PEI transfection as described 
above.  
2.11.3 Baby Spinach fluorescent RNA characterisation 
Fluorescence measurements were performed with a Varian Cary Eclipse fluorescence 
spectrophotometer in a Hellma Quartz cuvette (105253-QS); excitation wavelength 460 nm, 
emission wavelength 475-650 nm, slit widths 50 nm. 
For RNA-only measurements 1 µM RNA was assembled in 1X RNA aptamer buffer on ice, 
with or without 20 µM DFHBI-1T (Lucerna) as described by the manufacturer.  
For Cas9/gRNA complexes 1 µM RNA was assembled on ice with 1 µM Cas9 in in 1X RNA 
aptamer buffer, with or without 20 µM DFHBI-1T. Complexes were either incubated at 37 °C 




2.12 CRISPR kits 
2.12.1 GeneArt™ gRNA Synthesis and Precision™ Cas9 nuclease transfection 
gRNAs were synthesised using the GeneArt™ Precision gRNA synthesis kit (Invitrogen) as per 
the manufacturer’s instructions and purified with GeneJET™ RNA purification micro columns 
(Thermo). HeLa cells were seeded 24 hours prior to transfection in a 24-well plate format at 
0.05 x 106 cells per well. The GeneArt™ Platinum™ SpyCas9 nuclease and in vitro transcribed 
gRNAs were transfected with Lipofectamine™ CRISPRMAX™ (Thermo) as per the 
manufacturer’s instructions (500 ng Cas9 nuclease and 125 ng gRNA per well).  
Table 22 GCDA gRNA target sequences 






2.12.2 CRISPR GeneArt™ Genomic Cleavage Detection Assay (Life Technologies) 
The GCDA assay provides a quick readout of efficiency of DSB formation by CRISPR at the 
desired site. The kit was used as per the manufacturer’s instructions. DNA is extracted from 
cells which have been transfected with CRISPR components and a PCR is performed to 
selectively amplify a loci of interest which contains the site targeted for DSB formation, Table 
23. The PCR products are melted and reannealed. If CRISPR has been effective, the target 
site will be highly variable between PCR amplicons, resulting in mismatches when PCR 
amplicons are reannealed. These mismatches are selectively cleaved by a T7 endonuclease 
detection enzyme to give two smaller DNA strands. 
Table 23 GCDA PCR primers 
gRNA target Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′) 
HPRT AGCAGCTGTTCTGAGTACTTGC (22) GGTATCTCCATAAGACAGAATGC (23) 
COX1 GAAAATCACCTCGGAGCTGG (20) TTTGGTATTGGGTTATGGCAGG (22) 
COX2 CGAACCCCCCAAAGCTGG (18) CAGCTCATGAGTGCAAGACGTC (22) 









3.1 Mammalian cell expression systems for Cas9 
At the time of writing this thesis in 2018, the range of commercially available plasmids, kits 
and reagents to facilitate CRISPR workflows is extensive: Addgene has over 6,300 CRISPR 
plasmids contributed by over 330 labs worldwide164, and most laboratory suppliers have their 
own flavour of CRISPR kits available. The story was quite different when we began this project 
in 2014. Although there had already been an outpouring of CRISPR products, the number of 
available CRISPR plasmids was only a fraction of those available today; these first CRISPR 
kits were only in their first iterations and required much troubleshooting.  
Chapter 3 describes the use of a commercial plasmid expression system to target SpyCas9 
to mammalian mitochondria using the cytochrome c oxidase subunit viii (COX8A) MTS 
introduced in section 1.3.4. The results are inconclusive, since the efficiency of 
transformation of SpyCas9 was poor. Subsequent work from the MitoCRIPSR research group 
is described that confirms these early observations and shows that other CRISPR-Cas 
enzymes (in particular LbCas12a) with alternative MTSs can be efficiently transfected into 
cells and targeted to mitochondria. 
3.1.1 DNA transfection 
Advancements in mammalian culture transfection techniques have played an important role 
in driving advancements in genome editing. The efficiency with which CRISPR nucleases and 
gRNAs can be expressed within a cell line or model organism is pivotal to CRISPR efficacy, 
and remains one of the key challenges to implementation165. Although plasmid transfection 
techniques were initially commonplace, the field is now increasingly moving towards mRNA 
or ribonucleoprotein (RNP) complex transfection-based approaches, both of which have 
several advantages including shorter workflows and, dependent on application, greater 
efficiency of CRISPR action166. 
An overview of the main techniques for the delivery of CRISPR machinery to mammalian cells 
is given in the following sections, with a focus on whether each method would be appropriate 
for developing a MitoCRISPR system. This is summarised in Figure 3-1. 
 Mammalian expression vectors 
Mammalian expression vectors were the first available method of CRISPR delivery. An 
extensive range of plasmids are available which are: tailored to cell types and applications; 
have varying strengths of inducible and constitutively active promoters (Tet-ONiii and CMViv 
                                                     
iii Addgene plasmid #50661221 
iv Addgene plasmid #6998894 
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or CBhv are respective examples); incorporate a wide range of reporter genes and selectable 
markers such as GFP expression or drug resistance; express CRISPR nucleases and gRNAs 
from separate vectors, or a single combined vector. Moreover, delivery systems such as lipid-
based transfection and electroporation have been widely optimised for delivery of CRISPR 
components for standard applications167. As the doubling time of many culture cell lines is 
approximately 24 hours, transient transfection is often sufficient when CRISPR is being used 
for genome editing, such as for the generation of knock-out and disease model cell lines168, 
but mammalian expression vectors have also been used for generating cell lines stably 
expressing CRISPR components. 
 
Figure 3-1 Available technologies for delivering CRISPR machinery to mammalian cells include DNA transfection 
(red), RNA transfection (blue), and transfection of pre-formed ribonucleoproteins (RNPs, green). DNA encoding 
CRISPR components can be expressed stably or transiently, whereas RNA and RNP methods are only expressed 
transiently. Each route has several potential mechanisms of delivery which could theoretically be harnessed for 
delivery of a nuclear or mitochondrial targeted CRISPR system. 
                                                     
v Addgene plasmid #48138222 
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 Viral expression vectors 
All four major viral delivery systems (retroviruses, lentiviruses, adenoviruses and adeno-
associated viruses (AAVs)) have now been used to target DNA encoding CRISPR machinery 
to mammalian cells. Each have their own advantages and limitations, making them 
appropriate in different circumstances, as reviewed by Schmidt and Grimm169.  
Of particular concern at the beginning this project was the safety of using a viral delivery 
system for CRISPR tools, particularly given that - at that time - very few people at the University 
of Bristol were using CRISPR. AAVs are the only viral vector which do not contain any viral 
genes. Being derived from apathogenic viruses, AAVs have the lowest level of safety concern 
of all viral vectors as they are also incapable of replication. However, the AAV is likely not 
suitable for transfection of a MitoCas9. The vector has a size limit of 4.9 kbp, only just above 
that of the 4.2 kbp Cas9 coding sequence; once mitochondrial targeting sequences have 
been included, there would be limited space for necessary promoters and polyadenylation 
sequences, let alone the gRNA expression that would be required for full MitoCRISPR.  
Although there are several attenuated strains (which, like the AAVs do not contain viral genes) 
lenti-, retro-, and adenoviral vectors are all derived from pathogenic viruses. This makes 
safety concerns surrounding their handing, such as the accidental generation of a replication-
competent virus, more significant than AAVs. In the intervening years, using viral for CRISPR 
expression has become more commonplace, and their use is mentioned in the context of this 
project in section 3.4. 
3.1.2 Ribonucleoprotein (RNP) complex transfection 
Given that the focus of many CRISPR tools is genome editing, CRISPR machinery is only 
required in the target cell for a short period of activity. The persistence of Cas9 and gRNA in 
a cell for an extended period would potentially result in off-target activity; any way of 
expressing a CRISPR nuclease and gRNA in a cell for a limited time only will be advantageous 
in these cases. One way of doing this is to pre-form an RNP between the CRISPR nuclease 
and gRNA which is directly transfected into the cells. RNP transfection has been widely 
reported to be highly effective170,171. This approach also allows the incorporation of synthetic 
crRNA/tracrRNA or sgRNA, allowing modification of the RNA, which can increase efficacy in 
human cells, including fully chemically modified RNAs (without any 2'-OH groups)172,173 or the 
doping of deoxyribose nucleotides at specific positions to reduce synthesis costs174. 
Many companies now sell kits to facilitate RNP transfection into mammalian cells in culture 
and model organisms. The eventual dilution/degradation of the CRISPR-Cas system allows 
the edited cell lines or organisms to no longer contain the CRISPR machinery, which could be 
potentially useful if MitoCRISPR were to move to the clinic and be used in embryos. However, 
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it remains to be seen how a folded RNP would be delivered to the mitochondrial matrix; the 
RNP would either need to be completely unfolded to pass through TOM/TIM or enter the 
mitochondria independently.   
In the early stages of this project use of one of these kits, the GeneArt Genomic Cleavage 
Detection Assay (Invitrogen), was attempted. However, following limited success at 
optimising the kit this method was not pursued. The results of this are overviewed in Appendix 
A3-III. 
3.1.3 Cas9 mRNA and gRNA transfection 
A second method for transient CRISPR activity in cells is to in vitro transcribe the Cas9 gene 
and gRNA and transfect the mRNA and gRNA molecules into the cell175. The mRNA is then 
translated by the cells own machinery. Given that the mRNA and gRNA will not be replicated 
by the cell, they are instead degraded over time. Since proteins are translocated across the 
OMM and IMM unfolded, and there is a requirement for chaperones to aid the process of 
mitochondrial import, transfecting an mRNA to be transcribed in the cytosol shows potential 
for a MitoCRISPR system, but due to time constraints was not explored here. 
3.2 Plasmids for mammalian cell expression of Cas9  
The first approach which was taken for mammalian cell expression of Cas9 in this project 
was a plasmid DNA transient transfection technique. This decision was based partially on our 
concerns about the safety of a viral transfection technique, and on the higher level of 
expertise and understanding in our lab surrounding plasmid-based techniques for 
mammalian cell transfection over RNA or RNP-based methods. The goal was to clone a 
plasmid encoding SpyCas9 with an N-terminal COX8A MTS and express it in mammalian cell 
culture. 
3.2.1 pD1301 plasmid series 
Standard cloning techniques, as described in section 2.3.3, were used to edit a commercially 
available plasmid, pD1301-AD (Formerly DNA 2.0, now ATUM), Figure 3-2, to develop a library 
of plasmids for mammalian cell expression of nuclear and mitochondrial Cas9 and gRNAs. 
For final plasmid series, see Figure 3-5. 
pD1301 encodes the sequence for human codon optimised SpyCas9, flanked by two nuclear 
localisation sequences (NLS) and followed by DasherGFP, all under the control of the 
constitutive mammalian cytomegalovirus (CMV) promoter. DasherGFP is a synthetic non-
Aequorea fluorescent protein, developed by DNA2.0 (λexcitation = 505 nm; λemission = 525 nm). 
Coding sequences for Cas9 and DasherGFP are separated by a self-cleaving peptide, the cis-
acting hydroxylase element from the Thosea asigna virus (TAV CHYSEL)176. This allows for the 
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equal co-expression of both proteins, which are separated as the translating ribosome ‘skips’ 
at the C-terminus of the 18-residue CHYSEL sequence. pD1301 also encodes the gRNA 
scaffold under the control of a U6 promoter. gRNA spacer sequences can be added by 
circularising the plasmid and inserting a dsDNA with complimentary ends. 
 
Figure 3-2 pD1301i (DNA2.0)plasmid map. pD1301i encodes mammalian codon-optimised Cas9 flanked by 
two nuclear localisation sequences (NLSs) and DasherGFP under the control of the cytomegalovirus (CMV) 
promoter. Cas9 and GFP are separated by the Thosea asigna virus self-cleaving element (TAV). The plasmid 
also encodes the gRNA scaffold sequence under the control of the U6 promoter and Kanamycin resistance 
(KanR). 
Although there were several other CRISPR plasmids available at the time, pD1301 was 
chosen as it contains both the gRNA scaffold and Cas9 coding sequence in one plasmid. The 
CMV promoter is familiar to the lab and should give reliable expression in the cell types to be 
used (HeLa, RPE-1). Additionally, pD1301 is classed by DNA2.0 as “IP-free”, meaning it has 
few intellectual property limitations, something we considered to be advantageous regarding 
a potential future where we wished to patent a MitoCRISPR system. The following section, 
outlined in Figure 3-3, describes the cloning of a series of plasmids, based on pD1031, for 
mammalian cell expression of Cas9. Briefly, this included: replacing two NLSs with the COX8A 
MTS; removal of the gRNA region; removal of the TAV CHYSEL to give a Cas9-GFP fusion 
protein.  
pD1301 was delivered in a linear form, cut by DNA2.0 directly adjacent to the gRNA scaffold 
in preparation for use with the company’s CRISPR ELECTRA cloning systemvi. The ELECTRA 
system uses proprietary reagents to insert a 20 nt protospacer sequence and ligate the 
plasmid in one step. Following communication with DNA2.0, during which they were not 
willing to disclose the nature of the ends of the DNA fragment, a recircularisation method 
was developed as detailed in Figure 3-4 and Appendix A3: Primers were designed to amplify 




the linearised pD1301 plasmid by inverse PCR and introduce SapI restriction sites. The blunt-
end PCR was then ligated to form an intact plasmid, pD1301. 
 
 
Figure 3-3 pD1301 cloning scheme  is described above, including i plasmid recircularisation (expanded upon in 
Figure 3-4) A removal of 3′ nuclear localisation sequence (NLS), B gRNA sequence removal, C 5′ NLS removal 
and replacement with a mitochondrial targeting sequence (MTS) and E Thosea asigna virus self-cleaving 
element (TAV) removal. In each step where inverse PCR was used, the coloured arrows indicate the sites of 




SapI is a type IIS restriction enzyme which produces a staggered cut downstream of its 
recognition sequence, 5′-GCTCTTC-3ʹ. The choice of a type IIS enzyme facilitates ‘scarless’ 
insertion of spacer sequences; cutting with SapI will remove the fragment of the plasmid 
containing its own recognition sites. A 20 nt DNA fragment with corresponding overhanging 
ends can then be inserted into the protospacer region of the gRNA scaffold, Figure 3-4.  
 
Figure 3-4 pD1301 Recircularisation was carried out by inverse PCR, followed by blunt-end ligation. Primers were 
designed to introduce the recognition sites for SapI, a type IIS restriction enzyme (blue), thereby constructing a 
system to easily interchange protospacers in the gRNA scaffold. 
The 3′ NLS was removed by inverse PCR and the resulting plasmid, pD1301iA (9010 bp), 
was verified by sequencing and restriction digest, Appendix A3-I. 
Proteins must be unfolded prior to mitochondrial import via TOM/TIM. It was a consideration 
that the expression of gRNA in the cell might result in RNP formation, holding Cas9 in a folded 
state which hindered mitochondrial import. For this reason, an inverse PCR method was used 
to remove the gRNA region from pD1301iA – the U6 promoter and the gRNA scaffold coding 
sequence. The resulting plasmid, pD1301iAB (8570 bp), was verified by sequencing and 
restriction digest, Appendix A3-I. 
Initially, an inverse PCR method (as above) was attempted for removal of the NLS upstream 
of the Cas9 coding sequence, Appendix A3-II. Primers were designed with 50/46 nt 
overhangs which together would introduce the 96 bp MTS. However, although the primers 
were checked for hairpin and primer-dimer formation (OligoCalc177), the PCR was 
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unsuccessful, likely because the overhangs were too long. Secondly, a nested PCR method 
was attempted with a series of three sets of primers, successively longer in length, to 
construct the MTS sequence. However, PCR beyond the first round was also unsuccessful.  
For the successful cloning, a plasmid was synthesised (pEX-MTS, Eurofins) which contained 
the COX8A MTS insert, flanked by a 5′ PciI site and a 3′ AgeI site. pD1301iAB was amplified 
by inverse PCR to remove the 5′NLS sequence with primers which incorporated a naturally 
occurring 3′ NcoI site (which produces ends compatible with PciI) and a 5′ AgeI site. The 
fragments were ligated together to form pD1301iABC, which was sequence verified by 
restriction digest and full plasmid sequencing. The same process was repeated with 
pD1301iA to produce pD1301iAC. 
An inverse PCR method was also used to remove the TAV ribosomal stalling sequence from 
pD1301iABC and pD1301i to give pD1301iABCE and pD1301iE, constructs for the 
expression of mitochondrial and nuclear targeted Cas9-GFP fusion proteins, which were used 
by Zuriñe Anton, section 3.4. 
 
 
Figure 3-5 pD1301 plasmid series pD1301i forms the basis of this plasmid series which includes plasmids 
expressing nuclear targeted SpyCas9 (pD1301i, pD1301iE), mitochondrial targeted Cas9 (pD1301iAC, 
pD1301iABC and pD1301iABCE), and mitochondrial targeted GFP (pEGFP-N1 MTS), all under the control of the 
cytomegalovirus (CMV) promoter. pD1301i, pD1301iAC and pD1301iABC contain the Thosea asigna virus self-
cleaving element (TAV) between Cas9 and GFP, meaning the two proteins are transcribed separately. In 
contrast, pD1301iE and pD1301iABCE have had their TAV sequence removed so that they express a Cas9-GFP 
fusion protein. pD1301i, pD1301iAC and pD1301iABCE all contain the gRNA scaffold sequence under the 
control of the U6 promoter. All plasmids encode Kanamycin resistance (KanR). MTS = mitochondrial targeting 




3.3 Expression of nuclear and mitochondrial Cas9 in mammalian 
cell culture 
3.3.1 Verification of COX8A MTS function 
To verify the ability of the COX8A MTS to mitochondrially target a protein of interest, the 
COX8A MTS from pEX-MTS was cloned in to the multiple cloning site of pEGFP-N1 to produce 
pMTS-EGFP. HeLa cells transiently transfectedvii with pEGFP-N1 and pMTS-EGFP showed 
cytosolic and mitochondrial GFP localisations, respectively, Figure 3-6, confirming that under 
our experimental conditions the COX8A MTS, expressed under the CMV promoter can localise 
proteins to the mitochondria. 
 
Figure 3-6 HeLa cells transfected with pEGFP-N1 and pMTS-EFGP display cytosolic and mitochondrial GFP 
localisations, respectively DAPI (blue) 5ms; GFP (green), 250 ms Scale bar: 10 μm 
3.3.2 Transfection of NLS-Cas9 (pD1301i) and MTS-Cas9 (pD1301iABC) 
pD1301i and pD1301iABC were transiently transfected into HeLa and RPE-1 mammalian 
cell lines. Figure 3-7A shows widefield microscopy images of RPE-1 cells transfected with 
pD1301i and pD1301iABC. The TAV CHYSEL sequence between Cas9 and GFP means GFP 
fluorescence will not necessarily correlate with Cas9 localisation, instead GFP can be used 
as a marker of successful transfection. NLS-Cas9 and MTS-Cas9 localisation should differ as 
reported by anti-Cas9 antibodies. Figure 3-7A shows cells transfected with pD1301i (NLS-
Cas9), pD1301iABC (MTS-Cas9) and phCas9D10A (A commercial NLS-Cas9D10A). There is no 
observable difference between NLS-Cas9 and MTS-Cas9. There does appear to be some cell-
to-cell variation within each condition, but these variations do not correlate between anti-
Cas9 and GFP. Moreover, the GFP signal is low, and there is a high background signal with 
the anti-Cas9 antibody staining.  
                                                     
vii Unless stated otherwise, all transient transfections in this section were performed with 
Lipofectamine 2000 as detailed in section 2.6.3.1.  
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Figure 3-7B shows immunoblotting for anti-Cas9 and anti-GFP of whole-cell proteins 
extracted from HeLa and RPE-1 cells. An antibody against tubulin is used as a protein loading 
control. GFP is expressed in RPE-1 cells transfected with pEGFP-N1 and pMTS-EGFP, but 
there is no specific signal from the anti-Cas9 or anti-GFP antibody in any of the cells 
transfected with a range of CRISPR plasmids.  
phCas9D10A and phCas9WT are plasmids which have been successfully used by the Stephens 
lab (Bristol University) to generate CRISPR knock-out cell lines. They should be expected to 
be expressed well enough in cells when observed by immunoblotting and show a nuclear 
localisation in fluorescence microscopy – however neither were detected, Figure 3-7, though 
anti-Cas9 antibody staining did seem to be slightly correlated with raised GFP signal in some 
cells. 
 
Figure 3-7 Cas9 cellular expression  A Fluorescence microscopy of RPE-1 cells transfected with pD1301i (NLS-
Cas9), pD1301iABC (MTS-Cas9) and phCas9D10A; scale bar 10 μm B Immunoblotting HeLa and RPE-1 cells 




Following the poor expression of pD1301iABC (MTS-Cas9), RPE-1 cells were co-transfected 
with pD1301iABC and pDsRedMito, which expresses mitochondrial-targeted RFP under a 
CMV promoter. Cells taking up plasmid DNA should take up an equal mix of pDsRedMito and 
pD1301iABC, so RFP-positive cells should also be expressing pD1310iABC. Given both MTS-
Cas9 and RFP are expressed under the CMV promoter, they should also be transcribed at 
comparable levels.  
Figure 3-8 shows RPE-1 cells co-transfected with pD1301iABC and pDsRedMito. Although 
some cells showed RFP-positive cell mitochondrial networks (marked #), there was not any 
corresponding increase in GFP signal in these cells. Instead, the four cells marked # and * 
displayed similar GFP signal levels, despite having differing pDsRedMito expressions (# has 
high and * low pDsRedMito). This implies that the signal through the green channel could 
background, rather than a result of GFP expression from pD1301iABC – that is to say 
pD1301iABC is likely not being expressed in these cells.  
 
Figure 3-8 Co-transfection of pD1301iABC (MTS-Cas9) with pDsRed-Mito ; Scale bar 10 μm 
3.3.3 Fluorescence Activated Cell Sorting (FACS) 
Assuming a low level of transfection efficiency, we reasoned that successfully transfected 
cells could be separated and expanded from a small population by Fluorescence Activated 
Cell Sorting (FACS). FACS was used to separate a population of pD1301iABC and pD1301i 
expressing RPE-1 and HeLa cells from non-transfected cells, Figure 3-9. A population of non-
transfected parent cells (top panels) were used to gate the cells such that GFP-negative cells 
could be sorted from GFP-positive cells. The density plots below show the GFP fluorescence 
(y-axis) against incorporation of propidium iodide (PI) (x-axis), a cell viability dye. Living cells 
do not incorporate PI (purple box), whereas dead cells do (pink box). 
For HeLa cells, 0.76% of cells were GFP positive when transfected with pD1301iABC, Figure 
3-9 middle left and 2.24% when transfected with pD1301i, bottom left. In both cases, there 
was a decreased viability on transfection in comparison to non-transfected cells.  
According to the same gating parameters, RPE-1 cells transfected with pD1301iABC were 
21.75% positive for pD1301iABC, Figure 3-9 middle right. It is important to consider that 
some of this signal might not be due to GFP expression and instead cell autofluorescence. In 
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general, larger and more granular cells have more autofluorescence, as do cells undergoing 
apoptosis; In particular, RPE cells accumulate lipofuscin with age, which is 
autofluorescent178. The large shift in PI incorporation, as well as the gross change in 
fluorescence at 530/40 nm implies that these cells had undergone a large change in viability 
or morphology with respect to the non-transfected cells.  
 
 
Figure 3-9 FACS of HeLa and RPE-1 cells transfected with pD1301i (NLS-Cas9) and pD1301iABC (MTS-Cas9)  
All panels show y-axis: GFP fluorescence (λexcitation 488 nm; Filters: 530/40) x-axis: PI incorporation (λexcitation 
552 nm; Filters: 582/29) Colour scale is representative of number of cells (Blue -> Red) top panels parent, non-
transfected HeLa and RPE-1 cells middle panels HeLa and RPE-1 cells transfected with pD1301iABC (MTS-Cas9) 




3.4 Conclusions and further work targeting CRISPR nucleases to 
mitochondria 
Prior to embarking on this project, the mitochondrial targeting of Cas9 was expected to be 
straightforward, particularly given the wide range of proteins which have been successfully 
targeted to mitochondria detailed in section 1.3.4. However, using a plasmid DNA approach 
for cellular expression of nuclear targeted and mitochondrial COX8A-targeted SpyCas9 
demonstrated that delivery of Cas9 is instead a critical step. Not only was a very low 
transfection efficiency seen in mammalian cells transfected with pD1301iABC and pD1301i, 
(just 0.76 and 2.24% respectively in HeLa cells) but expressing COX8A-Cas9 seems to lead 
to decreased cell viability as measured by PI uptake, a result which was particularly severe 
in RPE-1 cells, Figure 3-9. These two conclusions drawn from the FACS data help explain why 
immunofluorescence and immunoblotting experiments were largely unsuccessful in Figure 
3-7 and Figure 3-8. 
In early 2017, a BBSRC funded grant was awarded from the Bristol BrisSynBio centre and Dr 
Zuriñe Anton and Dr Holly Ford joined the MitoCRISPR project as postdoctoral researchers. 
Whereas the focus of this thesis became the modifications of gRNAs for MitoCRISPR, Zuriñe 
Anton has continued the work started in this chapter. Using pD1301iABCE, some MTS-Cas9-
GFP signal can be seen in mitochondria 19h post-transfection in RPE-1 cells, Figure 3-10A. 
However, the signal is weak, and some cells still have nuclear and cytosolic GFP signal. NLS-
Cas9-GFP (pD1301iE) is mostly localised to the nucleus, but also with some cytosolic signal.  
Following longer expression periods (up to 48h), Figure 3-10A, there appeared to be an 
impact on mitochondrial health following MTS-Cas9-GFP expression, as the GFP signal 
became more cytosolic, and mitochondrial antibody staining (as seen by anti-TOM20 
antibody staining) was noticeably fainter. In contrast, mitochondria in the NLS-Cas9-GFP 
expressing cells appeared healthier. The impact of MTS-Cas9-GFP expression on 
mitochondrial health is supported by live imaging of transiently transfected cells stained with 
Mitotracker Red, Figure 3-10B. In early stages of transfection and in cells expressing low 
levels of MTS-Cas9-GFP (white dashed line), mitochondrial networks appear healthier than 
in later stages and in cells expressing high levels of MTS-Cas9-GFP (orange dashed line). This 
is indicated by mitochondria becoming fragmented and by a potential absence of 
mitochondrial membrane potential, as indicated by low Mitotracker staining. Together these 





Figure 3-10 A Fixed Cell imaging  RPE-1 cells transfected with pMTS-GFP, pD1301iE (NLS-Cas9-GFP) and 
pD1301iABCE (MTS-Cas9-GFP). Cells are healthier 19h post-transfection than 48h post-transfection B Live Cell 
Imaging RPE-1 cells transfected with pMTS-GFP, pD1301iE (NLS-Cas9-GFP) and pD1301iABCE (MTS-Cas9-GFP). 
Data collected by Zuriñe Anton. 
A range of alternative CRISPR nucleases were cloned for mammalian cell expression, 
including SaCas9, AsCas12a, and LbCas12a. In each case, mammalian codon-optimised 
sequences were used. Additionally, alternative MTSs were tested in addition to COX8a, 
including Su9 and Atg4D, both introduced in section 1.3.4. The mitochondrial targeting 
efficiency, as observed with immunoblotting and fluorescence microscopy, was greatest 
using LbCas12a transiently transfected in RPE-1 cells. MTS-LbCas12a-GFP transfected cells 
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looked much healthier than MTS-Cas9-GFP cells, and all the tested MTSs show mitochondrial 
localisation by fluorescence microscopy. Su9-LbCas12a-GFP signal was the most efficient 
when measured by immunoblotting, while COX8A-LbCas12a-GFP cells also showed some 
cytosolic signal, Figure 3-11. 
 
Figure 3-11 Cellular Expression of LbCas12a-GFP top Immunoblotting and bottom fluorescence microscopy of 
RPE-1 cells transfected with LbCas12a-GFP, mitochondrially targeted with a range of MTSs, including those from 
Atg4D, SU9 and COX8A. Scale bars 10 µm. Data collected by Zuriñe Anton. 
There are a number of reasons why SpyCas9 transfection and localisation is much poorer in 
comparison to LbCas12a and SaCas9. One could be the reduced size of SaCas9 (SaCas9 is 
130 kDa/1053 aa, in comparison to SpyCas9 being 160 kDa/1368 aa), however this is 
unlikely to be the sole factor - LbCas12a is not so much smaller. The relative charges and 
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amino acid bias of the proteins are likely to also play a role, as will the availability and identity 
of N-termini resulting in LbCas12a variants being trafficked and/or imported into the 
mitochondria more efficiently. In addition to factors favouring import, some unpublished 
reports suggest that Cas9 variants naturally have internal NLS-like sequences (Szczelkun, 


















4.1 Functionalising gRNAs for MitoCRISPR 
Several groups have successfully equipped the gRNA structure with functional RNA motifs. 
Modifications of the gRNA in this way can localise accessory functionalities including 
fluorescence, transcriptional activation and repression to the CRISPR RNP and targeted DNA 
locus108,156,179–181. Although these ‘accessorised’ gRNAs have been shown to still function 
broadly, little work has been done to understand the impacts of gRNA modification on CRISPR 
RNP complex formation and function. In this chapter, a library of modified gRNAs for 
MitoCRISPR are designed which incorporate RNA motifs into several distinct locations in the 
gRNA. Single molecule and ensemble biochemical techniques are used to understand the 
impacts of these modifications on gRNA loading by Cas9, subsequent R-loop formation and 
endonuclease activity.  
There are many distinct functionalities which might be advantageous to equip a MitoCRISPR 
gRNA with: structures which aid efficient cell uptake and mitochondrial localisation; 
fluorescence to allow gRNAs to be followed in the intracellular environment. Furthermore, by 
modulating interactions with mitochondrial proteins of interest one could better understand 
mitochondrial biology and dynamics or use interactions with mtDNA to understand 
mitochondrial nucleoid organisation, genetics and the DNA damage response. Of these 
functionalities, mitochondrial localisation is the most important for establishing MitoCRISPR, 
and as such the addition and characterisation of mitochondrial targeting structures to the 
gRNA form the focus of this chapter. 
4.2 Designing a library of gRNAs for MitoCRISPR 
The RNA structures described in section 1.5.2.2 have already proven therapeutic potential 
in disease cell lines and could provide a vector for mitochondrial delivery of gRNAs for 
MitoCRISPR. There have been several papers which add RNA modifications to gRNAs, 
however there has been no in-depth study of their impact on Cas9 RNP formation, 
intermolecular domain motions and target DNA cleavage. A library of gRNAs for MitoCRISPR 
which incorporated some of the mitochondrial targeting elements above was designed and 
transcribed with a view to firstly interrogate the impact of gRNA structural modifications in 
different sites, and secondly target them to mitochondria, which is studied in Chapter 6. This 
chapter firstly describes the design of a gRNA library for MitoCRISPR, and secondly 
interrogates the impact of bulky modifications to the gRNA structure on: gRNA loading with a 
FRET-based assay; R-loop formation using a magnetic tweezer set-up; endonuclease activity 
with a biochemical cleavage assay.    
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4.2.1 gRNA structure  
The structures of Apo182, RNA-bound183 and RNA/DNA-bound SpyCas9184 have been solved. 
The 2.5 Å crystal structure, shown in Figure 4-1A, is of SpyCas9 in complex with the minimised 
98 nt single gRNA targeting a 23 nt DNA. A 20 nt spacer sequence at the 5′ end of the gRNA 
binds the target DNA strand through Watson-Crick base pairing. A second highly folded region 
of the gRNA is responsible for binding Cas9 through contacts with several regions of self-
complementarity: the lower and upper stems, the nexus and hairpin regions, Figure 4-1B. 
The crystal structure reveals extensive contacts between the negatively-charged gRNA and 
the positively-charged surfaces of Cas9: Cas9 folds around the RNA/DNA duplex and the 
lower stem-bulge-upper stem region in two lobes, the recognition (REC) and nuclease (NUC) 
lobes; much of the hairpin regions of the gRNA contact a positively charged region on the 
Cas9 outer surface.  
Studying Cas9 crystal structure alone does not reveal many likely candidate sites for 
modification, as much of the gRNA structure is in contact with either target DNA or the inner 
surfaces of the protein. Indeed, the gRNA forms most of the interactions between the REC 
and NUC lobes of Cas9 which do not form extensive protein-protein interactions themselves. 
One exception to this is the upper stem of the gRNA, which has already shown to be tolerant 
of modification, being truncated relative to the naturally occurring crRNA/tracrRNA duplex89. 
In addition to solving the RNA/DNA-bound SpyCas9 crystal structure184, Nishimasu et al also 
studied the impact of mutated gRNAs on CRISPR-induced indels. Removing structures with 
extensive Cas9-contacts, such as the bulge and nexus, completely abolished Cas9 function. 
Mutations were tolerated in other regions of the gRNA, particularly those which are not 
directly in contact with Cas9 such as the first of the 3′ hairpin structures. Briner et al 185 more 
extensively characterised the functional modules of the gRNA required for directing 
specificity. Agreeing that the bulge and nexus are the most important structures for Cas9 
binding, this study also highlights the possibility of modifying the 5′ and 3′ termini, upper stem 
and hairpin 1 of the gRNA structure. Both of these studies are summarised as a theorised 











Figure 4-1 SpyCas9 gRNA structure  A The structure of SpyCas9 (blue) in complex with gRNA (black) and target 
DNA (grey) and simplified schematic (inset). PDB ID: 4OO8 184. B gRNA structure from A with structural features 
labelled: spacer (black); lower stem (green); bulge (orange); upper stem (blue); nexus (beige); hairpins (purple). 
C gRNA schematic with colouring consistent with B. D gRNA heatmap, based on Briner et al185 shows gRNA 




4.2.2 MitoCRISPR gRNA library  
Based on the evidence in the previous section, a library of gRNAs was designed which 
incorporated mitochondrial targeting (RP, MRP, F1D1, tRK1) and fluorescent aptamers (Baby 
Spinach (BS), Bunch of Baby Spinach (BoBS)) into four locations in the gRNA structure: the 
5′ end, 3′ end, upper stem (US) and hairpin 1 (H), Figure 4-2.  
 
Figure 4-2 gRNA library  schematics of modified gRNA Library with generalised imagined fold, right. See Appendix 
A4 for complete sequences, colouring is consistent with Figure 4-1. * denotes the ‘minimal’ library. 
 
The RP, MRP, F1D1 aptamers and the full tRK1 structure were incorporated into the gRNA 
structure for mitochondrial targeting. RP, as the smallest aptamer, was added most 
extensively, and the RP-incorporating library (i.e. with the RP hairpin at the 5′, 3′, US and 
H1/H2 - RNAs 4,5,6,7 & 8, as marked with an asterisk (*) in Figure 4-2) is considered the 
‘minimal’ set of gRNAs.  
Fluorescent RNA aptamers based on those developed by the Jaffreys’ lab186,187 were also 
incorporated into the gRNA structure. Baby Spinach (BS) is a 51 nucleotide G-quadruplex 
containing aptamer which becomes fluorescent when in complex with the small molecule 
DFHBI-1T. Bunch of Baby Spinaches (BoBS) is a 129 nt aptamer, containing three copies of 




4.2.3 MitoCRISPR gRNA library in vitro transcription (IVT)  
Using the gRNA template sequence from pD1301, modifications were made to introduce the 
coding sequences for mitochondrial targeting and fluorescent aptamers through inverse PCR 
and NEBuilder® HiFi assembly. DNA templates, once verified by sequencing, were amplified 
by PCR with primers to introduce the T7 promoter sequence at the 5ʹ of the PCR product, 
Figure 4-3A. This dsDNA product was purified by size exclusion spin-column chromatography, 
verified by agarose gel electrophoresis (Figure 4-3B), quantified using a spectrophotometer, 
and used as the substrates for in vitro transcription (IVT). RNAs were synthesised by IVT to 
give the modified gRNA library, Figure 4-2. The IVT products were DNase treated to remove 
the DNA template, purified by RNA size exclusion spin-column chromatography and verified 
by spectrophotometer and denaturing urea-PAGE, Figure 4-3C. 
 
 
Figure 4-3 gRNA library IVT  A gRNA sequences are stored in plasmids. gRNAs are transcribed by IVT from 
templates which are dsDNA PCR products amplified form plasmids with primers which introduce the T7 promoter 
upstream of the gRNA sequence. B Example PCRs to be used for IVT templates (1.5% (w/v) agarose gel) C 
Example gRNAs separated on denaturing urea 10% (w/v) PAGE (For B and C, gRNA names and reference 




4.3 Effect of gRNA modification on Cas9 gRNA loading - Cas9hinge 
FRET 
Cas9 loading of gRNAs was followed using a Förster resonance energy transfer (FRET)-based 
assay developed by Sternberg et al91,188. In FRET, a protein is labelled with two fluorophores 
with overlapping emission and excitation spectra. The labelled residues are chosen on 
protein domains which move within 1-10 nm of one-another. For the Cas9hinge mutant used 
in this assay, REC domain motions are followed as residues in the REC and RuvC domains 
move relative to one another upon loading of gRNAs. On excitation of the ‘donor’ fluorophore 
(here Cy3), the fluorophore’s emitted spectra will excite the ‘acceptor’ fluorophore (here Cy5), 
if they are close enough to allow non-radiative dipole-dipole coupling (within approximately 
10 nm). The extent to which the acceptor fluorophore is excited is a function of the distance 
between the two fluorophores.   
Cas9hinge is a mutant in which the natural cysteines are mutated to serine, and positions E945 
and D435 are mutated to cysteine for fluorophore labelling. Cas9hinge was purified and 
labelled with maleimide-Cy3 and -Cy5 (for protein purification and labelling see Materials and 
Methods and Appendix A4). In the Apo (gRNA unbound) state, the labelled residues are close 
to one another (21 Å), resulting in a high Cy5 acceptor fluorescence. As a gRNA is loaded into 
the Cas9 structure, the labelled residues are moved approximately 60 Å apart from one 
another (83 Å), resulting in a corresponding decrease in acceptor fluorescence relative to 
donor fluorescence (decrease in Cy5, increase in Cy3), Figure 4-4A. This relative change 
scales with increasing molar ratio of gRNA to Cas9, Figure 4-4B. The ratio between the Cy5 
peak as excited by Cy3 fluorescence relative to direct excitation with 630nm light, ratioA, 
Figure 4-4C&D, can be used as a proxy readout for energy transfer188. In the Apo state, where 
there is high donor-acceptor energy transfer, ratioA is high. Conversely, when donor-acceptor 
energy transfer is low, i.e. with a well bound gRNA, ratioA is low. 
Using the Cas9hinge construct, the gRNA library gives similar relative acceptor fluorescence 
changes, of approximately 0.1, which is comparable to an unmodified gRNA (G, blue), as 
shown in Figure 4-5. We can therefore conclude that gRNA modifications appear to be well 
tolerated and do not have a significant impact on the Cas9 structure with respect to REC lobe 







Figure 4-4 Cas9hinge FRET  A Cas9hinge is labelled with Cy3 and Cy5 at positions 435 and 945. In the Apo state, 
there is high acceptor fluorescence which decreases upon gRNA binding as fluorophores are moved apart B 
Donor (Cy3) fluorescence rises and acceptor (Cy5) fluorescence falls with increasing [gRNA] when the donor 
fluorophore is excited with 530 nm light, C/D RatioA can be calculated by dividing the integrated intensity 3 (The 
difference between Cas9hinge-Cy3/5 and Cas9hinge-Cy3 excited at 530 nm, between 650 and 800 nm) by the 
integrated intensity 4 (Cas9hinge-Cy3/5 directly excited at 630 nm between 650 and 800 nm) Exmaple traces 
are shown for Apo and gRNA bound states D RatioA for Apo and gRNA bound states from traces in C (N=3 ± SD) 
 
Figure 4-5 Modified gRNAs are loaded normally by Cas9hinge  Comparative ratioA (N=3 ± SD) for loading library of 
modified gRNAs. For example traces see Appendix A4-IV. 
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4.4 The effect of gRNA modification on R-loop formation  
Following gRNA loading, the Cas9 RNP searches the DNA for PAM sequences, binds, and 
forms a DNA/RNA hybrid (R-loop) at the target sequence by opening up the DNA double helix. 
One way to follow R-loop formation is with a magnetic tweezers-based assay, as previously 
described by this lab92. In the magnetic tweezers set-up, a linear DNA strand is tethered 
between a surface and a magnetic bead, Figure 4-6. 
 
Figure 4-6 Magnetic Tweezers set-up 
A magnet holds the bead so that it can be rotated, introducing DNA supercoiling. Proteins 
interacting with the tethered DNA can also result in changes to DNA supercoiling, which is 
translated to changes in the observed bead height. Bead height is followed by diffraction 
rings observed using video-microscopy, from which we can infer the z-height. The following 
experiments were carried out by Mark Szczelkun. 
The assay is started as Cas9/gRNA complex is flowed into the flow cell where the tethered 
DNA is held negatively supercoiled at constant force (0.312 pN). The DNA is underwound, 
and this encourages R-loop formation. As the R-loop is formed, the opening bubble is 
translated into a decrease in negative supercoiling and observed as a raise in magnetic bead 
height, Figure 4-6A. Cas9 does not ‘turnover’, and so R-loops will not spontaneously fall off. 
To encourage complex dissociation, the supercoiling is reversed (but with the force kept 
constant) so that the DNA is now overwound. As the R-loop dissociates, the positive 
supercoiling decreases and there is a corresponding raise in bead height, Figure 4-6B.  
Figure 4-7 shows magnetic tweezer traces for gRNAs with the RP hairpin in the 5′, 3′, upper 
stem and hairpin positions. The black line (right axis) displays the number of magnet 
rotations. At -6 rotations, DNA is negatively supercoiled and encourages R-loop formation, 
denoted by an increase in bead height (red arrows). Following R-loop formation, the magnet 
rotations are reversed to +4, positively supercoiling the DNA and encouraging R-loop 





Figure 4-7 Magnetic Tweezers example data for modified gRNAs. Grey = raw position data at 60 Hz, the black 
line = 1 s median filter. Arrows represent in (red) or out (blue) events. The Asterix (RP H2) denotes formation of 
a smaller R-loop; data collected by Mark Szczelkun. 
Following R-loop formation and dissociation in this way allows several distinct observations 
to be made including rate of R-loop formation and dissociation. The relative changes in bead 
height can also be correlated to the relative size of R-loop. Each of the modified gRNAs 
(minimal library) were observed in the magnetic tweezers assay to assess R-loop size and 
rates of association and dissociation. gRNAs with modifications at the 3′ end, upper stem, 
and hairpins are well tolerated, and form R-loops of comparative size to the unmodified gRNA, 
approximately the length of the spacer/protospacer RNA/DNA duplex, Figure 4-8. In contrast, 
a 20 nt hairpin addition to the 5′ end is not well tolerated, forming only a partial R-loop on 
target DNA of less than 10 nt, not surpassing the seed region. It might be hypothesised that 
this partial R-loop is formed due to the bulky 20 nt structure impeding RNA threading through 
the two strands of the DNA double helix. This would predict that the 5′ hairpin will have a 




Figure 4-8 5′ modified gRNAs form partial R-loops  left R-loop size (relative changes in bead height) for modified 
gRNAs; data collected by Mark Szczelkun right partial R-loop schematic 
4.5 Effect of gRNA modifications on Cas9 activity - library 
cleavage data 
To investigate further the impact of gRNA modifications, in vitro cleavage assays were 
performed on a supercoiled plasmid substrate to assess relative endonuclease activity. The 
substrate (pSP1) is a 2,726bp supercoiled tritium-labelled plasmid which contains a 
naturally-occurring protospacer sequence, derived from the first spacer (SP1) of the 
S.thermophilus CRISPR 3 array. Relative cleavage by modified gRNAs can be assessed by 
quantifying supercoiled, linear and open circle DNA by scintillation counting, Figure 4-9. A 
negative control plasmid (pUC19, 2686bp supercoiled) is not cleaved. Cleavage assay data 
for gRNAs with RP hairpins in each of the modified sites (except the 5′ end) are shown in 
Figure 4-10.  
 
Figure 4-9 Supercoiled plasmid cleavage assay   top The first strand of supercoiled DNA is cleaved to give an 
open circle (nicked) DNA plasmid, followed by second strand cleavage resulting in linear DNA. These three forms 
of DNA can be separated by agarose gel electrophoresis (bottom left). Tritiated-DNA bands are cut out from 





Figure 4-10 Scintillation data and example agarose gels from pSP1 cleavage assays.  A Unmodified gRNA B gRNA 
3′ RP C gRNA with upper stem (US) RP D gRNA with RP in hairpin v1 (H1) E gRNA with RP in hairpin v2 (H2) F 
gRNA with 3′ Baby Spinach (BS)   
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Following the time-dependent changes in DNA concentration in Berkeley Madonna enables 
simultaneous calculation of the rates of first and second strand cleavage (section 2.8.4), 
which can be compared for the library of modified gRNAs, Figure 4-11. As might be expected 
from the R-loop formation data, modified gRNAs which form full-length R-loops (namely 3′, 
upper stem and hairpin additions) cleave the first and second strands of supercoiled DNA at 
rates comparative to an unmodified gRNA. There are slight variations in ka, the rate of first 
strand cleavage which are within experimental error. There seems to be more systematic yet 
minor increase in kb, the rate of second strand cleavage, with upper stem and hairpin 
modifications. It might be hypothesised that this is due to the extra structure holding the 
Cas9/gRNA complex together more stably (the upper stem additions mimic the naturally 
occurring longer upper stem of the cr:tracrRNA) but more work on Cas9/gRNA complex 
formation would be needed to substantiate this.  
 
Figure 4-11 pSP1 cleavage assays with modified gRNAs ka, red is the rate of first strand cleavage, or appearance 
of open circle DNA; kb is the rate of second strand cleavage, or appearance of linear DNA from open circle DNA; 
table of data including rates for kini in Appendix A4  
In agreement with the magnetic tweezers data, the partial R-loop formed by 5′ additions 
almost completely prevent RNP endonuclease activity, with ka and kb below measurable 




Figure 4-12 5′ Additions severely hinder Cas9 endonuclease activity A 16 hour cleavage assays with 5′ modified 
gRNAs show minimal cleavage of pSP1 B gRNAs with additional uracils between RP and the gRNA spacer have 
minimal impact on cleavage activity 
After observing the minimal cleavage with the RP hairpin on the gRNA 5′ terminus, we 
wondered whether moving the RP modification away from the gRNA spacer would ameliorate 
cleavage. To this end, a set of gRNAs were designed with a variable number of uracil 
nucleotides (1, 2, 4 or 8) between the RP hairpin and the spacer, Figure 4-12B. Although 
there was a small increase in cleavage, gRNAs with 8U and 4U have a slightly higher 
percentage Linear DNA, this is largely negligible.  Another gRNA with minimal observed 
cleavage was with gRNA USBS, with the fluorescent Baby Spinach sequence in the upper 
stem, Figure 4-12A. This is intriguing given the US BS gRNA appeared to be loaded normally 
by Cas9hinge, Figure 4-5, and smaller modifications to the upper stem (RP US gRNA) had no 
significant impact on Cas9 endonuclease activity, Figure 4-11.  
4.6 Effect of gRNA modification on HNH domain movement - 
Cas9HNH FRET 
Crystal structures of Cas9 show the HNH cleavage domain to be positioned at least 30 Å 
away from the cleavage site184, randomly sampling closer cleavage-competent states. In this 
way, the conformational state of the HNH nuclease domain controls the cleavage activity of 
the RNA/DNA/Cas9 RNP. In the same study as detailed in section 4.3, Sternberg et al 
designed a FRET construct to follow HNH endonuclease domain motion. dCas9HNH is a mutant 
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in which the natural cysteines are mutated to serine, and positions S355 and S867 are 
mutated to cysteine to be labelled with Cy3 and Cy5. The nuclease null dCas9 mutant is used 
to follow HNH domain motion to sample a cleavage competent state without resulting in DSB 
formation, Figure 4-13.  
In the Apo state, Cy3 and Cy5 are held apart (59 Å), resulting in low acceptor fluorescence. 
When the HNH domain of a dCas9HNH/RNA/DNA complex moves into a cleavage competent 
state, the Cy3 and Cy5 fluorophores are moved close together (21 Å), resulting in high 
acceptor fluorescence, Figure 4-13A. As with Cas9hinge, the complete traces when excited at 
530 nm (Cy3) can be observed, or alternatively the ratioA can be determined as a proxy for 
FRET.  
Given that the decreased cleavage activity with 5′ modified gRNAs is mostly likely due to the 
reduced R-loop size observed by magnetic tweezers, one would expect that this would 
correlate to a decreased sampling of cleavage active conformations, as shown with 
dCas9HNH.  
  
Figure 4-13 Cas9HNH FRET  A dCas9HNH samples active conformations where the fluorophore-labelled HNH 
domain is brought into close proximity with the REC lobe. B under our experimental conditions, we do not see an 
increase in acceptor fluorescence (Cy5) when DNA and RNA are present.    
Unfortunately, although dCas9HNH was expressed and purified twice, there was not an 
observed change in donor fluorescence on binding target DNA, a 55 bp dsDNA fragment, 
Figure 4-13B. Although a change in fluorescence is seen between the Apo state (black trace) 
and the gRNA bound state (orange trace), there is no change when DNA is also introduced 
into the cuvette (red trace). This implies that the HNH domain is not sampling cleavage 
competent states under our experimental conditions, although this is something which we 
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know to be true as we do see endonuclease activity in the plasmid cleavage assay with these 
gRNAs.  
4.7 Conclusions  
Chapter 4 showed that it is possible to design and in vitro transcribe a library of gRNAs with 
modifications at five distinct sites – namely the 5′ and 3′ ends, the upper stem (US) and two 
locations in the hairpins (H1, H2). gRNAs with modifications at all of these sites are loaded 
normally by Cas9, as shown by a FRET-based assay with Cas9hinge.  gRNAs with modifications 
at the 3′ end, upper stem and hairpins will form R-loops and cleave a supercoiled plasmid 
substrate with comparative rate to an unmodified gRNA. One gRNA with upper stem 
modification, US BS, displayed decreased endonuclease activity. This is surprising given the 
US RP gRNA displays endonuclease activity similar to the unmodified gRNA. A possible 
explanation for this is that the US BS gRNA does not fold correctly, however this gRNA was 
established to be loaded functionally by Cas9hinge.  
gRNAs with 5′ modifications only form partial R-loops which significantly hinders their 
endonuclease activity; 5′ RP gRNAs have cleavage rates approaching 0 s-1. During DNA target 
binding, Cas9 first recognises the PAM, and searches nearby DNA for sequences 
complimentary to the gRNA91. At a correct target, a growing R-loop forms, requiring DNA 
unwinding and gRNA threading around the DNA helix to form the growing RNA/DNA 
heteroduplex. The bulky 5′ modification most likely impacts R-loop formation by hindering 
this gRNA threading through the separated DNA strands. 
Although gRNAs with 5′ modifications do not result in cleavage competent complexes, the 
tweezers assay demonstrates that they do still bind DNA. Section 1.4.5 detailed the many 
uses for nuclease-null dCas9 mutants, raising the potential of using this slower rate as a 
feature rather than a disadvantage. For example, switching available gRNA from unmodified 














5.1 The effect of 5′ Gs on Cas9 gRNAs 
Experiments in chapter 4 showed that Spy gRNAs do not tolerate modifications at the 5′ end, 
where they have a severe impact on R-loop formation and endonuclease activity. This chapter 
continues to question the generality of this effect, in particular: what is the impact of smaller 
modifications at the 5′ end of the gRNA? (which is addressed in section 5.1); and do our 
conclusions about SpyCas9 gRNAs hold true for LbCas12a crRNAs? (section 5.2). 
5.1.1 T7 polymerase requires a G in the (+1) position  
T7 bacteriophage RNA polymerase is commonly used in the laboratory for in vitro 
transcription of RNAs, giving high yields of high-fidelity RNA. The T7 promoter has been 
minimised for in vitro use; whereas naturally occurring initiation sequences have up to 3 
guanines in the +1, 2 and 3 positions, the minimal requirement for initiation is one guanine 
in the +1 position189 which results in a guanine in the 5′ position on transcribed RNA. T7 
polymerase has been used throughout this thesis for gRNA IVT. Given that the target DNA in 
pSP1 does not have a cytosine at the 3′ (PAM distal) end, all of the gRNAs in this thesis have 
therefore had a single nucleotide mismatch in this position, leading to an overhang of one 
guanine nucleotide, similar to the illustration in Figure 5-1, bottom right. 
We suspect there will be research groups transcribing gRNAs with up to 3 guanine 
nucleotides on the 5′ end, this being the maximum number that might be introduced by IVT 
using T7. Equally, common eukaryotic promoters also have initiation requirements; gRNAs 
expressed in mammalian cells under the U6 promoter require a G or A in the (+1) position 
for high expression. Consequently, we suspect 5′ mismatched nucleotides are a common 
occurrence on gRNAs.  
Given our observations regarding 5′ modifications in Chapter 4, we sought to investigate the 
impact of one, two and three 5ʹ guanine overhangs on gRNA loading, R-loop formation and 
endonuclease activity.  
5.1.2 gRNAs with 5′ guanines 
DNA templates were designed which introduced extra guanines at the +2 and +3 T7 promoter 
positions, 5′ of the 20 nt spacer, Figure 5-1, and gRNAs were in vitro transcribed to introduce 




Figure 5-1 GGG gRNAs   The template for gRNA 5′GGG IVT is a dsDNA PCR product containing the minimised T7 
promoter (red) and the gRNA spacer (green) and scaffold sequence (grey). IVT begins at the +1 position with a G. 
In this case, Gs have also been included in the +2 and +3 positions to result in a one, two and three-nucleotide 
overhang. 
5.1.3 gRNAs with 5′ guanines are loaded normally by Cas9 
As in section 4.3, Cas9hinge was used to follow gRNA loading by Cas9, here assessing the 
impact of 5′ guanine nucleotide overhangs. Based on previous observations that 
modifications to the gRNA 5′, including the 51 nt BS, are loaded normally by Cas9hinge (Figure 
4-5) we would not expect a loading effect. In line with this, Figure 5-2 shows that there is no 
significant impact between one to three 5′ guanines on gRNA loading by Cas9hinge.  
 
Figure 5-2 Impact of 5′ guanines on gRNA loading by Cas9hinge  Comparative ratioA (N = 3 ± SD) for loading 5′ G 
(blue)/GG(red)/GGG(green) gRNAs relative to Apo Cas9 (grey). 
5.1.4 5′ guanines impact R-loop dissociation 
To test the effect of the 5′ modifications on the next step in the process, R-loop formation, 
the magnetic tweezers assay detailed in section 4.4 was employed. Figure 5-3A shows 
characteristic bead traces for each of the gRNAs. Using the bead height as a representation 
of the R-loop formation, there was no significant difference in the size of R-loop formed with 




Figure 5-3 Impact of 5′ guanines on R-loop formation and dissociation  A G/GG/GGG gRNAs typical traces in 
magnetic tweezers - measurements carried out by Mark Szczelkun. Grey is the raw position data at 60 Hz, the 
black line a 1 s median filter. Arrows represent in (red) or out (blue) events. B Cumulative frequency plots of R-
loop formation (IN)/dissociation (OUT) events, fitted to an exponential distribution, allowing calculation of the 
time constant, plotted in C. Error bars were calculated from the average values divided by the square root of the 
number of points (n values) in the bin. 
Figure 5-3B shows cumulative frequency event lifetime plots for in and out events, measured 
as the time between the stop of each magnet rotation and the midpoint of the subsequent 
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R-loop formation or dissociation event. The events are fitted to an exponential distribution to 
calculate the time constant, plotted in Figure 5-3C. The association kinetics reveal complex 
formation rate to be independent of the number of 5′ guanines on the gRNAs. However, 
gRNAs with three 5′ guanines (GGG) have a larger time constant for R-loop dissociation in 
comparison to one or two guanines, implying that the R-loop formed by a gRNA with three 5′ 
guanines is approximately 2-fold longer-lived than that with one or two.  
5.1.5 5′ guanines have a stepwise effect on endonuclease activity 
 
Figure 5-4 5′ guanines impact Cas9 second strand endonuclease activity A Example pSP1 cleavage assay gels 
and corresponding Berkeley Madonna fitted data for each gRNA n=3 ± SE B Appearance of linear DNA from A 
n=3 ± SE C rates of first (ka) and second (kb) strand cleavage   
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The same supercoiled plasmid cleavage assay as in 4.5 was used to assess in vitro Cas9 
endonuclease activity with the three gRNAs, Figure 5-4. Figure 5-4A shows that increasing 
the number of overhanging guanines results in a stepwise decrease in RNP endonuclease 
activity. This effect is visible on the agarose gels themselves but is most clearly demonstrated 
by the appearance of linear DNA, Figure 5-4B; gRNAs with two and three guanines show a 
much lower percentage linear DNA at the same timepoints in comparison to gRNAs with one 
5′ guanine. Fitting the data in Berkeley Madonna allows calculation of the rates of first (ka) 
and second (kb) strand cleavage Figure 5-4C. ka is seen to be relatively consistent with all 
three gRNAs, whereas kb shows an almost 10-fold decrease in rate with each addition of a 
guanine residue.  
 The IVT protocol does not impact gRNA endonuclease activity 
The library of gRNAs used in Chapter 4 were synthesised by HiScribe™ T7 High Yield RNA 
synthesis whereas the G/GG/GGG gRNAs in Chapter 5.1 were generated by EnGen® sgRNA 
Synthesis, a one-tube method for gRNA transcription. The HiScribe™ IVT protocol requires an 
overnight incubation at 37°C with a dsDNA template, whereas the EnGen® method requires 
only a 30-minute reaction, where the user provides a ssDNA oligo with the T7 promoter, 
spacer sequence and an overlap region, Figure 5-5. Given the significant impact of 5′ Gs on 
endonuclease activity, we tested whether changes to the synthesis and processing of gRNAs 
also had an impact on RNP endonuclease activity. 
 
Figure 5-5 IVT templates For HiScribe (top), the dsDNA PCR template is user provided whereas for EnGen 
(bottom) the ssDNA oligo encoding the T7 and spacer sequence is user provided whereas the scaffold primer is 
supplied by the IVT kit.  
The impact of 5′ guanines on EnGen gRNAs in a supercoiled plasmid cleavage assay, Figure 
5-6, can be compared to analogous data with HiScribe gRNAs, Figure 5-4. The overall trend, 
i.e. the stepwise decrease in endonuclease activity, Figure 5-6A & B, is analogous to Figure 
5-4 above. Figure 5-6C shows the rates of first and second strand cleavage ka and kb 




Figure 5-6 Impact of 5′ guanines on endonuclease activity: EnGen IVT A Example pSP1 cleavage assay Berkeley 
Madonna fitted data for each gRNA n=3 ± SE B Appearance of linear DNA from A n=3 ± SE C rates of first (ka) 
and second (kb) strand cleavage 
5.1.6 Conclusions  
In Chapter 4, a combination of single molecule and ensemble biochemical techniques 
ascertained the impact of a 5′ 20 nucleotide aptamer on Cas9 RNP formation. Although 
gRNAs were loaded normally by Cas9, addition of a medium sized aptamer to the 5′ end lead 
to gRNAs forming only partial R-loops on target DNA, which in turn impacted their 
endonuclease activity on supercoiled DNA substrates. The work in chapter 5.1 sought to 
investigate the impact of smaller additions to the 5′ end of the gRNA. This is particularly 
pertinent as gRNAs are often in vitro transcribed by the T7 polymerase which can leave up to 
3 guanines at the 5′ end.  
Addition of one, two or three unpaired 5′ guanines alters endonuclease activity significantly 
in a stepwise fashion, Figure 5-4. The observed decrease is not the result of gRNA loading as 
all gRNAs are loaded similarly when observed with a FRET-based assay, Figure 5-2. The 
decrease also cannot be explained by R-loop formation rates. R-loops are formed with similar 
time constants implying that RNP complex initiation and PAM-binding proceed as normal. An 
alternative proposal would be that the R-loop complex is unstable and collapses before the 
second strand cleavage can occur. The observed second strand cleavage rate would then be 
the result of multiple consecutive R-loop formation-cleavage events. However, gRNAs with an 
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overhang of three 5′ guanines have longer residency time on DNA in comparison to one or 
two 5′ guanines, suggesting that the R-loop complex may be more stable. Based on the data, 
it is not possible to determine why this more stable state results in slower cleavage. It is 
suggested that conformational transitions of the HNH domain regulate DNA cleavage190. On 
this basis, one speculation could be that the stable R-loop state represents an off-pathway 
state where one nuclease domain can engage (for first strand cleavage), but the other in a 
less productive orientation (for second strand cleavage). A sophisticated method to test this 
would be to use FRET measurements of each nuclease domain.  
A simple test that could have been carried out here would have been to determine which 
strand was being nicked. The order of strand cleavage has not been explicitly shown as the 
rates of cleavage are similar; the three guanine gRNA could therefore provide information 
about this and this could be further validated by using the nicking mutants.  
The results in this chapter are of value to any lab which use in vitro T7 RNA polymerase 
transcription to produce gRNAs. Although efficiency is reduced, substrates with a single 5′ 
guanine should be favoured. The single guanine overhangs produced by eukaryotic 
promoters (e.g. U6) are not an issue since the rates are equivalent to the crRNA-tracrRNA 
which has no overhang. The Kim lab reported that the impact of an unpaired 5′ nucleotide is 
particularly severe with Cas9 mutants engineered to minimise off-target effects such as 
eCas91.1191 and Cas9-HF1192. To counter this, they designed a gRNA which incorporated a 
hammerhead ribozyme domain which removed the mismatched guanine prior to RNP 
formation and CRISPR activity193. Furthermore, the price of commercial RNA synthesis using 
phosphoramidites has decreased significantly in recent years, largely driven by research in 
the CRISPR field, meaning that unmatched 5′ guanines, and a corresponding sacrifice to 
cleavage activity, are now perhaps less of a problem than they used to be.  
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5.2 The impact of modifying Cas12a crRNAs for MitoCRISPR 
5.2.1 Modified Cas12a crRNAs  
Cas12a is a type V CRISPR endonuclease which naturally produces staggered nicks on DNA. 
Although most of the work in this thesis focusses on assessing the impact of modifications 
to Cas9 gRNAs on RNP activity and mitochondrial targeting, work by other members of the 
group, summarised in section 3.4, has shown Cas12a to be more efficiently expressed in 
mitochondria. LbCas12a is directed to target sequences on DNA by a single 44 nt crRNA. 
Given the conclusions in Chapter 4 on the effect of 5′ modifications on gRNAs, the 
experiments in this chapter sought to understand whether there were similar effects with 5 
and 3′ cRNA modifications. To this end, a small library of crRNAs was designed incorporating 
4 nt or 20 nt modifications to the 5′ and 3′ termini, Figure 5-7. 
 
 
Figure 5-7 Modified Cas12a crRNAs  4 nt and 20 nt modifications (red) were made to the 5′ and 3′ termini of 




5.2.2 Cas12a cleavage activity with modified crRNAs 
Modified crRNAs were used in supercoiled plasmid cleavage assays, similar to section 4.5, 
to determine whether there was an impact on Cas12a endonuclease function.  
 
Figure 5-8 Cas12a modified crRNA cleavage assays  Cas12a RNPs were formed with crRNAs (unmodified or with 
4 nt or 20 nt modifications) and endonuclease activity was measures in a cleavage assay against a supercoiled 
plasmid substrate, pSP1. n=3±SE. 
Following a single 5-minute timepoint, Cas12a in complex with an unmodified crRNA can be 
seen to cleave a supercoiled plasmid (pSP1) to 80% linear. Additions of 4 and 20 nts are 
tolerated at the 5′ end; after 5 minutes, 78% and 81% total DNA is linearised. In contrast, 
modifications are not tolerated at the 3′ end; after 3 hours, only 7% supercoiled DNA 
substrate has been linearised. 
5.2.3 Cas12a crRNA processing 
In addition to endonuclease activity, Cas12a processes RNA transcripts containing several 
pre-crRNA sequences into individual crRNAs. The requirements for crRNA processing are both 
sequence and structure dependent. In the type IV systems (such as SpyCas9) Cas1-Cas2 
proteins are required for RNA processing. 
The above modified crRNAs do not have any of the requirements for crRNA processing as 
reported in the literature194. However, crRNA processing does occur upstream of a hairpin 
structure of similar length to the RP hairpin. Given that crRNA processing would result in an 
unmodified crRNA, and therefore no change in cleavage activity, modified crRNAs were 




Figure 5-9 processing of crRNAs by Cas12a 2μM crRNA and 5′RP crRNA were incubated ± 10 μM Cas12a in 
1XRB or 1XSB at 37 °C for 1 hour. Samples were then separated by urea-PAGE and stained with SYBR-Gold. 
crRNAs with and without 5′RP hairpins were incubated with or without Cas12a in 1 X SB 
(cleavage assay sample buffer) and 1 X RB (cleavage assay reaction buffer) for 1 hour at 
37 °C, the standard RNP complex assembly conditions. Following this, RNAs were separated 
by denaturing urea-PAGE. Figure 5-9 shows that crRNAs both with and without the 5′ RP 
aptamer are processed in a magnesium dependent manner. Unmodified crRNAs undergo a 
small shift in size, perhaps due to the removal of only a couple of nucleotides. As with the 
SpyCas9 gRNAs, LbCas12a crRNAs also have an additional 5′ guanine, so it is likely that this 
extra nucleotide is what is being processed here. 5′RP crRNAs incubated with Cas12a in 
1XRB are processed to the same size as unmodified crRNAs, presumably the result of the RP 
hairpin being removed. We cannot explicitly state whether the observed cleavage in figure 5-
8 is the result of a processed RNA or not. 
5.2.4 Conclusions 
The structural components of Cas12a crRNAs and Cas9 gRNAs occur on the opposite ends 
of their DNA-targeting spacer sequences, Figure 1-6, page 20. Section 5.1 showed that 
additions of 2 or 3 nucleotides to the gRNA 5′ impact Cas9 endonuclease activity significantly. 
Similarly, 4 nt modifications at the 3′ end of Cas12a crRNAs severely impact cleavage. Given 
the directionality of the R-loop in Cas9 and Cas12a complexes respectively, this suggests 
there is a common mechanism between crRNA and gRNA DNA target site binding which is 
hindered by small nucleotide overhangs at the PAM distal end, i.e. the end of the RNA that is 
furthest from the point of initiation of R-loop formation. Since the completion of R-loop 
formation presumably requires the unbound distal end of the RNA to thread through the 
unwinding DNA, bulky additions to the 5′ end (Cas9) or 3′ end (Cas12a) might inhibit the 
processes. An alternative way to test this would be to add non-nucleotide chemical moieties 
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with different sizes to the distal ends of the RNAs, and to observe the effects on the size of 
the R-loop formed.  
The processing of 5′ modifications, and the unavailability of the crRNA 3′ end for modification 
might make crRNA targeting to the mitochondria with RNA aptamers difficult. However, there 
a number of opportunities which could be further explored. Firstly, extensions of the crRNA 
stem loop structure, analogous to the gRNA US position, were not explored here and might 
provide opportunity for modification. Secondly, several residues in Cas12a can be mutated 
to decrease RNA processing without impacting DNA cleavage194, and future work could 
involve investigating the impact of 5′ crRNA modifications on these enzymes.  
Alternatively, the RNA processing of Cas12a might be advantageous for a mitochondrial 
CRISPR system. If Cas12 were stably expressed so that it was only active within the 
mitochondrial matrix, mitochondrial targeting aptamers could be cleaved from crRNAs once 
they had been delivered into the matrix. This would also provide a mechanism for measuring 
RNA import, as processed RNAs would only be present in the mitochondrial matrix. To ensure 
no off-target activity on nDNA, this would rely on Cas12a expression or function exclusively 

















 Directing SpyCas9 gRNAs for 
mitochondrial import  
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6.1 Methods for assessing mitochondrial import   
As with much of the wider study of physiologically relevant RNAs, methods for determining in 
vivo subcellular RNA localisation are much less advanced than those for the study of proteins. 
Without one standardised technique to follow mitochondrial RNA import, the following 
chapter summarises several techniques which together can be used to determine whether 
our library of RNAs, as described in Chapter 4, can be imported into mitochondria.  
Chapter 6 uses techniques to assess RNA import into both whole cells and isolated 
mitochondria, Figure 6-1. In whole cells, gRNAs are transfected into mammalian cells grown 
in culture and their subcellular localisation is either followed by a fluorescent tag, or cells are 
fractionated and probed for the presence of gRNAs by Northern blotting. Given the end goal 
of this project is to be able to engineer mitochondrial genomes in whole cells and organisms, 
assaying gRNA import into whole cells is most relevant to the end tool.  
 
Figure 6-1 Whole cell and isolated mitochondrial assays for mitochondrial RNA import  can be used to follow RNA 
localisation within cells. Fluorescently labelled RNAs can be observed with widefield imaging in whole cells, and 
unlabelled RNA localisation can be followed by fractionating cells and using a Northern blotting technique. 




However, there are several complexities which come with assaying cellular localisation of 
RNAs in whole cells and so gRNA import is also assayed in vitro. Radiolabelling RNAs allow 
their import into isolated mitochondria to be followed, an analogous protocol is standard for 
assessing mitochondrial protein import. Isolated mitochondria are a useful model for 
measuring import and have several advantages over whole cell assays. Firstly, isolated 
mitochondrial assays are much quicker, not requiring the several days for growing and 
transfecting cells. Secondly, isolated mitochondria allow the import of radiolabelled RNAs, 
which is problematic in mammalian cell culture given the safety precautions when using 
sources of ionising radiation. Radioisotopes provide a sensitive method of labelling RNAs and 
are less intrusive than fluorophore-labelled nucleotides. This method also allows the 
potential for different interventions such as blocking electron transport to be easily tested. 
6.2 Whole cell methods - direct RNA transfection 
6.2.1 Northern blotting 
Northern blotting, summarised in Figure 6-2, is an indirect method of determining subcellular 
RNA localisation with radiolabelled DNA probes complimentary to the RNA of interest.  
 
Figure 6-2 Northern blotting protocol  Cells are plated in a 10 cm dish and transfected with RNA when 70-80% 
confluent. After 18 hours, cells are harvested, homogenised and fractionated. RNA is extracted from fractions 




HeLa cells, transfected with an RNA of interest (steps 1-3), are manually homogenised and 
then fractionated into cytoplasm, mitochondrial and nuclear fractions via differential 
centrifugation (step 4). RNA is extracted from each fraction (step 5) which is separated by 
denaturing urea-PAGE (step 6). Total separated RNA is transferred to a membrane (step 7) 
and RNAs of interest are probed for with radiolabelled DNA probes (step 8). Control RNAs 
against each fraction confirm fractionation has been successful. Here, a probe against a 
cytoplasmic RNA (tRNALys) and a mitochondrial RNA (tRNALeu) confirm each fraction to be 
enriched in their characteristic RNAs. Probes designed against the transfected RNA of 
interest identify which fraction the RNA has been extracted with. The sequences of the probes 
used in this chapter is given in Table 17. 
Kolesnikova et al122 designed small synthetic RNAs based on the yeast tRNALys (tRK1) with a 
range of reported in vitro mitochondrial targeting efficiencies. The most and least efficiently 
imported RNAs, F1D1 (FD) and AD1 (AD), respectively (Figure 6-3A), were used in protocol 
optimisation. Of note is that the AD RNA runs as two bands on the urea-PAGE. 
HeLa cells were transfected with AD and FD, and a time-course experiment was performed 
to determine the optimal time to harvest cells post-transfection, Figure 6-3C. Cell lysates at 
each timepoint were probed with the tRK1 probe (targeting AD and FD, Figure 6-3B), 
indicating that 18 hours post transfection gave the best signal for both AD and FD RNAs. After 
18 hours, the transfected RNAs appear degraded by the cells. Although the same amount of 
RNA was transfected into the cells, the AD signal was much lower than that for FD, 
presumably because the AD RNA ran as two bands on the urea-PAGE, diluting the signal. 
In Figure 6-3D, HeLa cells transfected with either AD or FD RNA were fractionated into 
cytoplasmic, mitochondrial and nuclear fractions 18h post-transfection. RNA was extracted 
from each fraction, separated by urea-PAGE and probed for cytoplasmic tRNALys 
mitochondrial tRNALeu and tRK1, Figure 6-3D. The cytoplasmic probe (tRNALys) and 
mitochondrial probe (tRNALeu) show that the mitochondrial and cytoplasmic fractions are 
enriched for their respective RNAs, as expected. However, it appears that the fractionation 
was not completely effective: the mitochondrial probe produces signal in the cytoplasmic 
fraction, and vice versa for the cytoplasmic probe. There are also very strong signals from the 
mitochondrial and cytoplasmic probes in the nuclear fraction. This can indicate 
contamination of the nuclear fraction with cytoplasmic/mitochondrial components. 
The tRK1 probe signal shows the F1D1 aptamer to be present in the mitochondrial fraction, 
but also in the nuclear fraction, as seen with the mitochondrial tRNALeu probe. The tRK1 probe 
shows that the majority of the AD RNA appears to be present in the nucleus. Unfortunately, 
Kolesnikova et al122 did not show nuclear fractions in any of their Northern blotting 
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experiments or the cellular localisation of the AD1 RNA (they just show its absence in 
mitochondria). Consequently, it is not possible to compare this result. 
 
 
Figure 6-3 Northern blotting HeLa cells for AD and FD  A AD and FD RNAs from 122 B 100 and 200 ng AD and FD 
separated by urea-PAGE (left) was transferred to nitrocellulose membrane and probed against tRK1 probe (right) 
C transfection time course for AD and FD RNA D Northern blotting for AD/FD, E 50 ng RNA gRNA and 5′FD gRNA 
separated by urea-PAGE transferred to nitrocellulose membrane and probed against gRNA probe F Northern 
blotting for gRNA, gRNA 5′ RP and gRNA 5′ FD; WCE = whole cell extract; Cyto = Cytoplasm; Mito = Mitochondria; 
Nuc = Nuclear; HP = Hybridisation probe. Bands in lane marked * on Cyto-probed membrane are over-spill from 
adjacent gRNA Nuclear lane.  
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Using the same protocol, cells were transfected with unmodified gRNA, gRNA with 5′RP and 
gRNA with 5′ FD, Figure 6-3F. The hybridisation signal is determined by the probe binding the 
hairpin region of the gRNA. Strong signals for all three gRNAs were produced in the nuclear 
fraction and, to a slightly lesser extent, the mitochondrial fraction. In contrast, the 5′ FD gRNA 
produced the least strong signal in the mitochondrial fraction, a result which is confirmed by 
a second northern blot, Appendix A6-I.  
6.2.2 Fluorescent RNAs  
Given the high level of sample processing required for the Northern blotting protocol, we 
sought to directly image RNA localisation in whole cells to complement the results in 6.2.1. 
The ability to use fluorescent-protein conjugated constructs has become an indispensable 
tool in cell biology, enabling visualisation of cellular protein distribution. In contrast, it has 
been difficult to pinpoint subcellular RNA distribution in the same way. There are several 
methods for labelling RNAs for imaging in cell culture which could be useful reporters of gRNA 
distribution, including: fluorescent RNA aptamers such as ‘Baby Spinach’ that can be 
appended to the gRNA structure (introduced in Chapter 4); and, Alexa™ fluorophore-coupled 
NTPs that can directly label RNAs when incorporated via IVT. 
 Alexa™-coupled NTPs 
The water soluble Alexa™ fluorophore-labelled nucleotides enable direct labelling of RNA and 
DNA without addition of bulky structures. Here, Alexa™ 488-5-UTP, Figure 6-4A, was 
incorporated randomly along the length of transcribed RNAs. The Alexa™ fluorophore is 
separated from the UTP nucleotide by a 5-atom linker to reduce interactions between the 
RNA and fluorophore. The gRNA, 5′ RP gRNA, 5′ FD gRNA, AD RNA and FD RNA were 
successfully in vitro transcribed with Alexa™ 488-5-UTP, Figure 6-4B, C. The RNAs run at their 





Figure 6-4 ChromaTide Alexa™ Fluor 488-5-UTP incorporation by IVT  A ChromaTide Alexa™ Fluor 488-5-UTP 
structure B 488-5-UTP incorporated RNAs separated by urea PAGE, stained with SYBR-Gold C 488-5-UTP 
incorporated RNAs separated by urea PAGE,488 fluorescence measured by Typhoon Scanner 
 
 Imaging fluorescent RNAs in mammalian cell culture  
Transfecting fluorescently-labelled RNAs into HeLa cells allows cellular localisation to be 
observed in intact whole cells195. Alexa™ 488-5-UTP-labelled AD and FD RNA were 
transfected into HeLa cells by PEI transfectionviii.  
AD RNA (AD-488), Figure 6-5A, was observed in discrete, punctate structures, visible 
throughout the cytosol. AD-488 structures are present mostly in a perinuclear distribution 
and rarely found in the nucleus or at the cell periphery. To assess mitochondrial localisation, 
the mitochondria were stained with anti-Tom20, a central component of the TOM 
(translocase of outer membrane) receptor complex. The enlarged (200 x 200 px) image 
shows that Alexa™-488 and Tom20 signals almost seem to be mutually exclusive, suggesting 
that there is not any colocalization as would be expected. A fluorescence profile, taken along 
a 150 px line, show a collection of peaks in Alexa™-488 between 75 and 100 px are directly 
between mitochondrial structures.  
                                                     
viii Several transfection methods including lipofectamine, PEI, calcium chloride and electroporation 




Figure 6-5 Alexa™-488 UTP labelled AD and FD RNAs  in both cases, AD (A) and FD (B) RNA is transfected into 
HeLa cells by PEI transfection. Cells are stained with DAPI and anti-TOM20 (2° anti-Mouse 647). DAPI: 30 ms; 






Figure 6-6 Alexa™-488-UTP incorpterated gRNA, 5′ RP gRNA and 5′FD gRNA in HeLa cells  RNA is transfected 
into HeLa cells by PEI transfection. Cells are stained with DAPI and anti-TOM20 (2° anti-Mouse 647). DAPI: 30 
ms; FITC: 500 ms; Cy 5: 2000 ms. Line profiles are taken along a representative 150 px line through the 
perinuclear region  
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Alexa™-488 UTP-labelled FD RNA (FD-488), Figure 6-5B, also appears located in perinuclear 
regions, though its distribution is not identical to AD-488. FD-488 contains some punctate 
structures, but overall is more diffuse throughout the cytosol. FD-488 does not seem to be 
explicitly mitochondrially localised. Although there are some regions of colocalisation, there 
is very little continuous overlap in the Tom20 and FD-488 signals. The more punctate FD-
488 structures, as with AD-488, are never colocalised to mitochondria, but some of the more 
diffuse signal could be interpreted as being mitochondrially localised. 
Alexa™ 488-5-UTP-labelled gRNAs (gRNA-488, 5′RPgRNA-488, 5′FDgRNA-488) were also 
transfected into HeLa cells by PEI transfection, Figure 6-6. All three gRNAs displayed similar 
localisations to one another – punctate and perinuclear in distribution, rarely colocalising 
with the nucleus or the cell periphery. The 488-labelled gRNAs show similarities to both the 
AD and FD-488 RNAs: Like AD-488, the most defined structures are explicitly found in 
locations distinct to the mitochondria – some of the most intense peaks in the line scans 
correlate with dips in mitochondrial signal - whereas some of the more diffuse regions could 
be interpreted as being mitochondrially associated. 
Overall, these results give an uncertain impression of transfected RNA localisation within the 
cell; it is unclear whether RNAs are mitochondrially localised, or just mitochondrial adjacent 
and in another cellular compartment. At times, the images directly contradict findings from 
northern blotting analysis; the enrichment of RNAs in the nucleus for example. Further work 
is required to determine whether they might be in an endocytic or lysosomal compartment. 
RNAs are not being degraded by autophagy, as they show no colocalisation with LC3, a 
marker of autophagosomes, Appendix A6-II. 
6.2.2.3 Fluorescent RNA aptamers  
Baby Spinach (BS) is a 51 nucleotide G-quadruplex-based aptamer which fluoresces when in 
complex with the small molecule chromophore DFHBi-1T, Figure 6-7A196. The Spinach-DFHBi-
1T conjugate fluoresces when excited at 460 nm, which can be conveniently imaged using a 
blue-light transilluminator (Figure 6-7C) or quantified in a spectrophotometer (Figure 6-7B). 
The emission spectra from 5′ and 3′ BS gRNAs in complex with DFHBi-1T were measured by 
fluorescence spectrophotometry (λex = 460 nm). Assembling and immediately measuring the 
5′ BS gRNA in complex with Cas9 and DFHBi-1T showed a six-fold increase in in fluorescence 
in comparison to gRNA/Cas9 RNP alone. Preassembly of the Cas9/5′ BS gRNA RNP for 1 
hour at 37°C before adding the chromophore produced a fourteen-fold increase, Figure 6-7D. 
The 3′ BS gRNA/Cas9 showed only a small increase in fluorescence upon incubation with 
DFHBi1T. One explanation is that the BS aptamer is not folding correctly, perhaps a result of 
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its proximity to the Cas9 or 3′ gRNA hairpins, Figure 6-7E. Alternatively, there could be a 
quenching effect, perhaps a result of misfolding due to proximity to Cas9. 
 
Figure 6-7 Baby Spinach gRNA fluorescence  A Baby Spinach theorised structure and DFHBi-1T (both from 197) B 
Spinach RNA ± DFHBi-1T fluorescence (λex = 560 nm) C Spinach RNA ± DFHBi-1T fluorescence, DarkReader 
transilluminator D and E 5′ and 3′ BS gRNA fluorescence ± Cas9 and DFHBi-1T (λex = 560 nm) 
Although the BS aptamer allows imaging of 5′ labelled gRNAs, its incompatibility with 3′ 
labelling and the impossibility of producing an ‘unmodified’ gRNA (as can be followed with 
Alexa™ or northern blotting for example) are limitations to its application in this study. Due to 
these reasons, as well as time constraints, the BS aptamer has not yet been used to study 
gRNA localisation in cell culture by this research group. Nevertheless, it’s characterisation 





6.3 Studying import in isolated mitochondria 
Whole-cell methods for assessing whether RNA aptamers are capable of localising gRNAs to 
the mitochondria were inconclusive. To clarify whether our in vitro transcribed gRNAs can be 
imported into mitochondria, assays were also performed with isolated mitochondria.  
6.3.1 Isolation of mitochondria from tissue culture cells  
Common sources of mammalian mitochondria for import assays include bovine heart and rat 
liver. Without an appropriate tissue source, isolation of mammalian mitochondria was first 
attempted from cells grown in tissue culture, using a similar homogenisation and 
centrifugation method as for northern blotting, section 6.2.1.  
A proton gradient and membrane potential are integral to mitochondrial structure and protein 
import. Given some RNAs have been suggested to be imported via the TOM/TIM machinery 
(section 1.5.2.1) it might be hypothesised that a proton gradient be a requirement for other 
RNA import pathways too. Accordingly, an assay for RNA mitochondrial import would ideally 
include coupled mitochondria. 
Respiration capacity of isolated mitochondria was assessed as a readout of mitochondrial 
viability. This was carried out in different variations with a classical O2 electrode, the Oroboros 
Oxygraph O2k (Oroboros Instruments), and the Xfe Extracellular Flux Analyser (Seahorse 
Bioscientific). Substrates and inhibitors of the complexes of the electron transport chain were 
added to the mitochondria, but analyses with both machines showed the isolated RPE-1 cell 
mitochondria to be largely uncoupled and unsuitable for use in RNA import assays, Figure 
6-8. This could be either due to damage during the isolation technique or due to the 
diminished respiratory capacity of cells grown in culture conditions. 
The trace from the mitochondrial respiration assay carried out with the Oxygraph-2k O2 
electrode is given in Figure 6-8A. The initial substrates added to the isolated mitochondria 
were glutamate and malate, both substrates of complex I, converted to NADH in the 
mitochondrial matrix. The rate of O2 consumption with glutamate and malate seen here is 
lower than would be expected for this concentration of mitochondria. This might be explained 
by the low concentration of mitochondria in the oxygraph chamber but could more likely be 
due to the poor functioning of the isolated mitochondria. Upon addition of ADP, an increase 
in respiration would imply the reliance on proton motive force for ATP generation, and the 
magnitude of this increase directly correlates to how coupled - i.e. how intact - the isolated 
mitochondria are198. The lack of any such increase in respiration upon addition of ADP implies 
that the isolated mitochondria are likely uncoupled or damaged. This conclusion is supported 
by the subsequent substrate and inhibitor additions: cytochrome c, which should feed 
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electrons into complex IV, showed no increase in O2 uptake; while rotenone and antimycin A, 
inhibitors of complex I and III respectively led to an overall plateau of mitochondrial activity.   
 
Figure 6-8 Isolated mammalian RPE-1 mitochondria  A O2 electrode measurements of RPE-1 mitochondrial 
respiration. Trace is for 30µg mitochondrial protein loaded into the O2 chamber; dips after each addition are due 
to mixing of substrate in the oxygen electrode chamber. G: Glutamate, M: Malate, cyt c: cytochrome c.  B Seahorse 
measurements of RPE-1 mitochondrial respiration - Each point average of 3 datapoints from three independent 
wells; OCR= Oxygen consumption rate  
Figure 6-8B shows the O2 consumption trace for isolated mitochondria respiration as 
measured with the XFe96 Analyser. The small-scale nature of the XF Analyser is better suited 
for small sample volumes compared with the traditional O2 electrode. The uncoupling agent 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) acts to dissipate the proton 
gradient across the mitochondrial membranes and is used to reveal maximal respiration rate. 
Upon addition of FCCP to the seahorse chamber, no change was seen in isolated 
mitochondria O2 consumption. This provides further evidence that the mitochondria are 
largely uncoupled, either due to damage during the isolation technique or due to their little 
respiratory capacity.  
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To assess whether it was the damage to the cells or the cells’ respiratory capacity 
themselves, RPE-1 cells permeabilised with digitonin were measured for oxygen consumption 
with the Oxygraph oxygen electrode (data not shown). This revealed no enhanced respiration 
compared to isolated mitochondria, suggesting that the failure of isolated mitochondria to 
respire could be a result of reduced dependence on mitochondrial function in the tissue 
culture environment where substrates are readily provided. In hindsight, growing cells in 
galactose containing media might have helped to push the cells to be more dependent on 
OXPHOS for cellular energy production. However, given it was also difficult to get a high 
concentration of mitochondrial protein, this was not revisited.  
Another common source of mitochondria for import assays are yeast, Saccharomyces 
cerevisiae. Yeast can be readily grown in large quantities and maintain their OXPHOS and 
membrane potential following freeze-thawing, a key advantage over mammalian 
mitochondria isolated from tissues. An established protocol from the Collinson lab (University 
of Bristol) for isolation of yeast mitochondria was used here. 
6.3.2 Isolation of yeast mitochondria  
 
Figure 6-9 Isolated Yeast mitochondria A O2 electrode measurements of isolated yeast mitochondrial respiration. 
Trace is for 500µg mitochondrial protein loaded into the O2 chamber; at t=0, mitochondria are given 1 mM NADH, 
oligo = oligomycin B Data collected by Dr Holly Ford. Isolated yeast mitochondria import cytb2-DHFR precursor 
protein and cleave it to its mature form; ± import = ± VOA mix. 
Mitochondrial respiration capacity of isolated yeast mitochondria was assessed with the 
Oroboros Oxygraph O2k, Figure 6-9A. At the start of the measurement, isolated mitochondria 
are in a buffer containing NADH, the substrate for complex I. The increase in respiration upon 
addition of  ADP, a direct substrate for ATP synthase, shows that there is some proton motive 
force dependent ATP generation, unlike with the RPE-1 isolated mitochondria above. 
Oligomycin is an ATP synthase inhibitor and should drop O2 consumption, which is does 
slightly. However, healthy, coupled mitochondria should show a large increase in O2 
consumption on addition of FCCP, which establishes maximal respiratory capacity. This is not 
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seen here, and respiration only returns to a rate similar to before oligomycin treatment. 
Overall, these isolated mitochondria do not respire as efficiently as might be expected. 
However, this preparation of yeast mitochondria are capable of importing preproteins, Figure 
6-9B, which are processed into their mature form (MTS cleaved) in the mitochondrial matrix 
by MMP. Application of VOA, which abolishes membrane potential and proton motive force (- 
import) also abolishes import. Seen together this implies that, although compromised, yeast 
mitochondria (or at least a sub-population) are sufficiently intact and functional for assessing 
mitochondrial protein import – for this reason they were used in subsequent assays. 
6.3.3 Radiolabelled RNA import 
 
Figure 6-10 Assessing RNA import in isolated mitochondria  RNA import can be measured by directly importing 
radiolabelled RNAs   
Radiolabelled RNAs provide a sensitive method for following RNA import into isolated 
mitochondria. RNAs were in vitro transcribed with 33P-UTP in the reaction mixture, Figure 
6-11B. gRNAs and gRNAs with a 5′FD, the two most efficiently transcribed RNAs, were 
incubated with mitochondria with or without functioning import machinery (±VOA). Following 
a 10 minute incubation at 25 °C, mitochondria were treated with RNase to degrade non-
imported RNA. An RNase test was performed (Figure 6-11D, right) to ensure that the RNase 
treatment was sufficient to degrade total loaded RNA. In Figure 6-11C, whole import assay 
samples were directly separated on urea-PAGE whereas in Figure 6-11D, RNA was first 
extracted from the yeast import mix by TRIzol extraction. TRIzol extraction of RNAs lead to a 
much cleaner image with more discrete bands when exposed to a phosphor screen.  
Figure 6-11D shows both gRNAs and 5′FD gRNAs are protected by mitochondria: RNase 
treatment does not degrade all RNA in the sample. The gRNA protection by mitochondria is 
independent of VOA treatment, implying that if RNA import has been achieved it has been 
achieved independently of membrane potential. The protected gRNA bands appear to 
migrate more slowly than corresponding bands before treatment; this contrasts with the FD 
gRNA which appears as a single faint band of the same size. One possibility is that the gRNA 
is not fully imported, and the RNase can partially digest the polynucleotide. However, it should 
be noted that this assay does not explicitly demonstrate import, but rather demonstrates 
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protection. For the protein import assays, evidence of delivery to the matrix is ascertained by 
a change in the protein size as the MTS is proteolytically removed. There is no equivalent 
aptamer processing activity.  
 
 
Figure 6-11 Radiolabelled import of RNA into isolated yeast mitochondria  A cold IVT and B hot IVT incorporating 
33P UTP, 250 ng RNA loaded per lane. C and D For RNA import assay, 25 μg mitochondria were incubated with 8 
pmol 33P UTP-RNA for 10 minutes at 25°C. Unimported RNA was degraded with RNase and VOA dissipates 
membrane potential; C whole import sample on urea-PAGE, D TRIzol extracted RNA on urea-PAGE. Following 





In Chapter 6, three assays were used to assess gRNA import in both whole cells and isolated 
mitochondria. A Northern blotting protocol, Figure 6-3, was used to determine which 
mammalian cell fractions transfected gRNAs were enriched in. The results showed gRNAs 
with and without 5′ targeting aptamers to be mitochondrially localised, a result which is 
supported by assays following radiolabelled RNA import into isolated yeast mitochondria, 
Figure 6-11. gRNAs with and without 5′ targeting aptamers are protected from RNase 
degradation when incubated with yeast mitochondria. Imaging fluorescently labelled RNAs 
with and without targeting aptamers showed gRNAs to be perinuclear in distribution, but not 
necessarily mitochondrial – Alexa™ 488-UTP labelled gRNAs do not confidently colocalise 
with mitochondria, and at times seem to be explicitly distinct, Figure 6-6. Further to this, each 
of the protocols have several shortcomings which further complicate the findings. Each assay 
is commented upon further below:  
6.4.1 Northern blotting 
Although a significant period was spent optimising the Northern blotting protocol, cellular 
fractionation is not perfect, and fractions display a significant amount of overlap. Most 
significantly, the nuclear fraction is positive for both the mitochondrial and cytoplasmic 
probes. This can partially be explained as an artefact of the fractionation protocol: the nuclear 
fraction is the product of the first centrifugation step, and so any cells which have not been 
lysed will also be contained within this fraction. Indeed, the Alexa™ 488-UTP labelled gRNAs 
do not indicate a significant nuclear localisation and so most of this signal can be presumed 
to be from whole cells, rather than a genuine nuclear localisation. It cannot be dismissed 
however that in the case of a mitochondrial CRISPR system it would be important to be able 
to prevent off-target action in the nucleus. 
6.4.2 Fluorescently labelled gRNAs 
Alexa™ 488-UTP can be efficiently incorporated into gRNAs for their cellular imaging. 
However, the cellular localisation of the FD RNA, chosen as a positive marker of the 
mitochondrial compartment, does not confidently colocalise to mitochondrial protein. A 
potential impact could be on mitochondrial folding and hairpin formation: given that altering 
the 3-dimensional structure of RNAs has the potential to impact RNA import into the 
mitochondria, it is important to ensure that their incorporation has not impacted their normal 
fold and function. If incorporation of dyes does impact on gRNA folding, other possibilities for 
fluorescent UTP incorporation which might be less invasive could be explored such as end-
labelling. Although Alexa™ dyes are commonly used in cellular imaging, it is also worth asking 
whether the dye itself might preclude normal import through some other mechanism. 
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The Baby Spinach fluorescent aptamer can function when appended to the 5′ end of gRNAs, 
however it’s incompatibility with the 3′ end, meant we did not pursue it further for cellular 
imaging. 
6.4.3 Radiolabelled RNA import into isolated yeast mitochondria 
Although attempts were made to isolate mammalian mitochondria, only yeast mitochondria 
were viable for performing import assays. Yeast import assays with 33P labelled gRNAs and 
5′FD gRNA showed gRNAs to be protected from RNase treatment in a manner which is 
independent of membrane potential. It is important to remember that there might be some 
inconsistencies between yeast and mammalian mitochondrial import pathways. 
Furthermore, isolated mitochondria are not in the usual cytosolic context, meaning there 
might be missing cytosolic factors, such as PNPase (section 1.5.2.1.4), which aid import. 
Together, these results suggest that even unmodified gRNAs could be mitochondrially 
localised. Though none of the assays prove this definitively, there is mounting evidence that 
gRNAs can import without any modification, particularly given the recent data from Loutre et 
al156 showing import, though not function, of gRNAs independent of mitochondrial targeting 
motifs. This also lends credence to the 2014 Jo et al paper160. Reports of directed import of 
exogenous RNA, summarised in section 1.5.2.2, rely on addition of structured RNAs, typically 
made up of one or more hairpin structures. Since similar structures are found in gRNAs, it is 
possible that these are acting as intrinsic import aptamers, in a similar manner to intrinsic 
MTSs found internally in some proteins such as Atg4D61. However, RNA import is a 
controversial area125 and as noted above, the import assays as carried out do not provide 


















7.1 Summary  
There has been widespread agreement on the importance of communication with the public 
around genome editing199. Although many technological advances have the potential to 
shape ourselves and our society, no other tool holds quite the explicit power of editing DNA. 
Members of wider society, particularly those who might be impacted by advances in genome 
editing technologies, should have a level of scientific literacy which is sufficient to enable 
informed consent (in the case of medical interventions, for example) and informed debate 
around potential applications of genome editing technologies. As academics I believe it is 
important to see ourselves as part of society, rather than separate from it. Given our high 
level of understanding of the current and future possibilities of genome editing, we have a 
unique opportunity to contribute to the ongoing discourse surrounding scientific 
development, and to facilitate scientifically-grounded dialogue between publics, 
policymakers and the research community.  
Towards these aims, I undertook an art-based project that was funded by BrisSynBio and 
which was carried out during a 3-month internship, the ‘Professional Internship for PhD 
students’ (PIPs), which is a compulsory component of the South West Biosciences Doctoral 
Training Programme. This project directly drew on my experiences of using CRISPR in the lab. 
Created in collaboration with three Bristol-based artists, SynBioExpo was a week-long art 
exhibition which started a dialogue between Bristol-based publics and researchers 
surrounding genome editing. SynBioExpo allowed a space for members of the public to 
explore the current and future potential of genome editing, and to have an open and honest 
discussion with researchers currently working in the field. This chapter starts by 
contextualising SynBioExpo and describing the exhibition. As a researcher, SynBioExpo 
offered an opportunity to gauge the public perception of genome editing. The second part of 
this chapter evaluates the impact of SynBioExpo: the ways in which publics interacted with 
the exhibition; the impact on the scientists and artists involved; and whether the exhibition 
itself, and science-art more broadly, was an effective medium to start this dialogue in Bristol.  
7.2 Context: the need for public engagement in genome editing 
CRISPR has revolutionised biological research with clear possibilities of transfer to the clinic. 
The perceived power of the genome editing tool is such that some of the most influential 
names in the field, including Jennifer Doudna and George Church, called for a moratorium 
on research in 2015200. The group called for a pause in research whilst a consensus was 
found between research and governmental organisations over the scientific, medical, legal 
and ethical implications of CRISPR applications. The importance of engaging society in the 
genome editing field is highlighted by the public rejection of genetically modified organisms 
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(GMOs) in the 1980s and 1990s. 25 years on from the first commercialised GMO crop (the 
Flavr Savr tomato201) rejection of GMO crops across Europe has had major societal, scientific 
and economic implications202 meanwhile they are being profitably farmed across North and 
South America and China, without any measurable safety problems. The shadow that GM 
casts over the CRISPR debate highlights the importance of how we choose to frame 
conversations with the public, and how researchers can respectfully adapt and respond to 
public concerns. 
New technologies often follow a similar pattern with regards to their acceptance by the 
public203,204. When technologies are very new, they are commonly accepted, but with growing 
media coverage, a feeling of unease rises and there is a phase of public resistance. With 
time, technologies evolve and the understandings and expectations of the public change. 
Fears fall, and the new technologies are gradually re-accepted and finally assimilated into 
day-to-day life, and culture. However, it is not always this straightforward. The initial 
resistance phase can sometimes turn into a ‘technopanic’, with intense public backlash – as 
was the case with GMOs. As cultural and ethical baselines change even these adapt. In the 
case of GMOs, although there are still many people who are anti-GMO, this is a much smaller 
percentage of the population in comparison to the 1990s205. 
Given the potential power of CRISPR-based technologies, to completely halt genome editing 
research in the UK would be a huge disadvantage not only scientifically and economically, 
but also in not being able to realise a whole host of advantages. That being said, it is 
important that technological advancements are mindful of the power they create, especially 
when involving ethically sensitive topics such as germline genome editing. 
With fast-paced technological development, it is extremely difficult for regulatory measures 
to be sufficient to completely control technological applications. The Presidential Commission 
for the Study of Bioethical Issues’ report on Synthetic Biology stated that “creating a culture 
of responsibility in the synthetic biology community could do more to promote responsible 
stewardship in synthetic biology than any other single strategy”206. This fits with the growing 
expectation of institutions to take a responsible approach to their research and innovation; 
Research bodies are increasingly actively considering the wider context and impacts of 
research and being transparent with the public with regards to their research207. This is not 
to say that the onus should fall wholly onto the individual researcher – a job role which seems 
to be constantly expanding. But it is to say that individual researchers, as gatekeepers of this 
knowledge, should realise the potential impact they could have on the wellbeing of their own 
present and future societies. Knowledge sharing, driving excitement for world-class science, 
and encouraging best practice and ethical research practices in their direct research 
environment can all be powerful actions within the context of RRI.  
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A Wisconsin study208 found that a higher level of knowledge about genome editing (measured 
by participants who got more than 60% in a test) corresponded with greater acceptance of it 
(76% of the participants). Similar studies have also found that there is an appetite for 
learning about genome editing, but it is the responsibilities of experts and governments to 
ensure that there is information available.  
This is particularly pertinent as TALEN-based therapies are already being applied in human 
patients - a 2014 study was the first to administer TALEN edited cells to human patients with 
HIV209 - and CRISPR-based therapies are on the horizon. Although disease amelioration in 
somatic cells is one of the most widely accepted applications of genome engineering, being 
agreed on by 64% of people in one study208, impacted individuals have the right to access 
clear and open information. Such groups affected by advancements in the treatment of these 
diseases include patients and their families and carers; fertility patients, who are required 
for donation of supernumerary embryos to be used in research; and the medical 
professionals in contact with both groups. As the applications of CRISPR technologies 
broaden, an ever-increasing percentage of the population will be in contact with these them. 
Ideally, public literacy surrounding emerging technologies should develop alongside 
technological advances so that a common language and understanding has been developed 
well in advance of decision making210. 
7.2.1 Context: BrisSynBio 
BrisSynBio is a multidisciplinary £13M Research Council-funded Synthetic Biology Research 
Centre based at the University of Bristol. BrisSynBio are actively engaged in ethics and 
responsible research and innovation (RRI) and public engagement in Synthetic Biology, and 
as part of this provided £1,450 for the development of SynBioExpo. SynBioExpo was a new 
project which built on no previous art-science projects by BrisSynBio. It can be seen as a 
proof-of-concept to determine whether art-science collaborations and an exhibition format is 
an effective way of encouraging community dialogue around genome editing that could be 
more widely employed.  
7.2.2 Context: Art-Science Collaborations 
Following a swell in popularity in the early 2000s211, art-science collaborations have been 
becoming increasingly popular as a tool for public engagement. Although art itself does not 
equate to public engagement, art can provide an alternative ‘language’ through which to 
speak about ideas and welcome a different audience, and one that may be more acceptable 
to some people who, for one reason or another, are “science averse”. For the scientists 
involved, the collaborative process with artists is often found to be mutually enriching, 
encouraging them to reimagine and revaluate their work and its societal context. Equally, it 
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offers artists access to a world usually locked away in universities and research labs. The 
exhibition format allows a narrative journey, and a move away from traditional scientific 
settings and stereotypes; some groups can therefore find it easier to interact with a scientific 
topic which they may usually be intimidated by, or not have access to.  
7.3 SynBioExpo Aims 
SynBioExpo was a collaboration between three University of Bristol researchers and three 
local Bristol artists which culminated in a week-long exhibition. The overall aim of SynBioExpo 
was: 
To curate an art exhibition which facilitated discussion between members of the public and 
researchers about genome editing technologies.  
SynBioExpo aspired to achieve the following public engagement aims: 
1. To increase awareness of genome editing technologies, for example CRISPR. 
2. To share examples of research projects in Bristol which use genome editing. 
3. To enable visitors to interact with researchers who use genome editing. 
4. To encourage visitors to question their own opinions on the future applications of 
genome editing. 
 
And the following aims for us as the organisers: 
5. To help understand the public perception of genome editing. 
6. To assess whether science-art collaboration is a suitable format for starting an open 




7.4 SynBioExpo Exhibition Overview 
SynBioExpo was held in SPACE gallery, an exhibition space in Old Market, central Bristol. 
SPACE is co-owned by The Island and ArtSpace LiveSpace, two local community-run charities. 
Figure 7-1 shows the floorplan of the 3.8 x 6.2 m gallery space, which was split into three 
sections for SynBioExpo:  
1. What is CRISPR? An introduction to genome editing tools  
2. CRISPR in Bristol Three Bristol-based research projects which use CRISPR  
3. The Future  An invitation for visitors to imagine the future of CRISPR 
 
Although visitors could visit the pieces in any order, and they were left to explore the 
exhibition alone, the narrative worked best if visitors travelled through them in order, moving 
clockwise around the space starting at the door, Figure 7-1 bottom left. 
 
Figure 7-1 SynBioExpo left Floorplan of SPACE gallery, as seen from above. Right top photograph of visitors in the 
exhibition spaceix right bottom photograph of Arts West Side (SPACE gallery) on the opening night from the 
outsidex 
                                                     
ix Unless stated otherwise, all photographs in this chapter thanks to Joe Brown 
x Photo thanks to Alistair Scott 
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7.4.1 What is CRISPR 
The first section of SynBioExpo “What is CRISPR” served as an introduction to the exhibition. 
A floor-length banner “Symphony” by Theo Wood, a multimedia artist from Bristol. Shown in 
Figure 7-2 (left), “Symphony” displayed printed words which Theo Wood chose out of the 
artist-scientist exhibition development meetings. Theo Wood also developed a performance 
of the words displayed in the piece. “What is CRISPR” also included an introduction of the 
space consisting of a piece of writing containing information about genome editing tools, 
Figure 7-2 (right). 
 
Figure 7-2 What is CRISPR?  Left “Symphony” - Theo Wood and right exhibition introduction  
7.4.2 CRISPR in Bristol 
The second section of SynBioExpo “CRISPR in Bristol” focused on three University of Bristol 
research projects which utilise CRISPR. This section of the exhibition aimed to show the 
importance of genome editing tools to cutting-edge research projects which are currently 
ongoing; each project was represented in the exhibition with a short summary and two 
illustrations shown in Figure 7-3, one by Claudia Stocker and one by Imogen Coulter, both 
illustrators. The projects in this section of the exhibition aimed to highlight the importance of 
showing a broad range of research which were still in their infancy, some which are closer to 
basic research, and some which are more explicitly synthetic biology.  
132 
 
The first highlighted project was the work of Joe Hawksworth, a BrisSynBio funded PhD 
student in the Toye group working to use CRISPR to produce engineered red blood cells. 
Engineered blood may serve numerous purposes:  to mimic disease states for research; to 
develop a universally accepted blood type; to improve the lifespan or storage properties of 
cultured blood; for therapeutic purposes such as long-lasting drug delivery vehicles. 
The second project was the work of Amber Knapp-Wilson, a University of Bristol funded PhD 
student in the Kuwabara lab. Amber is using CRISPR to study mitochondrial protein import in 
the nematode Caenorhabditis elegans. Though C.elegans is one of the most extensively 
studied organisms genetic engineering of the worm has traditionally been difficult. The 
development of CRISPR tools for C.elegans has had a significant impact on the use of this 
model organism. We thought it important to reflect the significant impact of this basic science 
application of genome engineering technologies to show the impact having CRISPR as a 
standard laboratory tool. The MitoCRISPR project presented in the earlier chapters formed 
the third highlighted project in SynBioExpo. 
 
Figure 7-3 CRISPR in Bristol  left top Synthetic Blood – Claudia Stocker; left bottom Blood cells – Imogen Coulter; 
Right top Deconstructing C.Elegans – Claudia Stocker, C.Elegans – Imogen Coulter; right bottom Mitochondrial 
Chromosomes – Claudia Stocker, Mitochondria – Imogen Coulter    
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7.4.3 CRISPR in the future 
The third section of the exhibition prompted visitors to consider the future reimagined with 
CRISPR technologies. There were three pieces in this section, each encouraging increasing 
visitor engagement. “The future, bold and new” by Theo Wood featured under-lit brown 
bottles with flags, each holding an imagined future headline from different times down an 
imagined timeline of genome engineering. One of the headlines was accompanied by a small 
ceramic micropig, Figure 7-4.  
“Dilemmas”, also developed by Theo Wood, consisted of a set of cards, each with a different 
bioethical ‘dilemma’ on them, describing an application of genome engineering. After reading 
the scenario, readers were encouraged to vote on how comfortable they felt with the 
application by taking a counter and placing it into a box. Counters were colour coded on a 
traffic light system: Green for ok, amber for maybe and red for no. All the voting counters 
went into the same wooden box. Responses were not recorded. Instead, the action of the 
exercise was to prompt visitors to decide, have an internal (and perhaps external) dialogue. 
A full list of “dilemmas” is provided in Appendix A7-II. 
 
 
Figure 7-4 The Future 
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The future section also included a discussion podium, Figure 7-9. Three questions were 
posed to visitors, written around a podium in the centre of the exhibition space. Visitors were 
invited to respond to the questions, and other visitors’ comments, by taking a post-it note 
and sticking it on the podium. The podiums were particularly useful given many visitors came 
to the exhibition alone. Reading and responding to the other comments allowed a dialogue 
to emerge between visitors who were temporally separated.  
 
Figure 7-5 SynBioExpo 
 Invigilator/Scientist  
Throughout the time that the exhibition was open, there was always an invigilator in the 
space. This was usually myself, but at times I was accompanied by the scientists or artists.  
Some visitors were asked whether they would answer a few questions on their experiences 
of SynBioExpo, and were given the option to either fill in a questionnaire on an iPad, or to 
have their verbal answers transcribed. The 8 individuals all chose the latter, and the results 




7.5 Evaluating SynBioExpo 
Art itself does not equate to public engagement. In order to understand the public perception 
of genome editing, and to assess whether the engagement aims (section 7.3) were met, 
visitors to SynBioExpo were invited to participate in a number of evaluation processes, 
including discussion podiums (Figure 7-9), an evaluation graph (Figure 7-6) and evaluation 
questionnaire (Figure 7-8). Attendance records were also kept.  
To evaluate the impact of SynBioExpo on the artists and scientists: the University Centre for 
Public Engagement ran a focus group with the involved artists and scientists following the 
exhibition to study art-science collaborations 
 
 
Figure 7-6 Evaluation graph,  contributed to by 85 visitors. 34 green stickers - I have a keen interest in science 
(40%); 5 blue stickers – I am under 18 years old (6%); 21 yellow stickers – I have never heard of CRISPR before 
today (25%); 25 red stickers – I have enjoyed my visit here today (29%) 
7.5.1  Visitor attendance and makeup  
Over the week of the 24th April 2017, over 170 visitors came to SynBioExpo, Figure 7-7. 
Approximately 75 people came to the exhibition opening evening, most of whom knew either 
the scientists or researchers involved.  
Although this is not insignificant, much could be done to improve attendance in similar events 
in the future; several questionnaire participants mentioned that they thought the exhibition 
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would have wider appeal and should have attracted a larger audience; one visitor said in ther 
evaluation "Do you have any plans for this to be shown again after this? It really is fantastic!". 
A gallery space in a more central location and altering the run of the exhibition to include 
more weekend days would have been advantageous: the busiest day, excluding the opening 
night, was Saturday. Given the proximity to the Easter holidays, timing is also a consideration. 
Advertising was though leafleting (local cafés and community noticeboards), local radio, and 
social media, but paid advertisements (for example on social media) might have broadened 
the reach.  
 
Figure 7-7 SynBioExpo visitor attendance numbers  
7.5.2 Evaluating the impact of SynBioExpo on the public 
In this section, each of the engagement aims from section 7.3 will be discussed in turn.  
1. To increase awareness of genome editing technologies, for example CRISPR 
SynBioExpo was largely successful at achieving an increased awareness of genome editing 
technologies in its visitors. 25% of the visitors who placed a sticker on the evaluation graph 
(21/85 individuals) said they had never heard of CRISPR before their visit, Figure 7-6. All the 
8 questionnaire participants said they knew more about CRISPR on leaving, and 5 out of 8 
said they knew “a lot” more, Figure 7-8. The take-home messages for visitors were broader 
than just relating to genome editing, however. In response to the question “Can you tell us 
something you didn’t know before”, every respondent was able to give an answer. Some 
responses were project specific such as “I didn’t know there were that many blood groups”, 
and others drew on themes form the exhibition as a whole: “the potential [of CRISPR] is huge, 
covering all areas”.  
2. To share examples of research projects in Bristol which use genome editing. 
SynBioExpo had a deliberate focus on University of Bristol research projects using genome 
editing tools. When asked “Can you tell us one thing you have discovered today that you didn't 
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know before?” one participant replied, “That it’s all going on in Bristol - I didn’t realise it was 
such a hub for science and that this was all going on here”.  
When asked “Can you tell us one thing you have discovered today that you didn't know 
before?” more than half of the participants gave examples which was linked to the Bristol 
research projects such as “mitochondrial editing”, “the red blood cell research”. 
3. To allow publics to interact with researchers who use genome editing 
When asked “What is the most powerful image you are left with after your visit today?” one 
participant said “it's great to meet the people involved” 
 
Figure 7-8 Evaluation Questionnaire Summary 
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4. To encourage visitors to question their own opinions on the future applications of 
genome editing. 
Through interactive elements such as “Dilemmas” and the question podiums, SynBioExpo 
aimed to prompt visitors into forming new and questioning existing opinions about genome 
editing. There was no consensus between respondents to the evaluation questionnaire over 
whether SynBioExpo had changed their attitudes towards Synthetic Biology and genome 
editing. Some who had changed their opinion had become more positive, whereas some had 
become more concerned. Figure 7-8 displays some selected quotations from the 
questionnaire.  
7.5.3 The public perception of genome editing  
SynBioExpo gave an interesting insight into the public perception of genome editing, through 
evaluation responses, direct conversations or interactions with the exhibits and other visitors. 
 
 
Figure 7-9 Discussion Podiums 
Responses on the discussion podiums were a source of insight into the public’s hopes and 
fears. Most of the responses to the question “What is your biggest concern about CRISPR?” 
focused on a general lack of safety (“Is it safe?”; “Is it good?”) and misuse of genome editing 
tools (“weaponization”). Lack of regulation also featured heavily (“in the wrong hands what 
happens?”) although a small number of individuals were concerned with over-regulation 
(“people will stop the use of CRISPR through fear”) and the media response to technological 
advances (“'False facts' being propagated in the media”). Economically-themed concerns 
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were common (“Corporate misuse of dangerous technologies”; “tailoring humans to create 
what capitalism wants”; “misuse/abuse for profit”), with the potential for genome editing to 
worsen social inequality being a common fear. These ranged from issues which are already 
common place (“medical treatments or other advantages only available to the rich”) through 
to potential longer-term impacts (“creating a bigger rich/poor divide”; “two tier society of 
normal/enhanced humans”). A number of philosophical concerns were also aired (“how do 
we circumscribe what it means to be human”; “not being ‘human’ eventually). 
In contrast, “What would you most like to see CRISPR used for?” and “If you could change 
your DNA, would you? What would you change?” were much more positive. The 38 responses 
to “What would you most like to see CRISPR used for?” were roughly evenly split between 
applications in health (“Disease eradication”; cure of inherited disease”), society (“creating 
a more equal society”, “reduction of poverty and suffering”) and agriculture (“food security”; 
“reduced pesticide use”), though these responses can all be broadly summarised as the 
general “Improving quality of life”. Interestingly of the 55 responses to “If you could change 
your DNA, would you? What would you change?” only 4 responses were explicitly negative 
(“no”; “not for me personally”) though about 10 responses were joke comments.  
The evaluation graph shows us that those with a keen interest in science were, overall, more 
excited about CRISPR than those who had never heard of CRISPR before their visit, whereas 
those not from a science background were warier of genome editing. This is in line with 
previous studies mentioned in section 7.2 which find a correlation between knowledge and 
acceptance of a topic. 
7.5.4 On using art to start discussion about genome editing 
Overall, the response to whether an art exhibition was a good medium to introduce a scientific 
topic was positive. In the public evaluation questionnaire, 7 out of 8 respondents said that 
they enjoyed the format. The sentiment that the art brought something enjoyable was also 
brought up by a scientist in the focus group in the months following the exhibition, saying “I 
just think it's quite good for public engagement to generally inspire people in a sort of 
creative, fun way”.  
There was a general feeling that using visual images made it “very easy to break down the 
language barrier you might have”, in the words of one of the artists. “I think it's really good 
because a lot of science work can be really abstract…It's hard to picture” said one if the 
scientists, so it can help to “try and bridge that gap”. And this was sentiment was echoed by 
a visitor in the evaluation questionnaire who said the “powerful images help[ed] 
contextualise the scientific information”. Through providing “a different way of looking at it 
[the science]” the art certainly seemed to help visitors engage in the science, and perhaps 
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brought in a new audience, one visitor making the comment that “I wouldn’t have come if it 
was just a science exhibition”. 
7.5.5 Evaluating the impact of SynBioExpo on the artists involved 
The artist/scientist focus group gave some interesting insights into the artists’ experiences 
of the process, and how it has impacted on them personally, their understanding and working 
practices. It was clear that the project overall was enjoyable for the artists, but moreover it 
allowed them greater understanding and knowledge of the field. One artist said “[it was] a 
really interesting project to work on” and another “[it] force[ed] me to do things I'd never done 
before… [I was] learning from it.  So that's why I enjoyed doing it.” SynBioExpo set out to 
improve the science literacy of the public, and it appeared that this was seen with the artists 
too; “it was an opportunity to find out more… which was exciting, [it is] a very exciting topic” 
said one. Another is still actively researching the genome editing field “I did do a lot of 
research about what's out there ... and I continue to do it.” – indeed she still periodically 
sends emails around the group with science stories of interest.  
When asked what the most valuable part of the process was, one artist answered the 
“opportunity to work with actual scientists”. “I actually do like doing an art and science 
collaboration rather than just art interested in science” one artist said. Another commented 
that “collaboration ... enhances what you're making” – a sentiment which is thematic of the 
whole exhibition, as well as the individual pieces. In response to the question “Would you like 
to be involved in public engagement in the future?” there was an unanimously positive 
response – “I'd definitely be up for doing more” one keenly exclaimed. 
7.5.6 Evaluating the impact of SynBioExpo on the scientists involved  
The role of the scientists, excluding myself, was primarily in the development phase of 
SynBioExpo rather than delivery. This was partially due to time concerns, but also other 
motivations, such as a lack of confidence in, or desire to take part in public engagement. In 
the focus group, one individual said that “I did the classic scientist thing of not wanting to get 
involved with the public… this is the way for me to be involved in public engagement without 
having to talk to any members of the public”. Unfortunately, this might have led to some 
feelings of a lack of control over the end product; one scientist remarked “the outcome was 
amazing… but I didn't feel like it was very much down to me”. 
Although claiming, for example, that “art is quite far out of my comfort zone”, the two 
researchers said that they found the process useful (“a really valuable experience”). Both 
said it allowed them to articulate their own research in different ways; one saying it helped 
them in “knowing how to communicate [your] research and how to talk to people on a level 
they can understand”. When asked whether the process helped them in preparation for 
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talking to the public, the other responded that “it definitely helped me”. Moreover, 
SynBioExpo seemed to shape the scientists’ views of what public engagement could be, how 
it could be different from their pre-existing ideas, for example: “the thing that's changed for 
me, is just how to imagine future engagement projects”; and, “I feel like it's given me ideas 
on how to communicate … a bit more appreciation that it doesn't always have to be the same 
interpretation that you had imagined”. Overall, it appeared that it was valuable for the 
scientists to have an insight into the thoughts of the public; “it's very interesting to see how 
people respond to [the exhibition]”. 
When talking about whether being involved in the exhibition had changed the way they 
approach their work in the lab, it seems that changes have not been directly related to the 
scientists’ research, although they did spend time “thinking about the bigger picture of the 
actual applications of my work”. One scientist also said it impacted their teaching work 
alongside their PhD, saying it made them “change how I would write the tutorials to try and 
put it into a more visually engaging way”. One PhD student highlighted a perceived lack of 
confidence, saying that “I don't think it has changed the way I work, but I think it's definitely 
got the potential to - maybe it's partly because we're PhD students”.  
7.5.7 Comment on efficacy of the evaluation methods 
Broadly speaking, the evaluation methods for SynBioExpo were fit for purpose, with sufficient 
information collected to answer whether the engagement aims were met. However, a greater 
depth of information might have been able to be collected if the evaluation questionnaire 
had been collected by dictaphone as inputting the responses in to the iPad was awkward.  
An effort was made to have the discussion podiums and evaluation graph situated as far 
away from the invigilator’s desk as possible but given the small exhibition space there still 
might have been some impact on responses. The presence of the invigilator whilst all the 
evaluation questionnaires were filled out should also be taken into consideration.  
7.6 Conclusions and Recommendations  
SynBioExpo set out to “curate an art exhibition which facilitated discussion between 
members of the public and researchers about genome editing technologies”. The evaluation 
in section 7.5 showed this to be largely successful: an exhibition of work was developed and 
delivered which not only increased awareness of genome editing research but made a space 
for public discussion and debate surrounding how genome editing should, or shouldn’t, be 
implemented. Moreover, the context of an art exhibition seemed to work. The visual 
interpretation was enjoyed by visitors and facilitated them to engage with the research and 
gave the researchers involved a fresh perspective on their work.    
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Perhaps the greatest conclusion from the process of developing and delivering SynBioExpo 
was expressed by of one of the artists: “collaboration ... enhances what you're making”. All 
of the individuals involved with the project were pivotal to its development, perhaps because 
it was a project where all involved were working mutually away from their comfort zones; “art 
is quite far out of my comfort zone” said one of the scientists in the focus group, a comment 
mirrored by an artist comment that “[it] force[ed] me to do things I'd never done before… [I 
was] learning from it.  So that's why I enjoyed doing it”. As a result, the process can be said 
to have been beneficial to both the artists and scientists involved, as described in sections 
7.5.5 and 7.5.6. Interestingly, the scientists did not necessarily need to deliver the exhibition 
to the public for it to be of benefit to them. The process of meeting with the artists and 
speaking about their research in-depth to non-specialists itself was enriching, and the 
publics’ views were captured on the discussion podium. However, from the point of view of 
the artists and public, interacting with researchers is one of the most valuable parts of the 
exercise, of which there is no substitute.  
7.6.1 Reflections 
The following section details a few reflections on the exhibition which are worth considering 
if similar projects are developed in the future. 
Words 
Whilst advances in CRISPR have greatly accelerated the pace of genome editing, it is 
important to recognise that related ethical conversations are simply continuations of those 
already happening, for example surrounding ZFNs, TALENs and the MRT fertility treatments 
introduced in Chapter 1. Although the tools are changing, there is a core theme in the 
bioethical debate that is more general and will certainly continue to happen following future 
technological advancements. In this way, it is important to consider the language we choose 
to use in public engagement exercises, ensuring that the terminology of the tools does not 
interfere with the underlying debate. If the aim of a public engagement exercise is to equip 
publics with a scientific literacy which will enable them to take part in debate, using the 
names of specific tools perhaps unnecessarily narrows the topic being discussed, especially 
as new advances are made. There is, of course, a balance to be struck - whilst society has a 
right to discuss science without oversimplification, technical terms can obstruct 
communication. 
In the context of SynBioExpo, the term “CRISPR” was used a lot as it was the common 
technology used in the three research projects focussed on in the exhibition. Indeed, many 
general discussions about genome editing - in the exhibition space but also more widely in 
the media - have started to use “CRISPR” interchangeably with genome editing. To do this 
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limits not only the term CRISPR - as discussed in Chapter 1, the scope of CRISPR-based tools 
is so much more now - but also has the potential to restrict future conversations surrounding 
genome editing.  
We did not take time whilst developing SynBioExpo to consider whether it was necessary to 
use the term CRISPR. In hindsight, using several terms (genome editing, genome engineering, 
CRISPR and more) might have been confusing to visitors. It was clear that the amount of 
writing in the introduction to the exhibition should have been reduced, as highlighted by two 
visitors in the evaluation questionnaire: “To be honest there is an awful lot of reading - all 
these long words I think ooh, god!"; “there is a lot of text but actually it’s very easy to 
understand once you’ve started”. Nonetheless, CRISPR is a snappy acronym that is 
undoubtably memorable to many and has become a shorthand for editing more generally.  
“I don’t want this to be a PR thing” 
Throughout the process, the artists involved in SynBioExpo brought a refreshing perspective. 
One artist felt very strongly about the overall message of the exhibition: “I mean, I said very 
early on, ‘I don't want this to be a PR thing’” they recap in the focus group. Through this 
comment, the artist was stressing their desire that through SynBioExpo we make a space 
where conversations with the public were a genuine, two-way exchange. They wanted public 
voices to be respected and reflected-on by researchers. This comment went on to very much 
shape the exhibition.  
A very common concern among academics taking part in public engagement exercises is that 
they are going to be expected to defend science. They are wary of entering into tricky 
discussions in which they feel cornered and don’t have a simple answer. Due to the innately 
controversial nature of genome editing, this is an understandable concern. In developing 
SynBioExpo, we intended to make a space where people could honestly explore together their 
opinions regarding how genome editing technologies are used, now and in the future. It was 
important that public engagement in genome editing did not simply become an advertising 
campaign, but instead be a place where scientists themselves questioned their own motives 
behind their research, thought of themselves as citizen and scientist.  
Preaching to the converted 
Science public engagement activities are often heavily attended by scientists. From the 
engagement graph, this can be seen to be true of SynBioExpo too. In holding SynBioExpo in 
an exhibition space, we hoped to appeal to a new audience which would not usually interact 
with a science event, and avoid any science hierarchy, stereotypes. However, one of the 
artists commented on the podiums that “I could see a lot of researchers had been and almost 
hijacked that column”. The podium had several comments, which were clearly scientific ‘in-
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jokes’, written on it, and this artist was concerned that these comments would mean that the 
discussion podium “didn't work in the way that it was perhaps intended”. A deliberate choice 
was made not to censor the discussion podiums at all, but it is possible that these comments 
resulted in other visitors feeling that they could not comment openly without judgement.  
7.7 Legacy 
Much of the work developed and lessons learnt during SynBioExpo have been shared in new 
contexts since the SynBioExpo exhibition. The dilemma cards formed the basis of a workshop 
that I delivered at Hillfield’s Project Night, a youth group for 11 - 18-year olds run by a local 
charity in North East Bristol. This pilot session was used as the basis of a successful 
application to the Biochemical Society Diversity in Science Fund. The pieces themselves were 
also reexhibited at “Synthetic? | Synthetic Biology meets art”, an internal exhibition at 
BrisSynBio’s annual conference.  
In October 2017, the National Coordinating Centre for Public Engagement (NCCPE) arranged 
a Genome Engineering Public Engagement Synergy ‘What Works’ event at the Wellcome 
Trust, London. The event brought together a range of researchers, research councils, policy 
makers and public engagement professionals who are working in public engagement in 
genome engineering. I attended this event and hosted a sharing session about using art to 
engage with the public on genome engineering. The lessons learnt through the process were 
also summarised in an internal seminar that I presented as part of the Centre of Public 








Tools for manipulating mitochondrial genomes have been in development since the 1990s 
with the first mtDNA targeting restriction endonucleases. Since then, technological advances 
have often been applied to understanding the basic biology of the mitochondria, and for 
development of potential therapeutics through clearing mutated populations of mtDNA. 
Whereas tools for the manipulation of nDNA are extensive, in particular benefitting from a 
wave of CRISPR-based tools in the last half decade, there is an unmet challenge in the 
development of the same breadth of tools for mtDNA. The work detailed in this thesis seeks 
to expand the tools available for the study of mtDNA by beginning the development of 
MitoCRISPR, a suite of tools for the manipulation of mitochondrial genomes.  
Work in the early stages of this project highlighted that both achieving and assaying a 
SpyCas9 based system targeting mtDNA will be complicated given the inefficient 
mitochondrial targeting of the nuclease. Following an expansion in the research group in the 
intervening years development of the MitoCRISPR system, most likely a Cas12a-based 
system, is ongoing. 
Nevertheless, work detailed in this thesis has laid the foundations for how we might achieve 
the cellular implementation of MitoCRISPR. Through designing a library of gRNAs for 
MitoCRISPR, the work detailed in this thesis has interrogated the impact of gRNA structural 
modifications on gRNA/Cas9 complex formation and activity, the conclusions from which are 
of value to the CRISPR field more broadly. Additionally, although more work will need to be 
done in confirmation, we have evidence to suggest that unmodified and 5′ modified SpyCas9 
gRNAs are imported into the mitochondria, corroborating findings from other research 
groups156,160. 
8.1 Targeting CRISPR nucleases to mitochondria  
Chapter 3 detailed the steps taken to clone a plasmid encoding mitochondrial targeted 
SpyCas9 (COX8A-Cas9) under the CMV promoter. Unfortunately, transiently transfecting 
mammalian cells in culture with plasmid DNA lead to poor cellular expression of 
mitochondrial and nuclear localised Cas9 as measured by western blotting, 
immunofluorescence and FACS. Subsequent work by Dr Zuriñe Anton with the same 
construct showed that cells expressing SpyCas9 suffer a deterioration in mitochondrial 
health, which is likely impacting cell viability and health overall. At present, the exact cause 
of this impact on mitochondrial health is unknown, though overexpression and mitochondrial 
import of a large protein is likely largely disruptive to mitochondrial biology. In contrast, 
LbCas12a has since been successfully mitochondrially expressed with three MTSs, the most 
successful of which being Su9-Cas12a. Dr Anton is currently undergoing work to characterise 
a stable cell line expressing Su9-Cas12a-GFP. 
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The difference in mitochondrial targeting efficiency between Cas9 and Cas12a is intriguing. 
MTS accessibility is important for protein import, and it may be that the peptide is presented 
suboptimally on Cas9. Exploring mitochondrial targeting of Cas9 with alternative MTSs or 
introducing a flexible linker between the MTS and Cas9 structure in conjunction with in silico 
modelling might ameliorate this. However, the observed transfection of nuclear targeted 
Cas9 was also inefficient which might reflect expression problems at the RNA or protein level, 
overcome to some extent with Cas12a. Amino acid bias or differences in overall peptide 
charge of imported proteins should also be considered, as favourable interactions with 
TOM/TIM will encourage mitochondrial import. If features favouring Cas12a import over Cas9 
are understood there would be the potential to modify the Cas9 structure, optimising it for 
mitochondrial import. This is particularly attractive since there is now such a broad range of 
CRISPR tools which are optimised for the Cas9-based system. Furthermore, any general rules 
governing mitochondrial import could be screened for against the large number of CRISPR-
Cas variants in the pangenome. 
8.2 Modifying CRISPR RNAs for mitochondrial targeting  
Chapter 4 designed and in vitro transcribed a library of gRNAs with mitochondrial targeting 
and functional structures. Through a series of ensemble and single molecule assays, we 
determined that SpyCas9 gRNAs can be edited at several sites, namely the 3′ end, upper 
stem and hairpins with no impact on gRNA loading, R-loop formation or endonuclease activity. 
In contrast, even small modifications are not tolerated adjacent to the spacer at the 5′ end 
of the gRNA. gRNAs with a 20 nt hairpin on the 5′ end form small R-loops and consequently 
cannot cleave a supercoiled DNA substrate. Chapter 5.1 explored this effect further, finding 
that nucleotide mismatches at the 5′ end, such as from the natural T7 RNA polymerase, 
negatively impact endonuclease activity. Adding successive unmatched nucleotides in this 
position results in a stepwise reduction in endonuclease activity. 
Initially, the finding that 5′ gRNA modifications negatively impact endonuclease activity 
seems a disadvantage. However, of consideration is the fact that nuclease null Cas9 mutants 
have had widespread application in the growing CRISPR toolbox (section 1.4.5). Reframed in 
this context, the findings of chapters 4 and 5 begin to characterise a system where an active 
Cas9 can be “turned-off” by switching the available gRNA. There may also be other benefits 
to these overhanging nucleotides: gRNAs with two mismatched 5′ guanines have been shown 
to show decreased off-target CRISPR activity212. It is likely that the decreased cleavage at 
both on-target and off-target sites has a common mechanism, perhaps the result of altered 
RNP structure or stability. 
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Following the work in Chapter 3, it appears increasingly likely that LbCas12a, rather than 
SpyCas9, will be the CRISPR nuclease employed in a MitoCRISPR tool. Nevertheless, there is 
still benefit in understanding the impact of Cas9 gRNA structural modifications given the 
widespread application of gRNA structural and functional modifications in CRISPR/Cas9 
tools targeting nDNA.  
Unfortunately, the efficiency of Cas12a mitochondrial targeting was discovered too late in 
this project to study Cas12a crRNA modifications as rigorously as with SpyCas9 gRNAs; 
Chapter 5.2 briefly investigated the impact on crRNA modifications on endonuclease activity. 
Similar to the gRNA, crRNA modifications adjacent to the spacer - the LbCas12a crRNA 3′ 
end - were not tolerated by Cas12a. Four unmatched nucleotides on the 3′ end had a great 
impact on Cas12a endonuclease activity. Initially, 5′ crRNA modifications seemed to be 
tolerated by Cas12a. However, this is likely due to the fact that our crRNA 5′ modifications 
were cleaved off by Cas12a, which possesses RNase activity for processing pre-crRNAs, 
leaving an unmodified crRNA. 
This thesis was not able to explore whether Cas12a crRNAs are able to be mitochondrially 
targeted, though the smaller size of Cas12a crRNAs might be more favourable for 
mitochondrial import. Given that the 3′ end cannot be modified without compromising 
endonuclease activity and the 5′ end will be processed, upper stem modifications might be 
of interest. Alternatively, characterising and ensuring crRNA processing of targeting 
modifications once inside the mitochondria could also be advantageous. The MitoCRISPR 
research group is also currently pursuing methods for mitochondrial targeting of crRNAs 
which do not rely on RNA structures, as outlined below.  
8.3 Directing CRISPR RNAs to the mitochondria 
Much of this thesis focussed on the addition of RNA structures to SpyCas9 gRNAs with the 
expectation that they would be required in order to deliver these RNAs to the mitochondrial 
matrix. Work described in Chapter 6 tested whether this was indeed the case through assays 
with whole cells and isolated yeast mitochondria. In contrast to our initial expectations, work 
described in Chapter 6 adds to a growing body of research surrounding the mitochondrial 
localisation of unmodified gRNAs, without the requirement for targeting modifications 
125,156,160. It remains to be seen whether gRNAs are reliably delivered to mitochondria with 
RNA aptamers, and whether they are able to deliver the broad functionality available  for 
manipulation of nuclear DNA. 
Isolated yeast mitochondria import assays suggest that radiolabelled gRNAs are imported 
independently of membrane potential. Import is also seen by Northern blotting for unlabelled 
RNAs in whole mammalian cells, though the fractionation protocol was too crude to exclude 
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mixing of fractions mixed. The importation of Alexa™-labelled RNAs was less clear, and even 
FD-488 RNA, a positive control, did not show distinct mitochondrial localisation. In each of 
these assays, the addition of a mitochondrial targeting hairpin, be that RP or FD, did not 
appear to alter gRNA cellular localisation. Overall, it is worth following up these experiments 
with other techniques to ascertain whether RNAs are mitochondrially localised; of particular 
importance is the generation of assays for following mitochondrial import with clear positive 
and negative controls. 
Given the inconclusive nature of these studies using RNA structures, Dr Holly Ford is currently 
investigating alternative methods of targeting RNAs to the mitochondria including peptide-
RNA chimeras. Peptide MTSs have been crosslinked to oligonucleotides for delivery to the 
mitochondria via the TOM/TIM protein import machinery213–215. Using 44 nt ssDNA as a 
prototype for LbCas12a crRNA, Dr Ford has conjugated a truncated COX8A MTS to the 5′ or 
3′ end of a ssDNA and seen that the chimeras are imported into isolated yeast mitochondria. 
The chimeras are cleaved by the processing peptidase in the mitochondrial matrix and 
protected from subsequent treatment with proteinase. She is now moving on to develop 
peptide-RNA chimeras and measure their import by the same assay. As with the RNA 
aptamers, it will be necessary to ensure peptide modifications are not inhibitory to Cas12a 
complex formation and endonuclease activity, whether that be through Cas12a RNA 
processing or other means. The obvious limitation to a peptide-RNA fusion is that 
endogenous expression from a recombinant plasmid or virus would not be possible. 
Nevertheless, there could be advantages, such as the peptide being cleaved off by MPP after 
mitochondrial import, providing a method for measuring import, and the incorporation of 
other reporters or functionalities. 
There are also several other methods which could be explored for the mitochondrial targeting 
of RNAs if unmodified gRNAs are not targeted to the mitochondria, or if mitochondrial 
localisation is to be enhanced. Non-specific RNA binding proteins such as DHFR have been 
shown to be able to deliver RNAs to mitochondria216. RNAs could also be delivered to 
mitochondria in vesicles such as with MITOporter, a liposome-based system for delivery of 
macromolecules in to the mitochondria. MITOporter liposomes have a  diameter of 
approximately 200 nm and have been used to deliver RNA217 and proteins67 to the 
mitochondria. They could be efficacious for delivery of RNPs for mtDNA manipulation, which 
might have benefits over stable expression, or separate delivery of RNA and protein 
compionents, as discussed in Chapter 3. Similarly, dequalinium amphiphile nanoparticles, 
DQAsomes, self-assemble around DNA, and interact with cardiolipin in the mitochondrial 
membrane, and could be used for delivery of RNA218–220. 
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8.4 The manipulation of mitochondrial genomes 
Given the impact that tools for the efficient manipulation of mtDNA would have on the study 
of mtDNA and disease, it is not surprising that there have been several published efforts to 
develop MitoCRISPR tools by other research groups during the course of this PhD. Though 
there have been several studies published, summarised in 1.6, none have yet described a 
tool that is as efficient as the best ZFN and TALEN examples. The most successful iteration 
to date has achieved a depletion of mtDNA copy number156, but CRISPR-mediated 
heteroplasmy purification has yet to be achieved. Based on our findings, we would suggest 
that the development of MitoCRISPR is a more complex task than was first anticipated. 
Given the difficulties developing MitoCRISPR, other methods for mtDNA manipulation which 
have previously been demonstrated to work (such as TALENs), may be more suitable for 
further development. Although MitoCRISPR may not be available in the short term, or possibly 
never125, development and refinement of alternative tools may drive mtDNA editing into wider 
use. 
As research progresses and we are able to edit genomes more efficiently and at lower cost 
than ever before, there is a pressing need to address the bioethical implications of the tools 
we are developing. The successful use of heteroplasmy purification technologies in model 
organisms shows that mtDNA editing technologies are perhaps not far from the clinic, a fact 
which has real bioethical implications. The widespread public acceptance and licencing of 
MRT fertility treatments means that there is a precedent for mtDNA interventions to be 
accepted by the public. Nevertheless, it is important for researchers to be actively involved 
in discourse with the public surrounding the application of such technologies from the offset, 
in doing so facilitating the avoidance of a ‘technopanic’ of the scale seen with GMO crops.  
To this end, Chapter 7 detailed an art-science public engagement exercise, through which we 
evidenced that simple projects can impact upon the public understanding of and attitude 
towards genome editing technologies. The evaluation of the SynBioExpo project lead us to a 
number of conclusions which might be of use to researchers conducting similar exercises. In 
particular, rather than a ‘PR exercise’ it is important that public engagement surrounding 
controversial issues such as genome editing are entered into expecting a 2-way exchange, 
where researchers respect and listen to the voices of the public. It is important that 
researchers be reflexive with respect to exploring their own role in society and research 
practices and are open to entering into discussion. Importantly, exercises should be 
developed to be mindful of the language they use, striking a balance between discussing 
science without over simplification whilst not obstructing important bioethical debate with 







A1  Chapter 1  
 
A2  Chapter 2 
The following sequences were supplied by Eurofins Genomics as synthesised gene fragments 
in pEX plasmids, listed in Table 9. All sequences are given 5′ - 3′ 












pEX-A2-g#GM SP1gRNA 5′ RP 
GGTACCTCTCCCTGAGCTTCAGGGAGCGCTAAAGAGGAAGAGGACAGTTTTAGAGCTAGAAATAGCAAGT
TAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTC 
pEX-A2-g#GM SP1gRNA 3′ RP 
GGTACCCGCTAAAGAGGAAGAGGACAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTT
ATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTCTCCCTGAGCTTCAGGGAGTTTTTTGAATTC 
pEX-A2-g#GM SP1gRNA US RP 
GGTACCCGCTAAAGAGGAAGAGGACAGTTTTAGAGCTCCCTGAGCTTCAGGGAGCAAGTTAAAATAAGGC
TAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTC 
pEX-A2-g#GM SP1gRNA H RP_1 
GGTACCCGCTAAAGAGGAAGAGGACAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTT
ATCAACTTGACTCCCTGAGCTTCAGGGAGAAAAGTGGCACCGAGTCGGTGCTTTTTTGAATTC 
pEX-A2-g#GM SP1gRNA H RP_2 
GGTACCCGCTAAAGAGGAAGAGGACAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAG
TCCGTTATCAACTCCCTGAGCTTCAGGGAGTGGCACCGAGTCGGTGCTTTTTTGAATTC 







A3  Chapter 3  
A3-I Cloning pD1301 
 
 
Figure A-1 pD1301 cloning  i left pD1301i PCR product centre pD1301i ligated and miniprepped right pD1301i 
linearised with SapI, showing introduction of sites by PCR. Two colonies pD1031i6 and pD1301i9 have the 
correct sequence (green circle) A left 5′ NLS removal by PCR gives 9010 bp product right pD1301iA is ligated 
and miniprepped. Removal of FseI site shows correct PCR amplification. Single cut with SapI shows correct size 
plasmid. B gRNA removal by PCR (not shown) gives a product of 8570 bp which Is ligated. Non-cutting with SapI 
confirms gRNA scaffold is removed, NcoI (single cutter) confirms correct length of product. All gels are 1% 




A3-II Cloning pD1301 
 
Figure A-2 pD1301 cloning C Method 1 Introducing MTS through inverse PCR Method 2 Introducing MTS through 
nesdted primer PCR Method 3 Introducing MTS as insert cout out of another plasmid pEX-MTS. bottom left PCR 
of pD1301iA and pD1301iAB to make pD1301iAC and pD1301iABC centre F103 bp MTS fragment cut out of 
pEX-MTS, separated on 10% native PAGE right Restriction digests to determine correct insertion of MTS into 





A3-III Genomic Cleavage Detection Assay 
Many kits were developed during the course of this project which advertised decreased 
timescales and increased efficiency through RNP approaches to CRISPR workflows. Following 
a lack of progress with the plasmid transfection approach for studying Cas9 localisation, we 
decided to attempt an RNP approach. This also provided a tool with which to look at the work 
from Jo et al, introduced in section 1.6, which claimed to show depletion of mtDNA with a 
nuclear-targeted Cas9 and an unmodified gRNA 160. Jo et al designed three mtDNA-targeted 
gRNAs targeting the mitochondrial COX1, COX2 and COX3 genes. Figure A-3 shows the 
GeneArt® Genomic Cleavage Detection Assay (Invitrogen) kit used to target a control nuclear 
gene (HPRT), provided with the kit, and the three mitochondrial genes COX1, COX2 and COX3. 
Very low cleavage was seen, with the kit’s positive control (nuclear HPRT), and no cleavage 
was seen with COX1-3. For a brief description of the GCDA assay, see section 2.12.2. 
 
 
Figure A-3 Genomic Cleavage Detection Assay HeLa cells were transfected with Cas9RNP targeting either the 
nuclear HPRT gene, or mitochondrial COX1/2/3 genes, using the GeneArt™ gRNA Synthesis and Precision™ 
Cas9 nuclease transfection protocol. A PCR was performed across the region of interest for use with the GCDA. 
The control HPRT reaction shows some cleavage (* bands) whereas there is no cleavage with COX1/2/3.    
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A4  Chapter 4  
 
Figure A-4 Chapter 4 gRNA library sequences colouring is consistent with Figure 4-1.   
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A4-II Cas9hinge purification 
 
Figure A-5 Cas9hinge purification  See section 2.7.1 for details 
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A4-III Cas9hinge labelling 
 
Figure A-6 Cas9hinge labelling  See section 2.7.1 for details 
159 
 
A4-IV Cas9hinge traces 
 
Figure A-7 Cas9hinge Example Fluorolog traces 
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A4-V Cas9HNH purification 
 






A4-VI Cas9HNH labelling 
 
Figure A-9 dCas9HNH Labelling See section 2.7.1 for details 
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A4-VII ka, kb kini and kini2 
Table 24 rates of first and second strand cleavage ± SEM Data from Figure 4-13
  ka kb kini kini2 
gRNA 0.099±0.004 0.104±0.007 0.005±0.001 0.006±0.0005 
US 0.093 0.139 0.008 0.01 
H1 0.116±0.010 0.157±0.018 0.006±0.004 0.011±0.001 
H2 0.087±0.004 0.160±0.016 0.007±0.005 0.010±0.002 




A5 Chapter 5  
 
Figure A-10 Chapter 5 gRNA and crRNA sequences 
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A6 Chapter 6  
A6-I gRNA Northern blotting 
 
Figure A-11 gRNA Northern blotting A Northern blotting for AD/FD B Northern blotting for gRNA, and gRNA 5′ FD; 













A6-II Fluorescent RNAs do not colocalise with LC3 
 
Figure A-12 Alexa™-labelled RNAs do not colocalise with LC3 AD-488, FD-488, gRNA-488, 5′RP gRNA-488 and 5′ 
FD gRNA-488 are transfected into HeLa cells by PEI transfection. Cells are stained with DAPI and anti-LC3 (2° 




A7 Chapter 7  
A7-I Artists/Scientists profiles 
Theo Wood 
Theo Wood is a multimedia artist from Bristol 
I was delighted on being invited to take part in this exhibition being an ardent 
science, sci- and future gazing fan. My ongoing project the Museum of Space 
Exploration is based on a future after the year 3000 – Synthetic Biology will be 
entrenched and more by then. For SynBioExpo my response has been to take 
a sideways look, consider the issues, and produce pieces of work that 
hopefully will provoke questions. Is this a good idea? Is this real or fake news? 
Theo Wood – April 2017 
Imogen Coulter 
Imogen Coulter is an illustrator from Bristol 
 
It has been a great experience being involved in such a unique exhibition. 
Having always been interested in science and art it’s been a great opportunity 
to actually work with the scientists first hand, looking and learning about each 
of their projects. 
Imogen Coulter – April 2017 
 
Claudia Stocker 
Claudia Stocker is a graphic designer and illustrator from Bristol.  
Visualising cutting edge science is something I'm fairly comfortable with - my 
day job is running the science illustration and graphic design company Vivid 
Biology. This is why I was drawn more towards the current technical details of 
the research rather than the future potential of the technology. This exhibition 
did give me the chance to work at a larger scale than usual. Most of my work 
is constrained by how big my scanner is. It also let me catch up on what was 
going on in the field (I studied synthetic biology as part of my MSci, but that 
was back in 2012). I tried to make the works as visually distinct as possible, 
I'm always a little a bit paranoid that by being too scientifically rigorous they 
become somewhat formulaic. There's only so many ways you can draw DNA 
before it veers into territory where you're making statements that are factually 
wrong. 





1. With synthetic biology, it could be possible to produce vegan cow’s milk, a liquid which 
has the same molecular identity as cow’s milk, but without the need for an actual 
cow. This ‘milk’ could then be used to make vegan cheese  — a cheese made from 
what is essentially real cow’s milk, only with zero animal involvement. Would you be 
happy to eat this? 
2. Research suggests that it will not be long before a strain of peanut (ground nut) will 
be available that will not create an allergic reaction (the gene causing this will  
3. There is a worldwide shortage of organs suitable for transplantation. It has previously 
been suggested that animal organs could be transplanted into humans, but no trials 
to date have been entirely successful. There is a much higher incidence of organ 
rejection in these animal-to-human transplant cases. It could be possible to modify 
the genes in the implanted animal organs that cause negative reactions in the human 
recipients. This could mean fewer cases of organ rejection/failure and perhaps 
freedom from having to take immune-suppressive drugs forever. Should this research 
continue?  
4. There is a worldwide shortage of organs suitable for transplantation. It has previously 
been suggested that animal organs could be transplanted into humans, but no trials 
to date have been entirely successful. There is a much higher incidence of organ 
rejection in these animal-to-human transplant cases.  
5. It could be possible to modify the human genes that cause negative reactions to 
animal transplants in the immune system. This could mean fewer cases of organ 
rejection/failure and perhaps freedom from having to take immune-suppressive 
drugs forever. Should this research continue?  
6. Mosquitoes have been genetically engineered so that they spread a lethal gene which 
cuts down populations of Zika carrying mosquitoes. Should they be released into the 
environment for testing?  
7. CRISPR creates the potential to reintroduce extinct species. Mammoth like elephants 
could be bred by including certain mammoth genes into an elephant embryo. To allow 
this to continue, an artificial womb would have to be created. Do you think research 
of this type is a good idea? 
8. A team of Chinese scientists have begun using genome-editing techniques on viable 
human embryos, creating embryos with genetic mutations. These cells are an exact 
model of embryonic disease which could be used in the development of new 
therapies to see if these could be corrected. The work is in early stages of 




9. ‘Genetically modified’ foods, as first released into the consumer market in the 90s, 
often involved the insertion of genes into crops which did not naturally occur in that 
species. In Europe, all food containing more than 0.9% GM products must be labelled. 
Do you think that consumer products which have been modified with CRISPR should 
be allowed to be sold without explicit labelling? 
10. CRISPR can be used to genetically modify some single-celled organisms (like yeast) 
so that they produce polymers and precursors to biofuels. Biomanufacture like this 
could be used to help alleviate our dependence on edible and crude oils. Do you think 
this is a good idea? 
11. CRISPR kits can now be bought commercially online for under £100, enabling anyone 
to become a “garage scientist” or “biohacker” and start tinkering with DNA from the 
comfort of their own home. Do you think these gene editing kits should be available 
commercially online? 
12. In the egg industry, male chicks are often slaughtered as they have no use. CRISPR 
could be used to help identify male eggs before they hatch, so that they can be 
redirected into another industry (such as vaccine production). Do you think CRISPR 
should be used to reduce the need for farmers to cull animals in the food industry in 
this way? 
13. Invasive species disrupt natural ecosystems worldwide, driving natural species 
extinct and threatening protected habitats. Where other methods of population 
control have failed, modifying a few members of the invasive species with CRISPR 
could be used to spread genes through the population and control numbers.  Do you 
think research of this type is a good idea? 
14. Many premium breeds of meat and dairy cattle have long horns. These can cause the 
animals to injure each other, particularly when they are packed into trailers for 
transport. As a result, the horns are often removed in a painful process. Using 
traditional methods of cross breeding to eliminate the horns in these premium cattle 
breeds has been unsuccessful as it produces low-quality offspring. CRISPR is being 
used to produce high quality cattle without horns. Do you think this technology should 
be used on animals in the food industry in this way? 
15. As tools for modifying DNA are developed, the potential for private businesses to 
commercialize human genetic enhancement could become a reality – resulting in an 
industry of ‘genome plastic surgery’. Do you think businesses of this type should be 
allowed? 
16. CRISPR provides the potential to develop cell based therapies – where cells can be 
taken out of a patient’s body, modified by CRISPR, and then replaced. An example 
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could be edited white blood cells which bolster the immune system of an HIV patient. 
Do you think edited cells should be used to treat human disease in this way? 
17. CRISPR provides the potential to edit the DNA in human somatic cells - all the cells 
except the sperm or eggs. This means that a patient could have a genetic mutation 
corrected, but would not pass on any edited DNA to future generations. Do you think 
edited cells should be used to treat human disease in this way? 
18. CRISPR provides the potential to edit the DNA in human cells – including the germ 
line cells, the sperm and the eggs. This means that a patient could have a genetic 
mutation corrected, and would pass on edited DNA to future generations. Do you 
think edited cells should be used to treat human disease in this way? 
19. Many successful modern drugs are based on molecules from natural products such 
as plants. In some cases using the natural product directly can lead to the extinction 
of its source. Using CRISPR to synthetically produce these products will mean this will 
no longer need to happen. Is this a good idea for future development?  
20. African swine fever is a virus which infects domestic pig herds and can have a 
detrimental impact on pig farmers. Some warthogs are naturally immune to African 
swine fever. Altering immune genes in domestic pigs to match more closely those of 
warthogs would confer resistance to the virus. If this is successful there would be a 
new breed of pig available as a food source and less disease in these pig herds. Do 
you think editing pig DNA to match more closely to warthogs should happen? 
21. Medical tourism is the name given to patients travelling to other countries to seek 
medical or fertility treatments which aren’t available in their own countries. The 
development of CRISPR technologies could lead to a new era of genetic tourism, 
where individuals travel abroad for unregulated procedures. Is genetic medical 
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